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Summary 
The emerging arbovirus, Chandipura virus (CHPV) has been implicated in epidemics 
of acute encephalitis in India with mortality rates in hospitalised children of over 
50%. CHPV is a member of the Vesiculovirus genus of the Rhabdoviridae family.  
Viruses are dependent on the host cell at every stage of their lifecycle.  The isolation 
of temperature-dependent host range (tdCE) mutants, which are characterised by 
growth impairment at 39°C in chick embryo (CE) cells but not in monkey cells, 
highlights a dependence of CHPV on undetermined host factors.  The 
characterisation of three tdCE mutants was carried out.  Each of the mutants contain 
one or more coding mutations in the RNA polymerase gene and two contain 
additional mutations in the attachment protein gene.  Using a reverse genetics system 
of CHPV recombinant viruses containing the specific mutations were generated.  
This demonstrated that a single amino acid change in the virus RNA polymerase of 
each mutant, located either between domains III and IV or within domain IV or VI 
was responsible for host range specificity, the tdCE phenomenon.  In CE cells at 
39°C the tdCE lesions were shown to disrupt the assembly of cytoplasmic replication 
complexes.   
A recombinant virus with a Flag tag attached to the L protein was generated and used 
to infect mammalian and avian cells.  Potential L/Flag interacting partners were co-
immunoprecipitated and analysed by mass spectrometry.  The predominant cellular 
functions of the identified proteins were in gene expression and the cytoskeleton.         
To investigate the neuropathogenisis and cell tropism of CHPV in vivo and ex vivo 
models of CHPV disease were established.  The virus was shown to principally 
localise to the cerebellum in the mouse brain with the virus targeting immature 
neurons, granule cells and microglia.  Mature neurons, oligodendrocytes and 
astrocytes were permissive to infection with CHPV but their infection occurred 
infrequently.       
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CHAPTER 1 
2 
1 Introduction 
 
1.1. Emerging viruses 
In an increasingly interconnected, globalised society emerging viruses pose a 
substantial threat to public health at a local, national and global scale.  Human 
population growth and the transformation of environments and ecosystems by people 
throughout the world has provided and will continue to provide opportunities for the 
emergence of new viruses, the spread of existing viruses into new geographical 
locations or expansion of their host range.   
Recently emerged viruses belong to a wide range of virus families including 
Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthomyxoviridae, 
Paramyxoviridae and Rhabdoviridae.  Many emerging viruses are zoonoses that are 
unable to transmit efficiently from human to human, examples of which include 
Ebola, Marburg, Hantaan, Nipah and Hendra viruses.  The Filoviruses Ebola and 
Marburg are the causative agents of sporadic cases of severe haemorrhagic fever in 
humans and non-human primates in central Africa with high case fatality rates 
ranging from 25-90% and 25-80% respectively (MacNeil & Rollin, 2012).  Fruit bats 
have been implicated as the natural reservoir of both viruses (Leroy et al., 2005; 
Towner et al., 2007).  Bats have also been identified as the reservoirs of the 
emerging Paramyxoviruses Hendra and Nipah.  Hendra virus has caused outbreaks of 
severe acute respiratory disease in horses and humans in Australia since 1994 and 
has also been frequently isolated from pteropid bats, the natural host of the virus 
(Halpin et al., 2000).  Nipah virus first emerged in Malaysia in 1998 and has been 
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responsible for 12 outbreaks of acute febrile encephalitis in humans and pigs in 
South-East Asia (Aljofan, 2013).   
Other examples of zoonotic emerging virus are the Hantaviruses.  Over 20 New 
world hantaviruses, family Bunyaviridae, have been isolated in the Americas, 13 of 
which are associated with Hantavirus Pulmonary Syndrome (HPS) in humans and 
each of which have a different rodent host (Macneil et al., 2011).  HPS was first 
reported in 1993 in the southwestern United States and the etiological agent was 
identified as the novel hantavirus Sin Nombre virus.  Increased human contact with 
the natural host species of Sin Nombre virus, the deer mouse (Peromyscus 
maniculatus) is considered the overriding factor in the emergence of this virus.  This 
increased contact was brought about by a rise in the mouse population because of an 
abundance of food which has been linked to increased rainfall during the 1992-1993 
El Ni o (Engelthaler et al., 1999).   
Severe acute respiratory syndrome coronavirus (SARS-CoV) is an example of a 
recently emerged zoonotic virus which had adapted for highly efficient person to 
person transmission.  SARS-CoV originated in Guangdong province in southern 
China in late 2002 and subsequently spread rapidly around the world due to 
international air travel, resulting in a global outbreak of severe atypical pneumonia.  
By September 2003 8,098 people had been infected and 774 people died as a result, a 
case fatality rate of 9.6% (Graham et al., 2013).  The animal reservoirs of SARS-
CoV are Rhinolophus (horseshoe) bats but the virus has also been isolated from palm 
civets in live animal markets, which facilitated transmission of the virus to humans 
(Li et al., 2005b).  Virus isolates from the epidemic contained mutations in the 
receptor-binding domain of the spike glycoprotein which greatly enhanced the 
viruses affinity for human angiotensin-converting enzyme 2 (ACE2), the receptor of 
4 
SARS-CoV (Li et al., 2005a).  Since the epidemic of SARS-CoV many more novel 
bat coronaviruses have been isolated, highlighting the large potential for human 
disease within this virus family.  Another coronavirus, Middle East respiratory 
syndrome coronavirus (MERS-CoV) emerged in 2012.  The index human case 
occurred in Saudi Arabia and there have been a further 16 cases in the Arabian 
Peninsula and the UK with a case fatality rate of 50% of people who were 
hospitalised (Graham et al., 2013).  Bats have been implicated as the natural host of 
MERS-CoV (Zaki et al., 2012).                 
Unlike the epidemic of SARS-CoV, which despite being readily transmissible was 
controlled within 4 months, newly emerged influenza A virus H1N1 quickly spread 
to over 214 countries, becoming the first pandemic of the 21
st
 century (van 
Doremalen et al., 2011).  Influenza H1N1 emerged from Mexico and the United 
States in 2009 due to a gene reassortment event between the classical swine H1N1, 
Eurasian swine H1N1 and the triple-reassortment influenza viruses (Garten et al., 
2009).  The natural host of influenza A viruses is aquatic birds although pigs are also 
thought to play an important role in the transmission of novel influenza viruses to 
humans (Moncorge et al., 2013).        
Many emerging viruses are arthropod-borne such as West Nile virus (WNV), 
dengue, chikungunya and bluetongue viruses, all of which have recently emerged in 
new regions of the world as the geographical range of their vectors have expanded.  
The dengue viruses (serotypes 1-4), members of the Flaviviridae family, are the 
causative agents of dengue fever and the more serious clinical manifestation of the 
virus dengue haemorrhagic fever in tropical and sub-tropical regions of the world.  
Dengue viruses account for the largest number of arbovirus infections worldwide and 
have spread considerably in recent years with prolonged transmission of the virus in 
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Europe now threatening (Mackenzie & Jeggo, 2013).  This expansion of 
geographical range occurred due to the continued establishment of Aedes aegypti 
mosquitoes (the principle vector of the virus) in expanding urban areas and also the 
spread of Aedes albopictus mosquitoes into North America and Europe (Mackenzie 
& Jeggo, 2013).  The spread of Aedes aegypti mosquitoes into new habitats is also 
responsible for the increase in range and incidence of chikungunya virus infections.  
Indian Ocean epidemic isolates of the virus frequently contain an A226V amino acid 
mutation in the envelope glycoprotein which enhances transmissibility by Aedes 
albopictus mosquitoes and thus there is potential for the virus to become endemic in 
Southern Europe and the Americas (Tsetsarkin et al., 2007).  This possibility was 
highlighted when a localised outbreak of chikungunya occurred in Italy in 2007 
infecting 254 people (Burt et al., 2012; Mackenzie & Jeggo, 2013).          
The lesser-known emerging arbovirus Chandipura virus was the focus of this 
investigation.  This Rhabdovirus is transmitted by Phlebotomus sandflies and is the 
causative agent of a number of outbreaks of encephalitis in children in central states 
in India since 2003 (Chadha et al., 2005; Gurav et al., 2010; Tandale et al., 2008).  
The virus has also been isolated from sand flies in the northern region of Senegal 
(Traore-Lamizana et al., 2001) and in a pygmy hedgehog in Nigeria (Fontenille et 
al., 1994), indicating the presence of the virus and thus the potential for human 
disease outside of India.  The nature of CHPV disease is discussed in section 1.5.    
1.2. Chandipura virus (CHPV) classification 
1.2.1. Order Mononegavirales 
CHPV is a non-segmented, negative stranded RNA virus belonging to group V 
(negative sense ssRNA viruses) in the Baltimore classification system.  CHPV is 
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classified within the order Mononegavirales, family Rhabdoviridae and genus 
vesiculovirus.  The order Mononegavirales is comprised of four virus families: 
Bornaviridae, Filoviridae, Paramyxoviridae and Rhabdoviridae and contains a large 
number of viruses of public health, veterinary and economic significance such as 
Marburg and Ebola viruses (Filoviridae), measles and respiratory syncytial virus 
(RSV) (Paramyxoviridae), rabies and vesicular stomatitis virus (VSV) 
(Rhabdoviridae).  The phylogenetic relationships between the members of the 
Mononegavirales are depicted in Figure 1.1.       
     
                      
Figure 1.1| Unrooted phylogenetic tree of the Mononegavirales based on L gene 
alignment (obtained from the Ninth report of the International Committee on Taxonomy of 
Viruses) 
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1.2.2. Family Rhabdoviridae 
Rhabdoviruses have a wide host range and greater than 200 rhabdoviruses have been 
isolated to date from plants, invertebrates and vertebrates (Walker et al., 2011) with 
some members of the family able to replicate in both plants and invertebrates and 
others in invertebrates and vertebrates (Easton & Pringle, 2011).  There are nine 
genera within the family Rhabdoviridae, six are composed of animal viruses: 
Vesiculovirus, Lyssavirus, Ephemerovirus, Tibrovirus, Perhabdovirus (fish viruses) 
and Novirhabdovirus (fish viruses), two contain plant viruses: Cytorhabdovirus and 
Nucleorhabdovirus and the Sigmavirus  genus is comprised of viruses which infect 
dipterans (Dietzgen et al., 2011).  Members of the family Rhabdoviridae are listed in 
Table 1.1 and the phylogenetic relationships between them are illustrated in Figure 
1.2.  Recently, several novel rhabdoviruses have been characterised, emphasising the 
likelihood that there are many more unidentified rhabdoviruses and that the full 
diversity of this virus family is yet to be exposed.  Examples of such viruses include 
Niakha virus, which was isolated from phlebotomine sandflies in Senegal (Vasilakis 
et al., 2013a). Also, the recently identified and highly divergent Bas Congo 
Rhabdovirus was associated with a small outbreak of acute hemorrhagic fever in 
humans in the Democratic Republic of Congo in 2009 (Grard et al., 2012).   
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Genus Type virus Other viruses Host(s) 
Cytorhabdovirus  Lettuce necrotic 
yellow virus 
Barley yellow striate mosaic virus 
Broccoli necrotic yellows virus 
Festuca leaf streak virus 
Lettuce yellow mottle virus 
Northern cereal mosaic virus 
Sonchus virus 
Strawberry crinkle virus 
Wheat American striate mosaic virus 
 
Plants, insect 
vectors (aphids, 
leafhoppers, 
planthoppers) 
Ephemerovirus Bovine ephemeral 
fever virus 
Adelaide River virus 
Berrimah virus 
 
Cattle, mosquitoes 
Lyssavirus Rabies virus Aravan virus 
Australian bat lyssavirus 
Duvenhage virus 
European bat lyssavirus 1 
European bat lyssavirus 2 
Irkut virus 
Khujand virus 
Lagos bat virus 
Mokola virus 
Shimoni bat virus 
West Caucasian bat virus 
 
Mammals 
Novirhabdovirus Infectious 
hematopoietic 
necrosis virus 
Hirame rhabdovirus 
Snakehead virus 
Viral hemorrhagic septicemia virus 
 
Fish 
Nucleorhabdovirus 
 
Potato yellow 
dwarf virus 
Datura yellow vein virus 
Eggplant mottled dwarf virus 
Maize fine streak virus 
Maize Iranian mosaic virus 
Maize mosaic virus 
Rice yellow stunt virus 
Sonchus yellow net virus 
Sowthistle yellow vein virus 
Taro vein chlorosis virus 
 
Plants, insect 
vectors 
Perhabdovirus Perch rhabdovirus   Anguillid rhabdovirus 
  Sea trout rhabdovirus 
Fish 
Sigmavirus Drosophila 
melanogaster 
sigmavirus 
  Drosophila affinis sigmavirus 
  Drosophila ananassae sigmavirus 
  Drosophila immigrans sigmavirus 
  Drosophila obscura sigmavirus 
  Drosophila tristis sigmavirus 
  Muscina stabulans sigmavirus 
Dipterans 
Tibrovirus Tibrogargan virus   Coastal Plains virus Cattle, midges 
Vesiculovirus Vesicular 
stomatitis Indiana 
virus 
Carajas virus 
Chandipura virus 
Cocal virus 
Isfahan virus 
Maraba virus 
Piry virus 
Spring viraemia of carp virus 
Vesicular stomatitis Alagoas virus 
Vesicular stomatitis New Jersey virus 
 
Humans, cattle, 
horses, swine, sand 
flies, black flies, 
mosquitoes 
Table 1.1| Members of the Rhabdoviridae family  
Species belonging to each of the nine genera of the Rhabdoviridae family are listed.  The prototype 
viruses and the host(s) are also shown.         
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Figure 1.2| Unrooted phylogenetic tree of the Rhabdoviridae based on L gene alignment 
 
1.2.3. Genus Vesiculovirus 
Currently, ten virus species are assigned to the vesiculovirus genus and there is 
evidence to suggest that several other viruses should also be members (Table 1.2).  
This genus contains predominantly zoonotic viruses which are capable of causing a 
diverse range of clinical manifestations including flu-like and encephalitic illnesses 
in humans, vesicular disease in livestock, persistent infections in insects and 
hemorrhagic disease in fish.   
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  Virus 
Vesiculovirus Carajas virus 
Chandipura virus 
Cocal virus 
Isfahan virus 
Maraba virus 
Piry virus 
Spring viraemia of carp virus 
Vesicular stomatitis Alagoas virus 
Vesicular stomatitis Indiana virus 
Vesicular stomatitis New Jersey virus 
Tentative vesiculovirus Boteke virus 
Farmington virus 
Gray Lodge virus 
Jug Bogdanovac virus 
Jurona virus 
Keuraliba virus 
Klamath virus 
Kwatta virus 
La Joya virus 
Malpais spring virus 
Perinet virus 
Porton virus 
Radi virus 
 
Table 1.2| Confirmed and putative vesiculoviruses 
Members of the vesiculovirus genus, as confirmed by the ICTV and species currently being 
considered for assignment to this genus (Vasilakis et al., 2013b).  Highlighted viruses have 
been shown to cause flu-like illness in humans (green), encephalitis in humans (red) and 
hemorrhagic disease in fish (blue).   
 
The type species, the arbovirus vesicular stomatitis virus (VSV) is the causative 
agent of vesicular stomatitis (VS), a disease of ruminants, pigs and several other 
wildlife species found in large areas of the Americas.  The clinical presentations in 
domestic animals resemble those of foot-and-mouth disease with vesicular lesions on 
the mouth, tongue, hooves and teats and this has significant economic consequences 
as well as being a welfare concern (Perez et al., 2010).  Putative biological vectors of 
VSV include black flies, sand flies (Lutzomyia spp) and biting midges.  However, 
transmission by direct contact and infected fomites has also been demonstrated 
(Perez et al., 2010).   
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VSV is endemic from northern South America to southern Mexico whereas disease 
presentations have occurred in approximately 10 year cycles in the southwestern 
United States and sporadically since the mid 1970’s (only in wildlife species) in 
southeastern states (Rodriguez, 2002).  The regular re-emergence of VSV in the 
southwestern US is due to the novel introduction of the virus from the endemic 
regions of Mexico and these events have been associated with high precipitation 
levels in the months preceding an outbreak, although there are likely to be a range of 
contributing factors which are not fully understood (Rainwater-Lovett et al., 2007).  
VSV has also been shown to over-winter, thus causing incidences of disease for a 
few years after the first reported case (Perez et al., 2010).  Of the two serotypes of 
VSV (VSV New Jersey and VSV Indiana) VSV New Jersey accounts for the 
majority of infections in the US.      
Two other vesiculoviruses, Cocal and Alagoas are responsible for the periodic 
incidences of vesicular disease in Brazil and Argentina (Rodriguez, 2002).  The 
geographical distribution of these and other vesiculoviruses is shown in Figure 1.3.  
The mosquito-borne Malpais spring virus was first isolated in New Mexico in 1985 
(Clark et al., 1988) and a recent genetic analysis strongly indicated that it should be 
assigned to the Vesiculovirus genus (Vasilakis et al., 2013b).  This virus infects deer 
and horses and there is a high seroprevalence of  Malpais spring virus antibodies 
among ungulates throughout New Mexico (Vasilakis et al., 2013b). 
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Figure 1.3| Geographical distribution of vesiculoviruses 
The approximate locations of virus isolations are shown.  The large circles represent >2 
isolations and the smaller circles represent 1 or 2 isolations of virus.  VSV New Jersey and 
VSV Indiana are not included because of their large geographical spread throughout North, 
Central and South America.  The distribution of phlebotomine sandflies is shown by a dotted 
line.        
 
CHPV replicates within, and is transmitted by, phlebotomine sand flies, the 
geographical distribution of which is shown in Figure 1.3.  However, the virus has 
only been isolated in India where it has caused several human epidemics of acute 
encephalitis and in West Africa from the vector (Traore-Lamizana et al., 2001) and 
one other non-human isolation (Fontenille et al., 1994).  The vesiculovirus most 
Phlebotomine sandfly belt 
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closely related to CHPV, Isfahan virus (IFHV), was isolated from phlebotomine sand 
flies in Iran in 1975 (Tesh et al., 1977).  While there have been no documented 
outbreaks of IFHV-associated disease in humans it has been associated with a small 
number of sporadic cases of febrile illness. 
  
1.3. CHPV structure and lifecycle 
Although first isolated in 1965 there has been limited research into CHPV, especially 
until the recent epidemics, with much of our understanding of the molecular aspects 
of replication shaped by analogy with the extensively studied VSV, the prototype 
vesiculovirus.   
 
1.3.1. CHPV structure 
CHPV is an enveloped, bullet-shaped, helical virus containing 11,119 nucleotides of 
non-segmented single-stranded, negative sense RNA (Marriott, 2005) (Figure 1.4).  
By analogy with VSV, the CHPV genome is encapsidated by approximately 1,200 
molecules of the 48kDa nucleocapsid (N) protein to generate the core 
ribonucleoprotein (RNP) complex, functioning as the template for CHPV RNA 
synthesis (Figure 1.4a).  In addition, the two constituents of the viral RNA dependent 
RNA polymerase (RdRp); the 238.5 kDa large (L) protein (the catalytic subunit) and 
the phosphorylated form of 32.6 kDa phosphoprotein (P) (the cofactor) are closely 
associated with the RNP in mature virus particles (Basak et al., 2007; Mondal et al., 
2010).  The RNP is the minimal unit required for rhabdovirus infection (Thornton et 
al., 1983).  The 26kDa matrix (M) protein covers the inner membrane of the virus 
and attaches the RNP particle to the envelope.  The attachment and fusion 
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glycoprotein (G) is embedded in and protrudes from the envelope of the virion.  
These can be clearly seen coating the surface of the virus particle in electron 
micrographs of the virus (Figure 1.4b).      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4| Structure of CHPV 
A. Diagram of a CHPV particle 
B. Transmission electron micrograph of CHPV (Rao et al., 2004).  Scale bar is 100 nm.  A 
released RNP particle is shown in the insert.       
 
 
1.3.2. Genome organisation 
The CHPV genome contains (from 3’ to 5’): a 49 nucleotide untranslated, non-
capped, non-polyadenylated leader RNA, 5 genes encoding the five structural 
proteins of the virus; N, P, M, G, L proteins, each of which  is separated by a 
conserved (G/CA) dinucleotide intergenic sequence, and a 46 nucleotide trailer 
sequence (Basak et al., 2004) (Figure 1.5).  Each gene also has cis-acting stop 
sequences at the 5’ terminus and 3’ start sequences, which are required for mRNA 
synthesis.   
a b 
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Figure 1.5| CHPV genome 
The nucleotide positions within the 11,119 nt CHPV genome are indicated.  The locations of 
the genes encoding the 5 virus proteins are indicated.   
 
1.3.3. Replication cycle 
The life cycle of all vesiculoviruses is entirely cytoplasmic and is the product of an 
intimate association with numerous host cell proteins, which act as both positive and 
negative regulators of viral replication.  There is limited information about these 
cellular factors, however, a recent RNAi screen identified 72 mammalian genes as 
essential for VSV infection (Panda et al., 2011)  A summary of the vesiculovirus 
replication cycle with the names of host cell proteins known to be involved at each 
stage is shown in Figure 1.6.  Table 1.3 gives details of the cellular proteins shown to 
be involved in vesiculovirus replication.   
 
Following adsorption and entry into the cell by clathrin-mediated endocytosis (step 
1, Figure 1.6), a low pH-triggered fusion event takes place between the G spike 
proteins protruding from the vesiculovirus envelope and the membranes of acidified 
endosomes, resulting in the liberation of virion constituents into the cytoplasm 
(Basak et al., 2007) (step 2, Figure 1.6).  Delivery of the nucleocapsid into the 
cytoplasm marks the initiation of vesiculovirus infection.        
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Figure 1.6| Replication cycle of VSV (adapted from Flint et al., 2009) 
Stages of the VSV replication (purple): entry and endocytosis (1), uncoating (2), primary 
transcription (3), translation (4), ER membrane-associated translation of the G protein (5), 
replication (6), secondary transcription and replication (7, 8), transport of the G protein 
through the secretory pathway (9, 10), assembly (11, 12) and budding of the virion from the 
host cell (13).  Cellular processes involved in the vesiculovirus life cycle are shown in blue.  
Specific host proteins which have been shown to be vital for or support virus replication are 
in red and those shown to suppress virus growth are in green.  Cellular genes whose 
expression has been demonstrated to be required for VSV replication by RNAi screening 
(Panda et al., 2011) are given in black.  
 
IFITM3 
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Cellular factors Interactions 
with virus 
Roles 
Actin  ND Entry into cells (Cureton et al., 2009)
 
Actin-related protein 3 (APR3) ND  
Alanine deamininase like (ADAL) ND Assembly and budding of nascent VSV virions (Panda et al., 2011)
 
ARF1 ND Activator of COP1 (Panda et al., 2011) 
ATPIF1 gene ND ATPIF1 encodes a mitochondrial ATPase inhibitor, shown to be required for VSV infection (Panda 
et al., 2011)
 
BBC3 gene, encodes Bcl2 binding 
component 3 
ND Required for VSV infection (Panda et al., 2011).  Cellular function is to induce apoptosis through 
the mitochondrial apoptotic pathway 
BCL2L2 gene, encodes Bcl-2-like 
protein2 
ND Required for VSV infection (Panda et al., 2011).  Pro-apoptotic cellular factor.   
CEACAM7 ND  
Casein kinase II Phosphoprotein Modulate the activity of VSV and CHPV P (Chattopadhyay & Banerjee, 1987; Chattopadhyay & 
Raha, 1997)
 
Coatomer complex (COP) 1  ND COPZ1, COPG, COPB2, COPB1, COPA and ARCN1 gene expression is required for VSV 
infection.  Facilitates the processing of VSVG through its involvement in its transport through the 
secretory pathway (from the Goli to the ER) and also plays important roles in VSV gene 
expression (Panda et al., 2011).  Expression of COP1 is required for VSV internalisation (Cureton 
et al., 2012).   
Collapsin response mediator 
protein I (CRMPI) 
ND CRMP1 is involved in cytoskeleton remodelling and was found to be required for VSV infection 
during RNAi screening (Panda et al., 2011)
 
C-terminal Src kinase Phosphoprotein ? (Dinh et al., 2011)
 
Cyclophilin A Nucleoprotein Essential for primary transcription of VSV New Jersey but not VSV Indiana (Bose et al., 2003)
 
Dynamin 1 and 2 Matrix protein Modulates clathrin-mediated endocytosis and is required for efficient progeny virus egress (Raux 
et al., 2010)
 
eIF2α and the eIF4F complex Matrix and (ND) Alters the phosphorylation state of the eIF2α and the eIF4F complexes, impairing host cell 
translation (Connor & Lyles, 2002)
 
EIF3 subunits A, G, I ND Shown to be essential for VSV infection during RNAi screening (Panda et al., 2011)
 
G protein couples receptor (GPCR) 
signalling proteins 
ND The following proteins involved in signalling from GPCRs were found to be upregulated during 
VSV-infection (GRM2, FRS2, RIT2, TAS2R48, P2RY10, OR7A10, GABBR2, ARHGAP23) 
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(Panda et al., 2011)
 
GBF1 ND An activator of COP1 (Panda et al., 2011) 
Genes involved in regulating 
transcription 
ND NRL, ZNF446, FOXF2, HIFOO, TOX, IFI35 genes were shown to be required for VSV infection.  
Their precise involvement in infection has not been established (Panda et al., 2011)
 
Genes involved in RNA processing ND NHP2L1, FBL, HNRPK, NOP56, FCF1, UTP6, UTP11L, DCAF13, PPP56 genes were shown to 
be required for VSV infection.  (Panda et al., 2011)
 
Cellular stress response genes ND GRN2, TIPIN, CARD14 genes were shown to be required for VSV infection (Panda et al., 2011) 
Heat shock protein (HSP) Nucleoprotein HSP90 was shown to be involved in VSV replication and maintaining L protein stability (Connor 
et al., 2007)
 
hnRNP K ND Required for VSV infection by inhibiting apoptosis, enhancing virus replication and release by 
modulating the expression of several host cell proteins including the upregulation of alanine 
deaminase like (ADAL), ARF1, Bcl-Xl, Bcl-2 and BagI and downregulation of Bcl-Xs and Bik 
(pro-apoptotic factors) (Dinh et al., 2013b) 
hnRNPU proteins Leader RNA Postulated to inhibit cellular mRNA synthesis (Gupta et al., 1998a)
 
HSPA9B gene (HSP9) ND Required for VSV infection (Panda et al., 2011).  Cellular function is to modulate cell proliferation 
IFN-induced transmembrane 
family (IFITM) 3 
ND Negatively regulates VSV at an early stage of the virus lifecycle, prior to primary transcription but 
after endocytosis (Weidner et al., 2010)
 
La Leader RNA VSV leader RNA interacts with La in the nucleus to inhibit RNA polymerase III transcription 
(Kurilla & Keene, 1983)
 
Laminin gamma 3 (LAMC3) ND Involved in cellular adhesion 
LBPA, Alix, phosphatidylinositol-
3-phosphate and Snx16 
ND Release of nucleocapsids from multivesicular bodies into the cytoplasm (Le Blanc et al., 2005)
 
LDLR gene family Glycoprotein Cellular receptor (Finkelshtein et al., 2013)
 
MAPK Matrix protein Activates MAPK preventing CD1d antigen presentation to NKT cells (Renukaradhya et al., 2008)
 
MAT2A ND Required for VSV gene expression (Panda et al., 2011)
 
NEDD4 E3 ubiquitin ligases Matrix protein Budding of mature virus particles (Harty et al., 1999)
 
PKMYT1 gene, encodes a 
serine/threonine protein kinase 
ND RNAi screening identified a requirement for this kinase in VSV infection (Panda et al., 2011).  
This kinase inhibits the G2/M transition of the cell cycle.     
Poly(C)binding protein 1 (PCBP1) Phosphoprotein Inhibits primary viral transcription (Dinh et al., 2011)
 
Poly(C)binding protein 2 (PCBP2) Phosphoprotein Associates with VSV P to inhibit viral transcription and replication (Dinh et al., 2011)
 
Ppp1r15b gene which encodes ND RNAi screening identified a requirement for CReP in VSV infection (Panda et al., 2011).  CReP 
19 
CReP triggers dephosphorylation of eIF2(αP) by modulating the activity of protein phosphatases.   
RAB5C ND This GTPase was shown to be necessary for VSV infection (Panda et al., 2011)
 
RaeI Matrix protein Targets the nucleoporin Nup98 to inhibit the nuclear-cytoplasmic trafficking of host cell 
macromolecules in a Ran-TC4 GTPase-dependant manner (Rajani et al., 2012)
 
Solute transporters SLC46A1 
(PCFT), KCNH4, SLC9A3 
ND The SLC46A1 solute transporter was shown to be required at the entry and/or uncoating stage of 
VSV infection (Panda et al., 2011)
 
Stromal cell derived factor (SDF) 4 ND  
SYVN1 gene, encodes the E3 
ubiquitin ligase synoviolin 
ND RNAi screening identified a requirement for SYVN1 expression in VSV infection (Panda et al., 
2011).  The cellular function of synoviolin is to remove proteins from the ER to the cytoplasm.      
TATA-binding protein (TBP) Matrix protein Inhibits TBP activity which contributes to viral inhibition of cellular transcription (Ahmed & 
Lyles, 1998)
 
T-cell-restricted intracellular 
antigen 1 (TIA1) 
ND Suppresses VSV replication in conjunction with PCBP2 within stress granule-like complexes 
induced by VSV infection (Dinh et al., 2013a)
.
 
Tetherin ND Blocks VSV virion egress (Weidner et al., 2010)
 
TSEIOI (ESCRT complex) Matrix protein Budding of mature virus particles (Raux et al., 2010)
 
Tubulin Matrix protein Stimulates cell rounding (Melki et al., 1994)
 
and required for virus transcription (Moyer et al., 
1986)
 
Microtubules are required to transport the viral mRNA from replication complexes to the cell 
membrane and this is essential for efficient translation (Heinrich et al., 2010)
 
UQCRC1 gene, encodes a subunit 
of ubiquitinol cytochrome c 
reductase 
ND Demonstrated to be essential for VSV infection from RNAi screening (Panda et al., 2011)
 
Vaculolar-type H
+
-ATPase (V-
ATPase) subunits 
ND ATP6VOB, ATP6AP2 and ATP6VOD1 V-ATPase subunits were shown to be required for VSV 
infection (Panda et al., 2011)
 
 
Table 1.3| Cellular factors influencing vesiculovirus replication 
Known cellular interactions with virus RNA or proteins and details of the effects of such interactions are given.  The majority of the virus-host interactions 
above have been demonstrated only in VSV.  ND denotes not determined.     
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The current model for CHPV transcription is based on analogy with that for VSV in 
which the virus encoded RNA dependent RNA polymerase (RdRp) sequentially 
transcribes the virus genome, beginning at the 3’ end, by a stop-start mechanism to 
generate a gradient of capped and polyadenylated mRNA transcripts whereby the 
most abundant mRNA is that encoding the N protein (as it is nearest to the 3’ end) 
(steps 3,4,5 Figure 1.6).  This progressive attenuation of transcription is a 
consequence of the reduced capacity of RdRp to reinitiate transcription at each 
downstream intergenic sequence.  The levels of protein are believed to reflect the 
levels of each mRNA.  VSV primary transcription has been shown to take place 
throughout the cytoplasm but protein expression triggers a shift in the principal site 
of mRNA synthesis to cytoplasmic inclusions as the infection progresses (Heinrich et 
al., 2010).  Microtubules are utilised to transport viral mRNA from replication 
complexes to the cell membrane and this was demonstrated to be essential for 
efficient translation (Heinrich et al., 2010).  VSV infection induces the formation of 
stress granule-like complexes which are comprised of viral RNA, replicative proteins 
and several cellular antiviral proteins.  This has led to the suggestion that the 
generation of inclusions is host-cell mediated and that they are in fact the replication 
complexes described previously (Dinh et al., 2013a).          
 
Read-though of the termination signals at gene junctions by the same RdRp that 
carries out mRNA transcription produces full-length anti-genomic RNA, which 
subsequently serves as templates for progeny genomes (Bhattacharya et al., 2006) 
(step 6, Figure 1.6).  The precise explanation for the switch in polymerase function 
from transcription to replication remains elusive, although proposed mechanisms 
include the suppression of mRNA synthesis due to the accumulation of N protein on 
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nascent genomic RNA.  Formation of complexes of CHPV leader RNA and 
underphosphorylated P protein dimers has also been implicated in anti-termination at 
gene junctions and therefore replicative phase initiation (Basak et al., 2004; 
Mukhopadhyay et al., 2010).  Progeny genomes are then used as templates for 
secondary transcription or replication (steps 7 & 8, Figure 1.6) or are assembled into 
progeny virions by budding from host plasma membrane (steps 12 & 13, Figure 1.6).   
 
The sections below give a more detailed discussion about the current understanding 
of the roles of each of the viral proteins and the involvement of host cell proteins at 
each stage of the vesiculovirus lifecycle.         
        
1.3.4. Attachment and fusion mediated by the G protein  
The G envelope glycoprotein of CHPV is crucial in the initial phases of infection and 
is responsible for mediating both the attachment and fusion processes, as is the case 
for all Rhabdoviruses and many other enveloped viruses.  This dual function is made 
possible through the ability of the glycoprotein to exist in three forms and to undergo 
large scale reversible structural rearrangements to transition between them (Roche et 
al., 2008).  Mature Rhabdovirus G proteins are embedded on the virion surface as 
trimers with each monomer composed of three domains: an N-terminal ectodomain, 
a transmembrane domain (which functions to anchor the protein into the virion 
membrane) and a C-terminal cytoplasmic tail (Masters et al., 1989).  The ectodomain 
contains a cleavable signal peptide and two glycosylation sites and forms the external 
portion of the protein and as such is the major target of neutralising antibodies during 
infection.        
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Recently, research has shown that the cellular receptor of VSV is the ubiquitously 
expressed low density lipoprotein receptor (LDLR) with other members of the LDLR 
gene family also acting as receptors but at lower frequency (Finkelshtein et al., 
2013).  This is consistent with the broad tropism and pantropic nature of VSV.  It is 
this characteristic which has been harnessed to generate recombinant viral vectors for 
gene therapy, vaccination and viral oncolysis (Finkelshtein et al., 2013).  Soluble 
LDLR is able to prevent VSV infection by binding to receptors, thus making them 
unavailable for virus attachment in all cell types tested except in SF6 insect cells 
(Finkelshtein et al., 2013).  This indicates that the virus uses another receptor in 
insect cells and is interesting because of the markedly different manifestation of VSV 
infection in insect cells (non-cytopathic) compared to other cell types (highly 
cytopathic).  Currently, it is not known whether the other vesiculoviruses such as 
CHPV also use LDLR to gain entry into host cells.   
Following receptor recognition, the virus is able to hijack cellular trafficking 
pathways and is taken up by the cell by clathrin-mediated endocytosis.  Entry of 
VSV into cells occurs in vesicles only partially covered by clathrin and requires actin 
(Cureton et al., 2009) and dynamin-2 (Johannsdottir et al., 2009).  LDLR family 
proteins serve as ideal viral receptors as they are regularly endocytosed and recycled 
back to the plasma membrane even when a ligand is not bound (Finkelshtein et al., 
2013).    
The fusion peptides of the VSV G and CHPV G glycoproteins are distinct from the 
well-defined class I (e.g. HA of influenza) and class II (e.g. E1 protein of Semliki 
Forest virus) viral fusion glycoproteins and have recently been grouped into a third 
class together with the spike protein of other Rhabdoviruses, including rabies virus, 
and the orthologous gB of herpesviruses (Roche et al., 2006).  Crystal structures of 
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VSV G (Roche et al., 2006) and recently CHPV G proteins (Baquero et al., 2012) 
have been solved, providing further information about the three forms of G protein 
during the fusion process.   
The low pH of the endosomal lumen triggers a major conformational change in the G 
glycoprotein from the pre-fusion trimer (occurring above pH7) to the post-fusion 
trimeric conformation via a monomeric hydrophobic intermediate, resulting in the 
fusion of the viral envelope with endosomal membranes (at an optimum of pH 6) and 
releasing the nucleocapsid into intra-endosomal vesicles (Baquero et al., 2012; Le 
Blanc et al., 2005; Roche et al., 2006).  In contrast with class I or II fusion proteins, 
the G proteins of these vesiculoviruses transition through the three states in a 
completely reversible manner as the pre- and post-fusion conformations are in a pH-
dependent dynamic equilibrium in which the latter is favoured at low pH (Albertini 
et al., 2012).  This is crucial for the protein to exist in the native form on the virion 
envelope following transport through the low pH environment of the Golgi apparatus 
(Roche et al., 2008; Yao et al., 2003).  Therefore, the pre- and post-fusion trimers of 
vesiculovirus G proteins are equally stable, unlike the metastable pre-fusion form of 
the class I and II glycoproteins (Yao et al., 2003).                
Furthermore, it has been demonstrated that VSV G protein is also involved in the late 
stages of the infectious cycle assembling 100 to 150 nm G protein microdomains in 
the plasma membrane of infected cells that act as sites of progeny particle assembly 
(Brown & Lyles, 2003).  VSV G protein also promotes budding, a characteristic 
residing in the extracellular membrane proximal stem of the protein (Robison & 
Whitt, 2000; Rolls et al., 1994).    
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1.3.5. Transport of viral nucleocapsids through the endocytic pathway         
VSV has been shown to hijack the endocytic pathway, enabling the transport of viral 
nucleocapsids within vesicles of multivesicular bodies to late endosomes (via 
microtubules) and following fusion of the RNP-containing vesicle with the 
membrane of the endosome, release into perinuclear regions of the cytoplasm (Le 
Blanc et al., 2005).  The cargo contained within internal vesicles of multivesicular 
bodies is usually destined for degradation in lysosomes and thus VSV has evolved a 
mechanism to facilitate nucleocapsid release into the cytoplasm (and hence initiate 
infection) prior to encountering any lysosomes.  The precise mechanism has yet to be 
elucidated, although results show that the process is dependent on the cellular factors 
late endosomal lipid lysobisphophatidic acid (LBPA), Alix, phosphatidylinositol-3-
phosphate and Snx16, which are required for membrane fusion within late 
endosomes (Le Blanc et al., 2005).                      
1.3.6. Replication complex proteins 
1.3.6.1. Nucleocapsid (N) protein 
In VSV the viral RNA lies in a positively charged groove within consecutive N 
protein monomers, encapsidating the genome and forming the template for RNA 
synthesis (Green & Luo, 2006).  N protein monomers associate with the 3’ end of the 
viral RNA upon recognition of specific sequences at the start of the leader RNA 
(Bhattacharya et al., 2006).  Subsequently, additional N proteins bind and this has 
been hypothesised to trigger a structural change in the N protein which reduces the 
template specificity of the protein and thus promotes further N polymerisation 
(Basak et al., 2007).  The N protein contains two domains which serve as docking 
sites for the P protein.  The monomeric form of N protein is retained when the P 
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protein binds at the N-terminal domain of N (by partially blocking the 
oligomerisation domain) whereas interaction of the P and N proteins in the 
nucleoprotein complex occurs at the C-terminal domain and leads to recruitment of 
the L polymerase (Mondal et al., 2012).                 
1.3.6.2. Phosphoprotein (P) 
The VSV P protein is indispensable for viral transcription.  It has a highly flexible 
structure comprised of 3 domains; an N-terminal portion which binds L and N 
proteins that are not attached to the RNA, a central oligomerisation domain and an 
N-RNA-binding domain at the C-terminus (Green & Luo, 2009). The modules are 
linked together by long flexible disordered regions, which are thought to be intrinsic 
in enabling the protein to carry out its functions.  Also, phosphorylation of the P 
protein at specific sites by casein kinase II has been postulated to regulate P activities 
(Chattopadhyay & Banerjee, 1987; Chattopadhyay & Raha, 1997).  P protein dimers 
simultaneously bind to the N-RNA and the L protein, bringing the RNA template 
into contact with and at the correct orientation with the catalytic subunit of the 
polymerase to facilitate RNA polymerisation.  Studies have shown that P protein 
homodimers engage with every 5 N protein monomers along the N-RNA and the 
dynamic nature of the P protein supports uninterrupted transcription or replication as 
the downstream P protein is able to reach the approaching polymerase complex as it 
travels along the template (Leyrat et al., 2012; Morin et al., 2012).   
The P protein also has a role as an N protein chaperone by blocking N aggregation, 
modulating the addition of N protein to genomic RNA and inhibiting the aberrant 
binding of N to host cell RNA (Majumdar et al., 2004).  Moreover, there is evidence 
which indicates that the phosphoprotein stimulates the transient dissociation of N 
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protein from the RNA within the polymerase complex and thus enable RNA 
synthesis (Leyrat et al., 2012).  Recently, another key function of the P protein has 
been demonstrated; inducing the L protein into a more compact conformation, which 
is required for triggering RNA synthesis (Rahmeh et al., 2012).  It has also been 
found to be crucial in the assembly of infectious VSV particles (Das & Pattnaik, 
2005).                     
Poly(C) binding protein (PCBP) 1 and 2 associate with VSV P protein to inhibit 
primary transcription (PCBP1) or both gene expression and replication (PCBP2) 
(Dinh et al., 2011).    
1.3.6.3. Large (L) protein 
The large (L) protein of non-segmented RNA viruses are multifunctional and the 
rhabdovirus L proteins have been described as containing 6 functional domains of 
greater amino acid conservation and highly variable intra domains (Poch et al., 
1990).  The positions of the 6 domains within the CHPV amino acid sequence are 
given in Figure 1.7.  The more distantly related L proteins of the Morbillivirus genus 
have 3 conserved domains separated by 2 highly variable hinge regions.  The 
insertion of the eGFP gene within hinge region 2 of the measles virus genome 
(corresponding to a region between blocks V and VI in rhabdoviruses) resulted in a 
functional virus with only slightly attenuated polymerase activity, suggestive of some 
conformational independence between the domains (Duprex et al., 2002).  A 
recombinant VSV in which the eGFP ORF was inserted at a comparable position in 
the genome exhibited a temperature sensitive phenotype (Ruedas & Perrault, 2009).   
The L protein of non-segmented negative stranded RNA viruses contains all the 
enzymatic activities for RNA polymerisation, capping and polyadenylation.  The 
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molecular interrelationship between the domains in the VSV L protein have also 
been established with conserved blocks I-IV arranged into a ring structure containing 
the RNA polymerase activity and a flexibly linked appendage of domains V and VI 
responsible for capping (polyribonucleotidyltransferase, PRNTase) and methylation 
(methyltransferase, MTase) respectively (Rahmeh et al., 2010).  The viral RNA is 
thought to pass through the ring of the L protein during polymerisation.  
     
 
 
Figure 1.7| Domain structure of the CHPV L protein 
The location of highly conserved domains I to VI within the L protein are given.  The amino 
acid positions within the L protein are indicated.  Domains I-IV form the core polymerase 
ring (purple) and V and VI are the viral polyribonucleotidyltransferase (PRNTase) and 
methyltransferase (MTase) respectively, together comprising the appendage (green).  
Essential motifs are also shown.    
 
 
Domain III was found to confer the RNA dependent RNA polymerase (RdRp) 
activity of the L protein and the GDN motif, which is highly conserved in the domain 
III of non-segmented negative sense (NNS) RNA viruses and related to other viral 
RdRps, was shown to be essential for RNA synthesis (Sleat & Banerjee, 1993).  An 
analogous region to another well conserved motif, designated the pre-A motif, 
located upstream of the GDN sequence within block III of NNS RNA viruses has 
been suggested to be involved in template engagement in the segmented negative 
sense RNA Phlebovirus  Rift Valley fever virus (Muller et al., 1994).  The 
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rhabdovirus L protein is a dynamic structure that undergoes substantial 
reorganisation of its functional domains upon P protein binding, bringing the 
appendage into closer proximity of the RNA polymerase ring (Rahmeh et al., 2010).  
It has been postulated that this arrangement is more conducive for transcription and 
thus these structural changes may serve to coordinate RNA synthesis and capping.  
Dimeric L-P protein complexes have also been observed (Rahmeh et al., 2010).  It 
has recently been shown that the L protein is capable of initiating RNA synthesis 
without both the N and P proteins but that the latter are needed in a modulatory 
capacity (Morin et al., 2012).   
The NNS RNA viruses have a unique capping mechanism provided by the viral 
PRNTase.  In contrast with the conventional capping enzymes of eukaryotes and 
DNA viruses, the VSV PRNTase (following the hydrolysis of GTP to GDP by the 
GTPase activity of the L protein) catalyses the transfer of newly synthesised 5’-
monophosphorylated mRNA with the conserved AACAG mRNA start sequence onto 
GDP (instead of GMP) to produce a GpppN cap via a covalent L-pRNA intermediate 
(Ogino & Banerjee, 2007; 2010).  The strikingly conserved histidine-arginine (HR) 
motif located within domain V of the VSV L protein (H1217, R1218 in CHPV and 
H1227, R1228 in VSV) was shown to be critical for this process with the active site 
histidine residue required to bind through a phosphoamide linkage to the viral RNA 
start sequence (Ogino et al., 2010).  An arginine residue positioned slightly upstream 
of the HR motif (R1211 in CHPV and R1221 in VSV) is also essential for 5’ cap 
addition in rhabdoviruses (Ogino et al., 2010).  The highly conserved GxxT(n)HR 
motif , which incorporates the upstream residues G1154 and T1157 in the VSV L 
protein and the HR sequence was also found to be essential for VSV capping (Li et 
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al., 2008), as well as for 3’ polyadenylation and the efficient transcription of 
downstream genes (Li et al., 2009).        
Following the addition of a 5’ cap to nascent viral mRNA, the VSV encoded MTase 
(containing the catalytic tetrad K-D-K-E at the C-terminus of L) methylates the 
structure by a unique mechanism distinct to that of eukaryotes and other viral 
MTases.  The VSV MTase catalyses modification of the ribose 2’-O position which 
in turn leads to methylation at guanine N-7 resulting in the generation of 
7mGpppNpmNp (Li et al., 2006; Rahmeh et al., 2009).  Both methylation activities 
utilise the same S-adenosyl-L-methionine-binding site (GxGxG motif) within 
domain VI (Rahmeh et al., 2009).     
Another role of the L protein is to polyadenylate the viral mRNA on recognition of 
the 3’-AUACUUUUUUU-5’ sequence, thus triggering the termination of mRNA 
synthesis (Rahmeh et al., 2009).  A protein kinase activity was also shown to reside 
within the VSV L protein (Banerjee, 1987).  The cellular protein heat shock protein 
(HSP) 90 is required to maintain L protein stability (Connor et al., 2007).           
1.3.7. Matrix (M) protein 
The rhabdovirus matrix (M) protein is multifunctional and this is achieved through 
multiple interactions with other virion and host cell proteins.  The crystal structure of 
a thermolysin cleaved VSV Indiana Orsay strain M protein has been described 
(Gaudier et al., 2002) and despite low amino acid sequence conservation among the 
vesiculoviruses (28% identity with CHPV) the protein structure and functions are 
thought to be highly similar (Taylor et al., 1999).  The M protein is an important 
structural constituent of mature rhabdovirus particles, being responsible for: 
condensing RNP complexes into coiled helices (Newcomb & Brown, 1981), linking 
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them to the phospholipid bilayer of the virion via a positively charged N-terminus 
containing eight lysine residues (Ogden et al., 1986; Rose & Gallione, 1981) and 
associating with the cytoplasmic portions of the G protein.   
Assembly of progeny particles and budding out of host cells are both directed by the 
M protein, and a flexible structure between the membrane binding domain and the 
rest of the protein, which is also present in other negative sense RNA viruses and the 
Gag protein in retroviruses, is essential for these processes (Gaudier et al., 2002).  
The M protein interacts with, and recruits, RNP complexes to the membrane for 
assembly and induces the budding of mature virus particles.  The latter has been 
shown to be facilitated through the association of host cell proteins with two late 
domains (PPXY and P(S/T)AP) in the flexible N-terminal structure of the VSV M 
protein (Raux et al., 2010).  The PPXY amino acid sequence binds the WW domain 
of the cellular proteins NEDD4 E3 ubiquitin ligases, which interact with cellular 
endosomal sorting complexes required for transport (ESCRT) complexes involved in 
vesicle biogenesis (Harty et al., 1999).  The second late domain of the M protein, 
containing the P(S/T)AP motif has been found to interact with the ESCRT 
constituent TSG1O1 (Raux et al., 2010).  Mutations in the late domains of VSV M 
protein disable release of fully-formed progeny particles and result in their 
accumulation at the plasma membrane (Jayakar et al., 2000).  The N-terminus of 
VSV M protein also binds dynamin 1 and 2 at the pleckstrin homology (PH) domain, 
an interaction which interferes with clathrin-mediated endocytosis and has been 
shown to be essential for efficient progeny virus egress (Raux et al., 2010).                                               
Another important role of vesiculovirus M proteins is the induction of a number of 
cytopathic effects including inhibiting host transcription, nuclear-cytoplasmic 
transport and translation.  Induction of apoptosis via the mitochondrial pathway also 
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occurs due to the depression of host cell gene expression (Gaddy & Lyles, 2005).  
Inhibition of host cell transcription has been demonstrated for VSV with cellular 
RNA polymerases I, II and III (Ahmed & Lyles, 1998; Black & Lyles, 1992) and 
CHPV with RNA polymerase II (Taylor et al., 1999).  This is thought to be 
facilitated by the M protein entering the nucleus and the VSV M protein has been 
identified in the nucleus (Lyles et al., 1988).  The mechanism for inhibition has yet 
to be fully worked out, however there is some data to suggest the M protein impairs 
the activity of TATA-binding protein (TBP) (Ahmed & Lyles, 1998).  M protein 
inhibits the nuclear-cytoplasmic trafficking of host cell macromolecules in a Ran-
TC4 GTPase-dependent manner (Her et al., 1997) by directly binding to the cellular 
export factor RaeI, which targets the nucleoporin Nup98 (Rajani et al., 2012; von 
Kobbe et al., 2000).  However, many other host cell proteins are thought to play a 
role in this process (Rajani et al., 2012).  The M protein of CHPV blocks nuclear 
transport by the greatest extent compared to other host cell proteins (Petersen et al., 
2001).  Moreover, VSV M specifically impairs host translation by altering the 
phosphorylation state of eIF2α and the eIF4F complex in addition to the decrease of 
host polypeptides attributed to the reduction in host mRNA as a consequence of 
virus-mediated depressed transcription (Connor & Lyles, 2002).  There is evidence to 
suggest that the M protein is involved in modulating translation in this way but that 
another viral protein is primarily responsible (Connor & Lyles, 2002).   
One study has found the 37PSAP40 motif in the M protein of VSV to be an important 
determinant of species specific pathogenicity.  Recombinant viruses in which the 
motif was changed to four alanines exhibited significantly reduced pathogenicity in 
mice but enhanced cytopathogenicity in insect C6/36 cells, indicating a role for the 
PSAP sequence in persistence (Irie et al., 2012).  The VSV M protein has also been 
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shown to supress host antiviral responses by downregulating interferon β gene 
expression (Ahmed et al., 2003) and depressing the natural killer T (NKT) cell 
response. The latter is achieved by inhibiting CD1d antigen presentation to NKT 
cells through p38 mitogen-activated protein kinase (MAPK) activation 
(Renukaradhya et al., 2008).   VSV M protein stimulates cell rounding (Blondel et 
al., 1990) through an interaction with tubulin (Melki et al., 1994), an association 
which has been demonstrated to be essential for virus transcription (Moyer et al., 
1986).    
1.3.8. Leader RNA 
The major function established for the leader RNA is in containing the sequence 
required to initiate encapsidation of template RNA by the N protein (Bhattacharya et 
al., 2006).  It has been postulated that the leader RNA is also present in the nucleus 
of infected cells where it associates with the cellular protein La to modulate 
transcription by RNA polymerase III (Kurilla & Keene, 1983).  An interaction 
between VSV-leader RNA and hnRNPU proteins in the nucleus has also been 
demonstrated, indicating a further role for this transcript in regulating cellular DNA 
synthesis (Gupta et al., 1998a).    
 
1.4. Host range (hr) and temperature-dependent host range (tdCE) 
mutants  
Viruses are obligate intracellular parasites with host cell factors intrinsic to their 
lifecycles.  These host factors can therefore determine the outcome of an infection in 
a cell.  Essential host factors for CHPV are largely unknown.  Section 1.3 and Table 
1.3 gives details of host cell proteins involved in VSV replication.  The critical 
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involvement of host factors in the replication of vesiculoviruses was highlighted by 
the isolation of VSV Indiana, VSV New Jersey and CHPV temperature-dependent 
host range (tdCE) mutants by mutagenesis using 50-200 µg/ml 5-fluorouracil 
(Gadkari & Pringle, 1980; Pringle, 1978; Rasool & Pringle, 1986).  These mutants 
are characterised by their ability to grow at both 31ºC (the permissive temperature) 
and the restrictive temperature of 39ºC in BSC-1 or BHK-21 cells (the permissive 
host) to comparable titres to wild-type virus yet display temperature sensitivity in 
primary avian cells (chick embryonic fibroblasts, CE).  The tdCE mutant phenotype 
has been defined as viruses with an efficiency of plating (E.O.P.) in BSC-1 cells of 
<0.7 and in CE cells of >2, where E.O.P. is calculated as log10 PFU
39ºC 
subtracted 
from log10 PFU
31ºC
.  These E.O.P. values were selected arbitrarily to reflect 
significant growth impairment in CE cells compared to BSC-1 cells.  This phenotype 
demonstrates a dependence of these vesiculoviruses on undetermined host factors 
(Gadkari & Pringle, 1980; Rasool & Pringle, 1986).  All the CHPV tdCE mutants 
isolated and a summary of important characteristics are given in Table 1.4.          
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Mutant Additional host restriction(s) Efficiency of plating Transcriptase efficiency at 
39°C determined by the 
plateau method (%of wt) 
(Rasool and Pringle, 1986) 
Transcriptase efficiency at 39°C 
determined by the initial rate 
method (%of wt) 
(Rasool and Pringle, 1986) 
BSC-1 CE 
CH4
2
 ND 0.67 3.18 15 48 
CH63
2
 (re-cloned from CH859)
 
 ND 0.36 2.09 28 53 
CH72
2
 (re-cloned from CH565) ND 0.08 2.60 72 93 
CH90
2
 (re-cloned from CH530) ND 0.09 2.15 110 109 
CH112
2
 (re-cloned from CH514) ND 0.57 5.20 14 51 
CH151
2
 ND 0.00 2.91 11 41 
CH157
2
 ND 0.54 3.54 56 67 
CH194
2
 ND 0.12 3.45 91 113 
CH245
2
 ND 0.04 3.77 70 85 
CH256
2
 ND 0.15 4.37 37 29 
CH354
2
 ND 0.00 3.30 83 62 
CH380
2
 ND 0.06 3.05 23 40 
CH514
1
  None 0.40 3.18 X X 
CH516
1 
None 0.70 3.70 X X 
CH525
1 
None 0.78 5.00 X X 
CH530
1
  HE, RE, FEA, BEK, NIH/3T3, 
L929 
1.18 5.00 X X 
CH565
1
  BEK 1.18 3.00 X X 
CH859
1
  RE, BEK, NIH/3T3, L929 0.60 3.18 X X 
Table 1.4| Characteristics of CHPV tdCE mutants  
1
Denotes mutants isolated by Gadkari and Pringle (1980) and 
2 
isolated by Rasool and Pringle (1986).  Mutants highlighted in blue have been selected to 
analyse the tdCE phenotype in this study.  Impaired growth at the restrictive temperature in chick embryo (CE), hamster embryo (HE), rat embryo (RE), feline 
embryo (FEA), bovine embryo kidney (BEK), mouse embryo (NIH/3T3), mouse (L929) cells are noted for several of the mutants.  ND denotes not 
determined.       
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Two out of four of the VSV New Jersey tdCE mutants studied synthesised RNA to 
comparable levels as the wild type virus at 31°C and 39°C whereas the RNA 
transcriptases of the remaining mutants were shown to be severely disabled at the 
restrictive temperature in BHK-21 and CE cells in in vitro transcription assays 
(Szilagyi & Pringle, 1975).  Experiments in which transcribing nucleoprotein 
complexes (TNP) of the wild type and mutant viruses were dissociated and then 
reconstituted in various combinations suggested that the L protein contained the host 
range lesion (Szilagyi et al., 1977).  It was postulated that a host cell factor is 
required to counteract the thermoliability of the viral polymerase in tdCE mutants 
found to have depressed RNA transcriptase activity whereas mutants displaying 
normal RNA synthesis have a defect at a different (later) stage in the viral life cycle 
(Szilagyi & Pringle, 1975).          
   
Mutants that were unable to grow in CE and bovine kidney (MDBK) cells at any 
temperature, designated host restricted (hrCE) mutants, were also isolated from VSV 
New Jersey but not VSV Indiana or CHPV (Pringle, 1978; Rasool & Pringle, 1986).  
These mutants have provided a powerful tool for dissecting vesiculovirus replication.  
For hrCE and tdCE mutants of VSV, increasing the incubation temperature from 
31°C to 39°C after two hours post-inoculation was shown to have limited effect on 
VSV viral titre, whereas raising the temperature at an earlier time point severely 
disrupted virus replication, implying host restriction occurs at an early stage in viral 
replication (Pringle, 1978).  However, involvement of the attachment protein was 
discounted when pseudotyped virions expressing the G protein from the tdCE or 
hrCE VSV mutants grew to titres comparable with the wild type virus in CE cells.  
Together, these results added weight to the hypothesis that the host range phenotype 
36 
 
is caused by a genetic lesion in the virus polymerase which affects its association 
with host factor(s) that are not present in CE cells and are required to hold the 
polymerase in an active conformation at 39°C (Pringle, 1978). 
 
As well as differences in mRNA synthesis, mutants also differed in their host 
restriction (Pringle, 1978).  This is thought to highlight their unique characteristics 
and is suggestive of a range of mutational events and the involvement of more than 
one host cell factor.  CHPV mutants with additional host cell restrictions are detailed 
in Table 1.4.  A study of VSV tdCE mutants found no link between certain cell types 
and properties, for example morphology, and conditional growth mutants, except that 
embryonic cells appeared to be more conducive to temperature-sensitivity and 
restrictiveness of murine embryonal carcinoma cells decreased after differentiation 
(Pringle, 1978).                        
 
Upon further investigation, the tdCE mutants of VSV and CHPV were shown to have 
important intrinsic differences regarding the in vitro heat sensitivity of their viral 
RNA transcriptase.  Reduced RNA transcriptase activity in vitro at 39ºC resulting in 
significantly lower amounts of viral RNA synthesised was observed in 10 out of 12 
of CHPV tdCE mutants compared to wild-type virus and a gradient of this activity 
ranging from 11% of the wild-type to greater than wild-type were determined across 
the mutants studied (Rasool & Pringle, 1986).  This is in contrast with the severe 
impairment or wild type level RNA synthesis reported in the case of VSV tdCE 
mutants.  Moreover, viral protein synthesis was also found to be either considerably 
depressed or non-existent in all the transcriptionally deficient CHPV tdCE mutants 
grown in CE cells at the restrictive temperature, leading to the postulation that the 
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growth restriction is caused by diminished RNA synthesis which in turn results in 
decreased production of viral polypeptides (Rasool & Pringle, 1986).  In support of 
this, intracellular viral protein synthesis increased to wild-type levels when tdCE 
mutants reverted to a non-temperature sensitive phenotype (Rasool & Pringle, 1986).  
Furthermore, in vitro RNA methylation activity of the virus RNA dependent RNA 
polymerase and heat shock protein induction were found to occur at similar levels as 
the wild type virus in all tdCE mutants (Rasool & Pringle, 1986).        
 
VSV Indiana dual ts/hr mutants have also been isolated (Simpson & Obijeski, 1974).  
These mutants are restricted in many human cell lines including Hep-2 and display 
temperature sensitivity in CE and BHK cells.  One of these mutants, hr1 contains a 
D1671V amino acid substitution in the MTase domain VI of the VSV L protein 
(within a predicted S-adenosyl-L-methionine-binding motif) rendering the mutant 
completely incapable of catalysing the methylation of 5’ mRNA caps at both 
guanine-N7 and 2’-O-adenosine (Grdzelishvili et al., 2005; 2006; Hercyk et al., 
1988; Horikami & Moyer, 1982).  In contrast to hr1 mutant hr8 retained low levels 
of MTase activity at 2’-O-adenosine (but not at the guanine-N7 position).  This 
phenotype was shown to be the consequence of a G1481R amino acid substitution 
located between domains V and VI in the L protein in a region of 31 amino acids 
subsequently identified as essential for VSV MTase activities (Grdzelishvili et al., 
2006).   
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1.5. Vesiculovirus disease: infection of the central nervous system 
CHPV has been associated with central nervous system (CNS) disease in several 
outbreaks in India.  There are over 100 neurotropic viruses, capable of infecting the 
CNS and giving rise to neurological disease.  The most frequent clinical 
manifestations of such infections are viral meningitis and viral encephalitis, caused 
by inflammation of the meninges and brain parenchyma, respectively.  The key 
characteristic clinical symptoms of acute viral encephalitis are fever, headache and 
altered sensorium (Whitley & Gnann, 2002), although the precise range of symptoms 
experienced depends on the regions of the brain that are affected.  Areas of 
hyperintensity (a consequence of cerebral edema) and foci of intercerebral 
haemorrhage are often observed in the brains of patients with viral encephalitis using 
Magnetic Resonance Imaging (MRI).  Determining the specific regions of the brain 
affected by inflammation is often important in deducing the aetiological agent 
because some viruses have predilections for certain parts of the brain.  For example, 
abnormalities in the medial temporal lobes are suggestive of herpes simplex virus-
induced encephalitis (Solomon et al., 2012).  Viral encephalitis results in tissue 
necrosis, necrotising vasculitis, eosinophilic inclusions within glial cells and neurons 
and perivascular infiltration of lymphocytes, which can be observed by microscopy.  
Viral encephalitis is potentially life-threatening as severe cerebral edema places 
pressure on the brainstem, which controls heartbeat and respiration.                        
1.5.1. Causative agents of viral encephalitis 
Viral infections are responsible for the majority of encephalitis cases, with a global 
incidence of 7.4 per 100,000 people per year, although developing countries have a 
disproportionately higher disease burden (Griffin, 2010).  Table 1.5 lists the viruses 
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known to cause CNS disease.  Some of these viruses are ubiquitous in the global 
population but rarely cause neurological disease, such as the herpes simplex viruses 
which are the most common sporadic cause of viral encephalitis.  Other viruses 
rarely infect humans but when infection does occur it always manifests with CNS 
involvement, for example rabies virus (Whitley & Gnann, 2002).  
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Class Virus family Virus 
1 (double stranded DNA) Herpesviridae  Herpes simplex virus 
Varicella-zoster virus 
Cytomegalovirus 
Epstein-Barr virus 
Human herpesvirus 6 
B virus 
Adenoviridae  Adenovirus 
Polyomaviridae JC virus 
III (double stranded RNA) Reoviridae Colorado tick fever virus 
IV (positive sense single 
stranded RNA) 
Picornaviridae  Echovirus 
Coxsackievirus 
Poliovirus 
Enterovirus 
Togaviridae Eastern equine encephalitis virus 
Western equine encephalitis virus 
Venezuelan equine encephalitis virus 
Rubella virus 
Flaviviridae  St. Louis encephalitis virus 
Japanese encephalitis virus 
Murray valley encephalitis 
Ilheus virus 
Rocio virus 
Tick-borne encephalitis virus 
Far eastern 
Central European  
Kyasanur forest 
Louping ill virus 
Negishi 
West Nile virus 
Dengue virus 
Powassan virus 
V (negative sense single 
stranded RNA) 
Arenaviridae Lymphocytic choriomeningitis virus 
Orthomyxoviridae Influenza virus 
Paramyxoviridae Measles virus 
Mumps virus 
Nipah virus 
Bunyaviridae Californian encephalitis virus 
La Crosse virus 
Jamestown Canyon virus 
Snowshoe hare virus 
Tahyna virus 
Inkoo virus 
Rift valley virus 
Rhabdoviridae Rabies virus 
Chandipura virus 
VI  Retroviridae Human immunodeficiency virus type I 
 
 Table 1.5| Viruses known to cause CNS disease 
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Many important viral encephalitides are arboviruses and these are therefore restricted 
to the geographical range of their vectors.  Arboviruses that cause encephalitis are 
shown in Table 1.6.  Recently, there has been a concern about the increased spread of 
viruses associated with CNS infections, many of which are arboviruses, and this 
poses a significant public health threat.  Japanese encephalitis virus (JEV), 
transmitted by Culex mosquitoes, is responsible for the largest number of cases of 
arthropod-borne viral encephalitis per year with approximately 50,000 cases (mainly 
children) and 15,000 deaths annually (Solomon et al., 2003).  JE emerged in Japan in 
the 1870s, with the virus first isolated in Japan in 1935, and has since spread 
throughout Asia and Northern Australia (Misra & Kalita, 2010).  The geographical 
range of the closely related flavivirus West Nile virus (WNV) considerably expanded 
from Africa and the Middle East into Southern Europe in 1996 and the East coast of 
the USA in 1999 (Whitley & Gnann, 2002) with enhanced avian virulence, 
neuroinvasiveness in humans and epidemic potential (Gubler, 2007). The virus has 
become established in the Americas, spreading westwards in the USA from 1999 to 
2004 and then reached countries in Central and Southern America in 2003 and 2004 
respectively (Gubler, 2007).    
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Virus family Virus Vector Geographical 
location 
Reoviridae Colorado tick fever 
virus 
Ticks (Dermacentor) Rocky mountain, 
USA 
Togaviridae Eastern equine 
encephalitis virus 
Mosquitos (Culiseta, 
Aedes) 
Eastern and gulf 
coasts of USA, 
Caribbean, South 
America  
Western equine 
encephalitis virus 
Mosquitos (Culiseta, 
Culex) 
Western USA, 
Canada 
Venezuelan equine 
encephalitis virus 
Mosquitos (Aedes, 
Culex and others) 
South and Central 
America, Florida, 
Southwest USA 
Flaviviridae 
  West Nile complex 
St Louis encephalitis 
virus 
Mosquitoes (Culex) USA 
Japanese encephalitis 
virus 
Mosquitoes (Culex) Japan, China, SE 
Asia, India 
Murray valley 
encephalitis virus 
Mosquitoes (Culex) Australia, New 
Guinea 
West Nile virus Mosquitoes (Culex) USA, Africa, 
Europe, Middle East, 
Asia 
Ilheus virus Mosquitoes 
(Psorophora) 
South and Central 
America 
Rocio virus Mosquitoes (?) Brazil 
  Tick-borne 
complex 
Far Eastern virus Ticks (Ixodes) Eastern Russia 
Central European 
virus 
Ticks (Ixodes) Central Europe 
Kyassanur Forest 
virus 
Ticks 
(Haemophysalis) 
India 
Louping-ill virus Ticks (Ixodes) England, Scotland, 
N. Ireland 
Powassan virus Ticks (Ixodes) Canada, N. USA 
Negishi virus Ticks (?) Japan 
Bunyaviridae Californian 
encephalitis virus 
Mosquitoes (Aedes) W. USA 
La Crosse virus Mosquitoes (Aedes) C. and E. USA 
Jamestown Canyon 
virus 
Mosquitoes 
(Culiseta) 
USA, Alaska 
Snowshoe Hare virus Mosquitoes 
(Culiseta) 
Canada, Alaska, N. 
USA 
Tahyna virus Mosquitoes (Aedes, 
Culiseta) 
E. Europe 
Inkoo virus Mosquitoes (?) Finland 
Rift Valley virus Mosquitoes (Culex, 
Aedes) 
E. Africa 
Rhabdoviridae Chandipura virus Sand flies 
(Phlebotomus) 
India, W. Africa 
 
Table 1.6| Arboviruses that cause encephalitis  
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1.5.2. Viral encephalitis in India 
India has a high incidence of viral encephalitis and, as in the rest of Asia, the 
majority of cases were historically attributed to JEV.  However a recent analysis of 
outbreak and surveillance studies indicated a possible shift in the aetiology of viral 
encephalitis in India with Chandipura virus (CHPV) and enteroviruses accounting for 
the largest proportion of outbreaks after 2000, whereas JEV was identified as the 
major agent of acute viral encephalitis from 1975 to 1999 (Joshi et al., 2012).  
Possible explanations for this alteration in incidence include the high coverage JEV 
vaccination programme in endemic regions of India allowing the detection of non-
JEV causes of acute viral encephalitis with considerably lower incidences and the 
expansion of diagnostic testing for other causes (Joshi et al., 2012).  Highlighting 
this, there were a number of outbreaks of unconfirmed aetiology that produced 
encephalitic symptoms between 1954 and 2002 in India in which chikungunya virus, 
JEV, dengue virus, measles and Reye’s syndrome have been tentatively implicated 
(Rao et al., 2004).  These encephalitis outbreaks had clinically identical symptoms to 
the human epidemics of CHPV encephalitis identified from 2003 onwards and 
therefore may have also been caused by CHPV (Rao et al., 2004).   
There is a temporal difference between CHPV and JEV activity in India, with the 
majority of CHPV encephalitis cases occurring in late summer and the early 
monsoon season (June to August) while outbreaks of JEV typically occur late in the 
monsoon season (from mid-September) (Tandale et al., 2008).        
1.5.3. Human epidemics of Chandipura virus encephalitis 
CHPV was first isolated in 1965 from two adults presenting with febrile illness in 
Nagpur district, Maharashtra state, India during screening for dengue and 
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chickungunya viruses (Bhatt & Rodrigues, 1967) and was later isolated from a 
patient suffering from encephalopathy syndrome in Madhya Pradesh in 1980 
(Rodrigues et al., 1983).  Following these initial isolations there were no further 
confirmed human cases of CHPV infections until epidemics of acute encephalitis in 
children occurred in Andhra Pradesh and Maharashtra in 2003, Gujarat state in 2004 
and Maharashtra in 2005 and 2007 (Chadha et al., 2005; Gurav et al., 2010; Tandale 
et al., 2008).  Thus, from 1965 until now the virus has been detected in four 
adjoining, predominantly rural, central Indian states: Madhya Pradesh, Andhra 
Pradesh, Maharashtra and Gujarat.  The locations of the outbreaks are shown in 
Figure 1.8.  The epidemic case fatality rates were high: 41% in Maharashtra in 2003, 
55.6% (183 out of 329 cases) in Andhra Pradesh in 2003, 78.3% (18 out of 23 cases) 
in Gujarat in 2004 and 44% (34 out of 78 cases) in Maharashtra in 2007 (Chadha et 
al., 2005; Gurav et al., 2010), giving an average of 54.8%.  Additionally, a hospital 
surveillance study carried out in Telangana district in Andhra Pradesh reported 90 
cases of encephalitis from May 2005 to April 2006 with a case fatality rate of 54% 
(49 out of 90 cases) (Tandale et al., 2008).  In 52 of these cases of acute viral 
encephalitis, CHPV aetiology was confirmed in 25 (by either viral RNA isolation or 
presence of IgM antibodies against CHPV), JEV aetiology in 5 cases and 22 cases of 
unknown aetiology (Tandale et al., 2008).                   
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Figure 1.8| Geographical distribution of CHPV 
Human epidemics have occurred in India and the virus has also been isolated from a pygmy 
hedgehog in Nigeria and from Phlebotomus sandflies in Senegal.  The year of each human 
epidemic and case fatality rate in percentage with the actual values is shown in brackets.  
There are no figures available for the 2003 Maharashtra outbreak.    
 
The true case fatality rates are likely to have been considerably lower as the figures 
only include hospital admissions.  Added to this, serological studies have shown the 
virus is widespread in India with 94% (adult non-contacts) to 97% (adult contacts) 
seropositivity in Andhra Pradesh during 2005 and 2006 (Tandale et al., 2008).  The 
same surveillance study also reported a lower anti-CHPV N antibody seroprevalence 
in children (70.6% of child non-contacts 73.3% of contacts), indicative of an 
endemic infection.  Isolation of anti-CHPV IgM antibodies from patients with fever 
but without CNS involvement and family contacts of a CHPV-confirmed case 
provided evidence of a disease continuum where infection with CHPV does not 
always result in the most severe manifestation of encephalitis but instead produces 
mild febrile symptoms or is asymptomatic (Rao et al., 2004).  Moreover, during all 
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of the documented outbreaks encephalitis only occurred in children (Chadha et al., 
2005; Rao et al., 2004). 
There is a great degree of variation in the quality of available data about the Indian 
CHPV outbreaks and those for which clear data are available are shown in Table 1.7.  
The documented clinical manifestations are consistent between the epidemics with 
all patients studied reporting a fever of rapid onset, which was of less than three days 
duration on admittance to hospital in 85% of patients in the 2007 outbreak in 
Maharashtra state (Gurav et al., 2010).  In contrast with JEV, a large proportion of 
patients also reported additional symptoms of vomiting and abdominal cramps (Van 
Ranst, 2004).  The majority of CHPV patients experienced convulsions, altered 
sensorium and diarrhoea.  No neurological sequelae was reported by survivors of any 
of the CHPV outbreaks (Chadha et al., 2005). 
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   2003  Andhra Pradesh  2003 Maharashtra 
(Nagpur division) 
2004 Gujarat (Vadodara 
and Panchmahal) 
 
2005- 2006 
Andhra Pradesh 
Mahatma Gandhi 
Memorial (MGM) 
Hospital, 
Warangal, north Telangana 
2007 Maharashtra 
(Nagpur division) 
Months June to September  9
th
 June to 14
th
 July May 2005 to April 2006 June to September 
Case fatality rate  55.6% (183/329) 41% 33 cases 78.3% (18/23) 54.4% (49/90) 43.6% (34/78) 
Confirmed cases 
(presence of virus, viral 
RNA, IgM antibodies) 
50.9% (28 out of 55 
cases investigated) 
 55% (11 out of 19 cases 
investigated) 
48.1% (25 out of 52 cases 
investigated) 
50% (39 out of 78 cases 
investigated) 
Ages of cases 9 months to 14 years  2-16 years (mean age 6.03 
years) 
9 months-13 years  
Male to female ratio 1: 0.77  1: 1 
 
1: 2 1:1.2 
Reported symptoms Fever (100%), vomiting 
(54%), altered sensorium 
(89%), convulsions 
(82%), diarrhoea (18%), 
neurological defect 
(14%), meningeal 
irritation (7%) 
 Fever (100%), altered 
sensorium (100%), 
convulsions (89%), vomiting 
(68%) diarrhoea (53%), 
chills preceding fever in 
(16%), cough (16%)    
(details for 19 patients) 
Acute onset fever (94%), 
altered consciousness 
(90%), convulsions (78%), 
vomiting (44%), diarrhoea 
(16%) 
Fever (100%), 
convulsions (76%), 
altered sensorium (34%), 
headache (24%), 
vomiting (45%), 
diarrhoea (24%) 
(details for 38 patients) 
% deaths within 24 
hours of hospitalisation 
  72.2%  60% 
% deaths within 48 
hours of hospitalisation 
   76%   
% identity to the 1965 
strain 
97% identical to 1965 
strain 
    
Detected in sandflies Yes, detected in a pool of 
sandflies in the house of 
a patient during the 
outbreak 
 No, tested 27 female and 54 
male Sergentomyia sandflies 
between July 9 and 11 2004 
from peridomestic habitats 
 In one of 2 pools of 
sandflies collected 
locally 
Table 1.7| Summary of CHPV outbreaks 
Key details of the Indian epidemics, including patient information (age, gender), clinical symptoms, case fatality rates, percentage of confirmed cases.  Isolations of the virus 
from phlebotomine sand flies, the putative vector of CHPV are also given.  The table is incomplete due to the variation in the data available for each outbreak.          
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There has been debate in the literature as to whether CHPV was directly responsible 
for the Indian epidemics of acute encephalitis (John, 2010).  Some researchers have 
argued that a causal relationship has not been fully established, primarily due to the 
inability to detect the presence of the virus, viral RNA or IgM antibodies in 50% of 
probable cases.  This has led to suggestions that CHPV is a passenger virus which 
despite being almost ubiquitous in the Indian population has no role in disease 
(Potharaju & Potharaju, 2006).        
1.5.4. Human clinical studies of CHPV infection 
The documented neurological manifestations of CHPV infection in humans includes 
abnormal plantar and deep tendon reflexes, slow pupillary reflexes, hypotonia (low 
muscle tone), hypertonia (increased rigidity of muscles), hemiparesis, facial nerve 
palsy and generalised convulsions (Chadha et al., 2005; Gurav et al., 2010; Rao et 
al., 2004; Tandale et al., 2008).  However, neurological sequelae in survivors were 
uncommon.  CSF analyses (colour, opening pressure, cell count, protein, glucose 
levels) were within the normal range in the majority of cases, although a clinical 
investigation of the 2005-2006 Andhra Pradesh outbreak reported increased 
intracranial pressure in 25% (13 out of 52) of patients (Tandale et al., 2008).  Diffuse 
edema of the brain parenchyma was observed by computerised tomography (CT) in 
15% (8 out of 52) of cases during the 2005-2006 Andhra Pradesh epidemic (Tandale 
et al., 2008).                          
1.5.5 Non-human isolations of CHPV 
The only known natural route of transmission of CHPV is by female phlebotomine 
sand flies (Mavale et al., 2007; Rao et al., 2004) as is the situation for the majority of 
vesiculoviruses.  However, transmission by Aedes aegypti mosquitos has also been 
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demonstrated in the laboratory (Mavale et al., 2005).  The virus has been isolated 
from pools of phlebotomine sandflies during the 2003 and 2007 (Gurav et al., 2010) 
Indian epidemics, although the species of sandfly were unidentified.  One study 
detected the virus in sandflies of the genus Sergentomyia which were collected in 
Andhra Pradesh following the 2005 outbreak (Geevarghese et al., 2005).  In the 
laboratory, vertical and venereal transmission of the virus by Phlebotomus papatasi 
(Mavale et al., 2006; Tesh & Modi, 1983) and transmission by bite by P. argentipes 
(Mavale et al., 2007), the predominant species in CHPV endemic areas, has also 
been demonstrated.   No human to human transmission has been documented.  Most 
of the human epidemics occurred during the monsoon period (July to December) 
when sandflies are present in their largest numbers (Rao et al., 2004).  CHPV 
seropositive animals have been detected in large parts of India demonstrating the 
widespread presence of CHPV infection (Jortner et al., 1973) and also in domestic 
animals during the 2003 Indian epidemic (Joshi et al., 2005).            
CHPV has also been isolated in West Africa: from a pygmy hedgehog in northern 
Nigeria (Fontenille et al., 1994) and from Phlebotomus sandflies in Senegal (Traore-
Lamizana et al., 2001), indicating the virus may be widespread in tropical regions 
(Figure 1.8).  Low seroprevalence of CHPV antibodies in the torque macaque 
population in Sri Lanka has also been demonstrated (1.74%, 2 out of 115 tested)  
(Peiris et al., 1993).   
1.6. Experimental CHPV infection and disease 
1.6.1. CHPV infection in cultured cells 
As with VSV, CHPV has a wide host range and can replicate in avian, mammalian 
and insect cells in culture, although the cytopathic effects (CPE) seen following 
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infection differ markedly.  The virus is highly cytopathic within a few hours in 
mammalian and CE cells and establishes a persistent infection with no CPE in insect 
cell lines despite the insect cells being highly susceptible to infection (Jadi et al., 
2010).  Interestingly the recently characterised rhabdovirus Niakha virus, which is 
postulated to be transmitted by phlebotomine sandflies, produces CPE in mammalian 
cells and in the mosquito cell line C6/36 (Aedes albopictus) but not in sandfly PP-9 
(Phlebotomus papatasi) cells (Vasilakis et al., 2013a).             
1.6.2. Mouse model of CHPV pathogenesis 
Mice are susceptible to CHPV infection and inoculation into the brain results in fatal 
encephalitis (Rao et al.,2004).  The virus has also been shown to cross the blood 
brain barrier to infect the CNS (after intraperitoneal or intravenous administration) 
resulting in a dose-dependent encephalitis (preceded by viremia) in young mice but 
not in adults (Balakrishan and Mishra, 2008).  In adult mice infection leading to 
encephalitis is only achieved by direct intracranial inoculation into the brain (Sokhei 
& Obukhova, 1984), though a single report suggested that intranasal inoculation in 
adult mice may lead to infection and seroconversion.  The mechanism of age-
dependent susceptibility of CHPV-induced encephalitis has not been characterised, 
however, important contributory factors are likely to include an immature host 
immune response and immature nervous system in young mice (Balakrishnan & 
Mishra, 2008).  A range of other neurotropic viruses have also been shown to 
produce age-related CNS disease including Japanese Encephalitis (JE), Yellow fever, 
St Louis Encephalitis, West Nile, Sindbis, measles, Semliki Forest and Herpes 
viruses (Oliver & Fazakerley, 1998).   
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Young mice infected with CHPV display a progressive paralysis prior to death.  The 
first signs of encephalitis are uncoordinated movements and unilateral paralysis of 
the hind limb nearest the injection site at approximately three days post infection.  
Paralysis progresses rapidly: bilateral hind limb paralysis occurring 3-4 days after 
infection, forelimb paralysis at about day 4-5 after which the mice succumb to 
infection, although the precise timings are both strain- and dose-dependent (Jortner et 
al., 1973).   
In young mice inoculated with CHPV intraperitoneally, virus was detected in the 
blood, skeletal muscle, liver, lung, spleen and subsequently at high titres in the brain 
(Jortner et al., 1973).  These findings suggest that peripheral infection of CHPV in 
young mice produces plasma viraemia allowing the virus to be disseminated 
throughout the body via haematogenous spread.  Also the higher brain viral titres 
indicate that the virus has a predilection for replication in the CNS or that virus is 
removed from the blood and other tissues due to the rapid production of anti-CHPV 
IgM antibodies (Balakrishnan & Mishra, 2008).  A recent study detected rising levels 
of CHPV RNA in nervous tissue progressively further away from the site of 
inoculation during the course of infection, following inoculation of the virus into a 
hind footpad of suckling mice (Anukumar et al., 2013).  This indicates that CHPV 
may also disseminate to the brain by axonal transport following infection of 
peripheral nerves.                 
Pathology associated with CHPV infection is mainly restricted to the CNS with 
marked necrotic lesions in the cerebellum, hippocampus, olfactory bulb and spinal 
cord grey matter (Jortner et al., 1973).  Necrosis was not detected in the other tissues 
that were shown to contain virus (lungs, liver, spleen, skeletal muscle).  Apoptotic 
cells, as determined by TUNEL staining, have been observed in the brains of young 
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mice 24 hours after intraperitoneal inoculation of the virus (Anukumar et al., 2013).  
In addition, CHPV-infected neuronal cells were shown to undergo apoptosis via the 
Fas-dependent extrinsic apoptotic pathway (Ghosh et al., 2013).         
There is a small but growing literature on the immunology of CHPV infection.  The 
innate immune response was shown to be intrinsic in infection outcomes.  
Experimentally infected mice had upregulated levels of proinflammatory cytokines 
and children who survived an infection with CHPV produced high levels of TNF-α 
(Balakrishnan & Mishra, 2008).  Significantly fewer CD4, CD8 and CD19 positive 
cells were also present in infected mice (Balakrishnan & Mishra, 2008).  Moreover, a 
role for Toll-like receptor 4 (TLR4) in CHPV pathogenesis was established.  TLR4-
mutant mice secreted significantly elevated levels of the cytokines MCP-1 and IFN-γ 
and had improved survival rates compared with the control mice which expressed 
wild type TLR4 (Anukumar & Shahir, 2012). 
1.7. Aims 
The aim of this project was to investigate the factors involved in CHPV host range.  
This had two principle objectives: to characterise the host range tdCE phenotype of 
CHPV and to investigate the neuropathogenesis of the virus.  The first objective 
involved determining the underlying molecular basis of host range specificity of 
three tdCE mutants of CHPV.  The effects of the specific mutations shown to affect 
host range on the formation of virus replication complexes in permissive and non-
permissive cells were explored.   
The second objective to investigate CHPV CNS disease involved establishing an in 
vivo model of CHPV-induced encephalitis.  Using this model, the site of CHPV 
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replication in the mouse brain and the pattern of dissemination of the virus were 
identified.   
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CHAPTER 2 
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2 Materials and Methods 
 
2.1. Cell lines and culture 
2.1.1. Cell lines 
The continuous African green monkey kidney cell line, BSC-1 and chick embryo 
fibroblasts (CE), prepared by previous members of the PVL laboratory were used to 
investigate the tdCE mutant phenotype.  The BSR-T7 cell line which was derived 
from the BHK-21 cell line and constitutively expresses the bacteriophage T7 RNA 
polymerase (Buchholz et al., 1999) was used in all minigenome and full-length virus 
rescue transfections.  BSC-1 cells were routinely maintained in Glasgow Modified 
Eagle’s Medium (GMEM) supplemented with 10% foetal bovine serum (FBS), 0.2 
mM L-glutamine and 100 µg/ml penicillin/streptomycin.  BSR-T7 cells were also 
grown in complete GMEM (as described above) and every second pass in GMEM 
supplemented with 1 mg/ml G418, an aminoglycoside antibiotic that prevents 
polypeptide synthesis by irreversibly attaching to the 80S ribosomal subunit.  G418 
is required for the selection of cells stably transfected with a plasmid encoding the 
T7 polymerase and the neomycin-phosphotransferase gene which confers resistance 
to G418.  Primary cultures of CE cells were maintained in medium 199 
supplemented with 10% FBS, 0.2 mM L-glutamine and 100 µg/ml 
penicillin/streptomycin. 
The mosquito (Aedes albopictus) cell line, C6/36 (Igarashi, 1978), was used to 
investigate the difference in cytopathic effect of CHPV in mammalian and insect 
cells.  C6/36 cells were grown in Leibovitz’s L-15 medium with 10% FBS, 0.2 mM 
L-glutamine and 100 µg/ml penicillin/streptomycin.  The packaging cell line HEK 
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293T was used to generate lentivirus for pseudotyping experiments as they 
constitutively express the large T antigen of simian virus 40 (SV40).  HEK 293T 
cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% FBS, 
0.2 mM L-glutamine and 100 µg/ml penicillin/streptomycin.  The astrocytoma U373, 
human embryonic oligodendrocyte Oligo/TL, human rhabdomyosarcoma (RD) and 
hepatocellular carcinoma Hep-2 cell lines were also used in this investigation.  U373 
cells were cultivated in Eagle’s Minimal Essential Medium (EMEM), while 
Oligo/TL, RD and Hep-2 cells were grown in DMEM, all supplemented with 10% 
FBS, 0.2 mM L-glutamine and 100 µg/ml penicillin/streptomycin.                 
2.1.2. Maintenance of cells in culture 
Cultures of each of the cell lines were grown in 75 cm
2
 tissue culture flasks with 20 
ml of the appropriate medium and incubated at 37°C in 5% CO2, except C6/36 cells 
which were incubated at 28°C without CO2.  Cells were passaged every 3-4 days in 1 
in 4 (C6/36, U373) 1 in 6 (BSC-1, Hep-2 and CE) or 1 in 8 (BSR-T7, 293T, 
Oligo/TL and RD) dilutions.  Confluent monolayers of cells were washed in 1:6 
trypsin (0.25% (w/v) trypsin in PBS, pH 7.4 (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4) /versene (0.02% (w/v) EDTA and 0.002% (w/v) phenol 
red in PBS, pH 7.4) before incubation at 37°C (28°C for C6/36 cells) with trypsin 
until all the cells had detached from the flask surface, approximately 5-10 minutes.  
Growth medium was then added to inhibit trypsin activity and cells were 
resuspended to a homogenous suspension and an aliquot transferred to seed a new 
flask or roller bottle containing fresh medium or a tissue culture plate.  
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2.1.3. CHPV minigenome rescue 
BSR-T7 cells were seeded into 12-well tissue culture plates 24 hours before 
transfection so that the cells were approximately 70% confluent when transfected.  
0.6 µg pT7N, 0.1 µg pT7P, 0.1 µg pT7L and 0.2 µg mgT7NGFPL (a minigenome 
containing an eGFP reporter gene cloned between the N and L gene) were 
transfected using TransIT®-LT1 transfection reagent (Mirus, USA).  DNA was 
added to Opti-MEM® Reduced Serum Medium (Invitrogen Life Technologies, UK) 
and gently mixed before 3 µl of TransIT®-LT1 transfection reagent was added to the 
diluted DNA.  The TransIT®-LT1 reagent: DNA complexes were gently mixed and 
incubated at room temperature for 15-30 minutes, after which the complexes were 
added dropwise to the cells and incubated at 37°C for 24 hours.  The level of GFP 
expression was determined by fluorescence microscopy.  The plasmids used in the 
minigenome rescue were all obtained from Dr A. C. Marriott (Marriott & Hornsey, 
2011).                   
2.1.4. Rescue of infectious recombinant viruses 
BSR-T7 cells grown to approximately 70% confluence were transfected with 0.8 µg 
pT7CV (the whole genome clone) and the support plasmids in the following 
proportions: 0.2 µg pT7N, 0.15 µg pT7P, 0.15 µg pT7L using 6 µl TransIT®-LT1 
transfection reagent, as described in section 2.1.3.  48 hours after transfection the 
supernatant (containing virus) was inoculated onto confluent monolayers of BSC-1 
cells growing in complete GMEM with 2% FBS.  The supernatant was harvested 
approximately 24 hours post infection.         
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2.1.5. Generation of CHPV-G glycoprotein pseudotyped lentivirus 
The established HIV-1-based self-inactivating lentiviral vector system (Coleman et 
al., 2003) was used to generated lentivirus pseudotyped with the CHPV G 
glycoprotein.  The CHPV G gene was cloned into the pHEF-VSVG envelope 
plasmid (Addgene plasmid 22501) to give pHEF-CHPVG.  HEK 293T cells grown 
to approximately 90% confluence in T75 cm
2
 tissue culture flasks were transfected 
with 7.1 µg pNHP (Addgene plasmid 22500), 3.5 µg pTYF-1xSYN-EGFP (Addgene 
plasmid 19973) and 2.8 µg of either pHEF-VSVG or pHEF-CHPVG.  Virus was 
harvested 24 hours and 48 hours post-transfection and pooled.                 
2.1.6. Cryopreservation of cell lines     
Cells were treated with trypsin/versene as described in section 2.1.2.  Following 
addition of complete growth medium, the cells were transferred into falcon tubes and 
centrifuged at 1,300 rpm in a benchtop centrifuge (Sorvall Legend) at 4°C for 5 
minutes.  The supernatant was then discarded and the cells resuspended in an 
appropriate volume (1 ml per T75 cm
2
 tissue culture flask) of freezing medium, 
comprising of 90% FBS and 10% dimethyl sulfoxide (DMSO) (Sigma, USA).  
Aliquots were transferred into cryovials and placed in a Mr Frosty freezing container 
(Thermo Scientific, USA) which was immediately placed at -70°C.  For long-term 
storage (>1 month), vials of cells were transferred to liquid nitrogen after 24 hours at 
-70°C.                         
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2.2. Viruses and virus growth 
2.2.1. Viruses 
CHPV strain I653514 (GenBank accession number KF468775) and temperature 
sensitive derivatives from it (Gadkari & Pringle, 1980) (GenBank accession numbers 
KF468772, KF468773, KF468774 for tdCE mutants CH112, CH157 and CH256 
respectively) were obtained from Prof. A.J. Easton.  Recombinant viruses CVeGFP 
(which contains the gene for enhanced green fluorescent protein inserted between the 
M and G genes of CHPV) and CVPRFP (in which the red fluorescent protein ORF 
mRFP1 (Campbell et al., 2002) was fused in-frame within a putative hinge region of 
the CHPV phosphoprotein, between residues 213 and 214 of P) were made by Dr 
A.C. Marriott.    
2.2.2. Growth of CHPV stocks 
BSC-1 cells were grown to confluence in glass roller bottles and infected with CHPV 
at a M.O.I. of 0.01 pfu/cell in complete GMEM with 2% FBS.  Cells were incubated 
at 37°C and virus harvested when all cells exhibited CPE, approximately 24-48 hours 
after infection.  Sterile glass beads were used to break open any remaining cells that 
had not lysed.  Cell debris was removed by low speed centrifugation and aliquots of 
the virus stocks were stored at -70°C.       
2.2.3. Determination of virus titre by plaque assay 
Cells were grown to 90-100% confluence in 6 well plates.  Serial, 10-fold dilutions 
of virus were made up to the 10
-9 
dilution and 200 µl of the virus dilutions (or mock) 
were used to inoculate each well, with each dilution assayed in duplicate.  The cells 
were incubated with the inoculum at the required temperature for 1 hour.  Following 
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this, the inoculum was removed and 1% carboxymethyl cellulose (CMC)-GMEM 
(supplemented with 2% FBS, 0.2 mM L-glutamine and 100 µg/ml 
penicillin/streptomycin) overlay was added to each well.  Cells were then incubated 
at the required temperature.  Once plaques were clearly visible cells were fixed using 
4% gluteraldehyde in PBS for 2 hours at room temperature followed by staining with 
crystal violet for 15 minutes.  The plates were then washed, dried and plaques 
counted. 
2.2.4. Microplaque assay 
BSC-1 cells were grown to 90% confluence in 96 well tissue culture plates and 
infected in triplicate with 10-fold serial dilutions of wild-type CHPV for 1 hour at 
37°C.  Following this, the inoculum was replaced with complete GMEM with 2% 
FBS and incubated for 6 hours.  The cells were then fixed with 1:1 acetone: methanol 
for 1 hour, washed once in TBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl) and 
blocked in 1% (w/v) BSA in TBS for 1 hour at room temperature.  Cells were 
washed once in TBS before being incubated with 50 µl of polyclonal sheep anti-
CHPV antibody (diluted 1 in 100 in 1% BSA (w/v) in TBS) for 1 hour at room 
temperature.  The cells were washed three times in TBS prior to incubation with 50 
µl of donkey anti-sheep biotin (Amersham LS) diluted at 1 in 400 in 1% BSA (w/v) 
in TBS for 1 hour.  After three washing steps, 50 µl of alkaline phosphatase-
conjugated streptavidin at 1 in 3000 in 1% BSA (w/v) in TBS was added to the cells 
and incubated for 1 hour.  The cells were washed three times in TBS and alkaline 
phosphatase activity was detected using the BCIP/NBT (5-bromo-4-chloro-3-indolyl-
phosphate/nitro blue tetrazolium) detection system, according to the manufacturer’s 
instructions (Sigma).   
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2.2.5. Virus growth curves 
BSC-1 or CE cells were grown to 90-100% confluence in 6 well plates and infected 
with the appropriate virus at an M.O.I. of 10 pfu/cell.  The inoculum was incubated 
at 33°C for 1 hour, after which the cells were washed three times in PBS and 3 ml of 
complete medium with 2% FBS was added.  Medium was removed at 0, 1, 2, 3, 4, 5, 
6, 7, and 8 hours post infection and the virus titre at each time point deduced by 
plaque assay (section 2.2.3).  The assays were performed in duplicate.        
2.2.6. Semi-purifying virus 
Virus was underlaid with a 20% sucrose cushion in PBS and centrifuged at 120,000 x 
g for 45 minutes in a Beckman Coulter optima L-90K ultracentrifuge, SW50.1 rotor 
at 4°C.  The pellet was resuspended in PBS.   
 
2.3. Mice 
All animal experiments were approved by the University of Warwick’s Ethical 
Review Committee and the UK Home Office.   
2.3.1. In vivo infection with CHPV 
8 day old ICR (CD1) mice (bred in-house) of both sexes were used to investigate the 
neuropathogenesis of CHPV.  Litters of 6 mice (housed with their mothers) were 
used in the study.  Animals were kept at 19-23°C and 45-65% relative humidity.  
Mice were inoculated intraperitoneally with wild-type or recombinant CHPV at the 
required dose (or PBS as a control) in a volume of 50µl.  After infection, mice were 
monitored, given a clinical score and each group of mice was weighed daily (or twice 
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daily for titration experiments, see section 2.3.2).  The quantitative clinical scoring 
system used in all experiments required individual mice to be scored as follows: 1 
point for healthy, 2 points for displaying the first signs of clinical disease (abnormal 
gait), 3 points for unilateral hind limb paralysis (at the side adjacent to the site of 
inoculation), 4 points for paralysis in two limbs or showing little activity, 5 points for 
dead.  The animals were monitored for a maximum of 10 days.  Any animals 
presenting with bilateral paralysis (score of 4) were immediately culled using a 
schedule 1 method.  All surviving animals were culled using a schedule 1 method at 
the end of the 10 day observation period.   
2.3.2. Titration of CHPV 
In order to determine the dose of the strains of CHPV required to cause encephalitis 
groups of 3 animals were infected by the intraperitoneal route with various doses of 
CHPV, starting at a dose of 1.0 x 10
4
 pfu (informed by an earlier study).  If no 
disease was seen a further group of three mice was infected with 3.1 x 10
4
 pfu of 
virus and observed.  Conversely the dose was lowered if the disease onset was too 
rapid and a further group of three animals was tested.  The process was repeated 
(increasing by half log increments or lowered appropriately) until a dose of virus was 
identified that caused observable disease in all three animals with bilateral paralysis 
seen on or near day three after infection.  The animals were monitored twice daily 
from the time of infection for signs of disease and the weight of the group was 
measured daily.   
2.3.3. Timecourse of infection with CHPV 
Using the information from the procedure described in section 2.3.2.  5 groups of 6 
mice were infected with a dose of wild type or mutant CHPV sufficient to cause 
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signs of clinical disease (as described in section 2.3.1.) and one group of 6 mice was 
inoculated with PBS.  All infected and control mice were observed at daily intervals 
for signs of disease and the weight of the animals in each group was recorded.  At 
daily intervals 1 mouse from each experimental group was sacrificed using a 
schedule 1 method.  The process concluded when the remaining mice presented with 
bilateral paralysis or at ten days after infection, whichever was sooner, at which point 
all animals affected were sacrificed.  The brains were removed from all of the 
sacrificed animals and divided into two (down the midsagittal plane).  One half of 
each brain was fixed in 4% paraformaldehyde in PBS for pathological examination 
and the other frozen at -70°C (for storage).   
2.3.4. Homogenising tissue 
Brain samples (section 2.3.3.) were thawed and homogenised in 500 µl PBS using a 
21 gauge needle.  Lungs, kidneys, liver samples were homogenized with sterile sand 
in a pestle and mortar in 1 ml PBS and centrifuged to remove debris before titrating 
(section 2.2.3.).            
2.3.5. Sectioning of fresh brain tissue 
Immediately after harvesting, brains were transferred in ice-cold ACSF (low sodium 
Artificial Cerebrospinal Fluid; 1mM calcium chloride, 10mM D-glucose, 4mM 
potassium chloride, 5mM magnesium chloride, 26mM sodium bicarbonate, 246mM 
sucrose, pH 7.3) previously bubbled with carbogen (95% oxygen, 5% CO2).  300 µM 
coronal sections or parasagittal cerebellar sections were then made using a 
vibrotome.  The sections were fixed in 4% paraformaldedyde in PBS overnight, in 
preparation for immunohistochemistry (section 2.8.3.).    
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2.3.6. Deparaffinisation and rehydration of paraffin-embedded sections 
Paraffin-embedded brain sections were incubated in clearene solvent, a xylene 
substitute (Leica Biosystems) and washed in decreasing concentrations of ethanol 
(100, 95, 70, 50 and 30%).   
2.3.7. Heat-induced antigen retrieval  
Brain sections were microwaved (750 W) in sodium citrate buffer (0.1M Citric acid 
monohydrate, 0.1M Tri-sodium citrate) for 12 minutes and allowed to cool for 20 
minutes.  The sections were incubated with 20 µg/ml proteinase K solution at 37°C 
in a humid chamber for 15 minutes.  Immunohistochemical staining was then 
performed (section 2.8.3).       
   
2.4. Organotypic mouse cerebellar slice cultures   
2.4.1. Preparation and culture of cerebellar slice cultures  
Immediately after harvesting, brains were transferred in ice-cold ACSF previously 
bubbled with carbogen (as above).  The cerebellum was then sliced in parasagittal 
sections of 300 µM using a vibrotome and transferred to tissue culture plates 
containing culture plate inserts.  The slices were cultured in 75% Minimum Essential 
Medium (MEM), 25% heat-inactivated horse serum, 25 mM HEPES, 1mM 
glutamine, 5mg/ml glucose, 100 µg/ml penicillin/streptomycin at 37°C in 5% CO2.   
2.4.2. Viral infection of cerebellar slice cultures  
The slices were cultured (section 2.4.1.) for seven days before infection with 1 x 10
6 
pfu of CVeGFP.  The medium was replaced 90 minutes after infection.  24 hours 
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post-infection, the sections were fixed in 4% paraformaldehyde in PBS overnight.  
The fixed sections were used in immunohistochemistry to detect brain cell-specific 
markers (section 2.8.3.).     
 
2.5. Bacterial culture  
2.5.1. Bacterial culture 
E.coli DH5α were streaked onto L-broth agar plates (1% (w/v) bacto-tryptone, 1% 
(w/v) sodium chloride, 0.5% (w/v) yeast extract and 2% (w/v) agar) containing 100 
µg/ml ampicillin (if the bacteria carried plasmids conferring ampicillin resistance) 
and incubated overnight at 37°C.  Single colonies from freshly streaked plates of 
bacteria were picked, placed into 5 ml L-broth (1% (w/v) bacto-tryptone, 1% (w/v) 
sodium chloride and 0.5% (w/v) yeast extract at pH7.5) containing, if required, 100 
mg/ml ampicillin and incubated at 37°C with shaking (250 rpm) overnight.         
2.5.2. Preparation of competent E.coli DH5α cells  
Overnight cultures of E.coli DH5α (section 2.5.1.) were diluted 100-fold in pre-
warmed L-broth  and grown at 37°C with shaking (250 rpm) until the cells reached 
an optical density of 0.39 when measured at a wavelength of 600 nm.  The cultures 
were immediately placed on ice for 5 minutes and then centrifuged at 2000 rpm for 
15 minutes at 4°C in a benchtop centrifuge.  The bacterial cell pellet was 
resuspended in 2/5 of the original culture volume of filter sterilised ice-cold TfbI 
buffer (30 mM potassium acetate, 100 mM rubidium chloride, 10 mM calcium 
chloride. 50 mM manganese chloride, 15% (v/v) glycerol at pH 5.8 adjusted with 0.2 
M acetic acid) and left on ice for 1 hour.  Following this, the cells were centrifuged 
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as before and the resultant pellet resuspended in 1/25 of the original culture volume 
in filter sterilised ice-cold TfbII buffer (10 mM 3-(N-Morpholino)propanesulfonic 
acid (MOPS), 75 mM calcium chloride, 10 mM rubidium chloride, 15% (v/v) 
glycerol at pH 6.5 with 1M potassium hydroxide) and left on ice for 2 hours.  The 
competent cells were then aliquoted, snapped frozen in liquid nitrogen and stored at  
-70°C.   
2.5.3. Transformation of competent cells and culture of transformants 
100 ng of plasmid DNA was added to 100 µl of competent E.coli DH5α cells 
(section 2.5.2.), gently mixed and placed on ice for 20 minutes.  The bacteria were 
then heat shocked at 42°C for 1 minute before being returned to ice for a further 2 
minutes.  Following the addition of 900 µl of pre-warmed L-broth, the cells were 
incubated at 37°C with shaking at 200 rpm for between 30 minutes and an hour.  
After this, 50 µl, 100 µl and 150 µl aliquots of the culture was spread out onto L-
broth agar plates containing 100 mg/ml ampicillin and incubated overnight at 37°C.  
For blue/white screening to identify transformed bacteria containing the insert of 
interest L-broth agar plates supplemented with 40 mg/ml X-gal dissolved in 
dimethylformamide, 100 mg/ml isopropylthiogalactoside (IPTG) and 100 mg/ml 
ampicillin were used.  Single colonies (white colonies if blue/white screening) were 
picked and then cultured as described in 2.5.1.    
2.5.4. Preparation and recovery of glycerol stocks of bacteria 
Bacteria containing plasmids of interest were stored in 30% glycerol at -70°C.  The 
bacteria were recovered by streaking onto selective agar plates and incubating 
overnight at 37°C.     
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2.6. DNA techniques 
2.6.1. Plasmid DNA purification from transformed E.coli  
Overnight cultures of E.coli (2.5.1) were centrifuged at 3,000 x g for 10 minutes and 
the supernatant removed.  The QIAGEN Plasmid Mini kit and Plasmid Maxi kit 
(QIAGEN, The Netherlands) were used, according to the manufacturer’s protocols, 
for the small and large scale extraction of plasmid DNA from overnight cultures of 
E.coli.  Alternatively, for small scale preparation of plasmid DNA, pelleted bacteria 
were resuspended in 200 µl solution 1 (50 mM EDTA, 50 mM glucose, 25 mM Tris-
HCl pH8. 5 µg/ml RNase A), lysed with the addition of 200 µl solution 2 (0.2 M 
NaOH, 1% SDS) and then neutralised with the addition of 350 µl solution 3 (3 M 
KOAc, 2 M acetic acid).  Samples were centrifuged at 13,000 rpm for 10 minutes in 
a bench top microfuge and a 1 x volume of isopropanol was added to the recovered 
supernatant.  After mixing the mixture was centrifuged at 13,000 rpm for 20 minutes, 
as before, the supernatant was discarded and the pellet washed with 70% ethanol.  
The plasmid DNA was eluted from the pellet in an appropriate volume of sterile 
water (usually 50 µl).  DNA concentration was subsequently determined using a 
Nanodrop spectrophotometer at 260 nm.                 
2.6.2. Polymerase Chain Reaction (PCR) 
High-fidelity PCR using proof reading polymerases Pfu  (Promega, USA) or KOD 
hot start DNA polymerase (Novagen, Germany) was carried out when downstream 
cloning and DNA sequencing was required.  Pfu DNA polymerase was used for the 
amplification of DNA of up to 2 kb whereas KOD hot start DNA polymerase was 
employed when DNA fragments of over 2 kb were amplified.   
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For PCR reactions using Pfu: 1 x final concentration of Pfu DNA polymerase 10 x 
buffer with MgSO4, 200 µM each dNTP (Fermentas) 0.5 µM forward primer, 0.5 
µM reverse primer (Integrated DNA Technologies, refer to appendix for sequences), 
6 ng DNA template, 1.25 U Pfu and nuclease-free water to a final volume of 50 µl 
were added to thin-walled PCR tubes.  The standard PCR reaction mix using KOD 
hot start DNA polymerase contained 1 x buffer for KOD hot start DNA polymerase, 
0.2 mM dNTPs, 1 mM MgSO4, 6 ng template DNA, 0.3 µM forward primer, 0.3 µM 
reverse primer, 1 U/µl KOD in a total volume of 50 µl.  All PCR mixtures were 
mixed and briefly centrifuged before being transferred to a thermal cycler.  The 
standard reaction conditions were 94°C for 5 minutes, then 30 cycles of 94°C 20 
seconds, 55 °C for 30 seconds and 72°C for 1 minute per kb of DNA to be amplified, 
followed by 72 °C for 10 minutes.  Changes to the annealing temperature were 
sometimes required.  PCR products were purified from primers, nucleotides and 
other impurities from the PCR reaction prior to downstream reactions using 
QIAquick PCR purification kit (Qiagen).                 
2.6.3. Quickchange site-directed mutagenesis   
Quickchange site-directed mutagenesis was performed using Pfu DNA polymerase.  
The reactions contained 1 x final concentration of Pfu DNA polymerase 10 x buffer 
with MgSO4, 100 ng DNA template, 100 ng forward primer, 100 ng reverse primer, 
1 µl 10 mM dNTP mix, 1 µl Pfu and made up to 25 µl nuclease-free water.  The 
mixtures were mixed, briefly centrifuged and placed in a thermal cycler programmed 
for 95°C for 1 minute, then 18 cycles of 95°C for 1 minute, 55°C for 1 minute and 
65°C for 1 minute per kb of plasmid length.      
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2.6.4. Agarose gel electrophoresis 
Agarose gels were made at the appropriate percentage required for the length of 
DNA fragments to be electrophoresed: from 0.7 to 2% (w/v) agarose in TBE buffer 
(89 mM Tris-HCl pH 7.5, 89 mM boric acid, 10 mM EDTA, altered to pH 8).  0.5 
µg/ml ethidium bromide was added prior to the gel being poured.  1 x DNA loading 
buffer (0.25 % (w/v) bromophenol blue, 30% glycerol) was added to each DNA 
sample, after which they were loaded onto the gel alongside 5 µl Hyperladder 1 
(Bioline) size marker.  Agarose gels were run at 140 V for 30 minutes for 30 ml gels 
or 1 hour for 100 ml gels.         
2.6.5. Extraction of DNA from agarose gels  
Fragments of interest were excised from agarose gels using a clean scalpel and the 
DNA was extracted and purified from the gel using the QIAquick gel extraction kit 
(QIAGEN), following the manufacturer’s instructions and eluting in 30 µl EB buffer.       
2.6.6. Restriction digestion 
Up to 1 µg DNA was digested using 1 unit of the required restriction endonuclease(s) 
(Fermentas, New England Biolabs) at the optimal incubation temperature for the 
enzyme (usually 37°C) for more than 1 hour.  The reaction mixture contained the 1 x 
buffer recommended by the manufacturer and made up to a total volume of 20 µl 
with sterile water.  FastDigest® restriction enzymes (Fermentas) were incubated in 
either FastDigest or FastDigest green buffer (for the direct loading of the digest on a 
gel) at the appropriate temperature for 5 minutes.  All digestion mixtures were gently 
mixed and centrifuged briefly prior to incubation.   
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2.6.7. Ligation 
Cohesive and blunt ended ligation of a single insert was performed at an insert: 
vector molar ratio of 3:1 using T4 DNA ligase (Fermentas).  100 ng of vector DNA, 
insert DNA (3:1 molar ratio over the vector DNA), 1 x T4 DNA ligase buffer and 1 
unit of T4 DNA ligase were added together in total volumes of 20 µl, mixed and 
incubated at either 16°C overnight or for 1 hour at room temperature.   
2.6.8. DNA sequencing 
400 ng of purified plasmid DNA or 250 ng PCR product was added to 25 pmol of 
primer in 10 µl total volume.  DNA sequencing was carried out by GATC, Germany. 
 
2.7. RNA techniques 
2.7.1. Viral RNA extraction 
Virus RNA was isolated from virus stocks (cell supernatant) and homogenized tissue 
samples (2.3.4.) using TRIzol LS reagent® (Invitrogen Life technologies), according 
to the manufacturer’s protocol.  RNA concentration was determined using a 
Nanodrop spectrophotometer.     
2.7.2. Reverse transcription 
For each sample 1 x reaction buffer, 1 mM final concentration of dNTP mix, 100 
pmol random hexamers (Fermentas) or specific primer, up to 2 µg RNA and 200 
units of RevertAid™ Reverse Transcriptase (Fermentas) made up to 20 µl with 
RNase-free water was added to thin-walled PCR tubes.  The samples were briefly 
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mixed and centrifuged.  An automated PCR machine was then used to carry out 
sequential incubations of 42°C for 1 hour, followed by 70°C for 15 minutes.   
 
2.8. Protein techniques 
2.8.1. Antibodies 
Antibody Source Dilution used 
Anti gaba-a receptor α6 Merck Millipore (AB5610) 1:400 
ANTI-FLAG® M2 
magnetic beads 
Sigma (M8823) n/a 
Blotting grade goat anti-
mouse antibody 
BioRad 1:3000 
Blotting grade goat anti-
rabbit antibody 
BioRad 1:3000 
Donkey anti-goat (Alexa 
Fluor®488 
Abcam (ab150129) 1:1000 
Fluorescein horse anti-
mouse IgG antibody 
Vector Labs (FI-2000) 1:200 
Goat anti-GFP Abcam (ab5450) 1:500 
Goat anti-mouse (Alexa 
Fluor®568) 
Abcam (175473) 1:1000 
Goat anti-rabbit (Alexa 
Fluor®594) 
Abcam (150080) 1:1000 
Monoclonal ANTI-FLAG® 
M2 antibody produced in 
mouse  
Sigma (F1804) 1:500 
Mouse anti-bIII tubulin Abcam (ab11314) 1:500 
Mouse anti-calbindin  Abcam (ab82812) 1:1000 
Mouse anti-cc1 Abcam (ab16794) 1:500 
Mouse anti-MAP2 Abcam (ab28032) 1:500 
Mouse anti-MBP Abcam (ab62631) 1:500 
Mouse anti-neuN Abcam (ab104224) 1:200 
Rabbit anti-cd11b Abcam (ab133357) 1:200 
Rabbit anti-GFAP Abcam (ab7260) 1:500 
Rabbit anti-NG2 Abcam (ab101807) 1:200 
Rabbit anti-olig2 Abcam (ab81093) 1:500 
RFP rabbit polyclonal 
antibody, purified  
Invitrogen (R10367) 1:500 
RFP-Trap® magnetic 
particles 
Chromotek (rtm-20) n/a 
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2.8.2. Immunofluorescence  
Cells were grown on sterile glass coverslips in 12 well plates and infected with the 
appropriate virus.  At the required time post-infection cells were firstly washed twice 
in PBS, fixed in 10% formaldehyde in PBS for 10 minutes at room temperature, then 
washed three times in PBS and permeabilised by incubation with 0.5% NP40 in PBS 
for 10 minutes.  After a further three PBS washing steps, cells were blocked in 1% 
(w/v) BSA in PBS for 1 hour at room temperature.  Following this, cells were 
washed once in PBS before being incubated with 250 µl primary antibody at the 
required dilution in 1% BSA (w/v) in PBS for 1 hour at room temperature.  Anti-Flag 
M2 antibody (Sigma) was diluted 1 in 500.  The cells were washed three times in 
PBS prior to incubation with the secondary antibody coupled to a fluorophore at the 
appropriate dilution in 1% BSA (w/v) in PBS for 45 minutes in the dark.  A 1 in 200 
dilution of horse anti-mouse FITC-conjugated secondary antibody (VectorLabs) was 
used.  After this, the cells were washed three times in PBS and mounted onto glass 
slides using aqueous mounting medium containing DAPI.  Fluorescence was 
visualised using the Leica SP5 confocal fluorescence microscope.         
2.8.3. Immunohistochemistry 
After fixing brain sections in 4% paraformaldehyde in PBS overnight, the slices were 
washed in PBS and left in blocking solution (PBS containing 10% Normal goat 
serum (NGS), 0.2% Triton x100) for 4-6 hours at room temperature.  The blocking 
solution was then removed and primary antibody diluted in carrier solution (PBS 
containing 10% NGS, 0.05% triton) was added and incubated overnight at 4°C.  
After four washes in PBS the secondary antibody diluted in carrier solution was 
applied and the slices incubated for 4 hours at room temperature in the dark.  The 
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slices were washed four times in PBS and mounted onto slides with coverslips with 
aqueous mounting medium.      
2.8.4. Whole cell lysates 
Cells were grown in T75 cm
2
 tissue culture flasks and infected with virus.  Cells 
were washed in PBS and harvested using a cell scraper before being transferred into 
a falcon tube.  Cells were pelleted by centrifugation at 2,000 x g in a benchtop 
centrifuge at 4°C for 5 minutes.  The supernatant was then discarded and the cell 
pellet (approximately 1x10
7 
cells) resuspended in 200 µl of lysis buffer (10 mM 
Tris/Cl pH7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP-40) and incubated on ice for 
30 minutes.  Cells were transferred to tubes and microfuged at maximum speed for 5 
minutes after which lysates were removed and stored at -70°C.        
2.8.5. Immunoprecipitation of Flag fusion proteins using ANTI-FLAG® M2 
magnetic beads 
The anti-flag® M2 magnetic beads (Sigma) were used according to the 
manufacturer’s instructions.  200 µl cell lysate (2.8.4.) obtained from approximately 
1x10
7 
cells and 20 µl of packed beads were used in each immunoprecipitation 
reaction.  The cell lysate and beads were incubated together overnight.  Flag fusion 
proteins were eluted with 0.1M glycine HCl, pH 3 and neutralised with 0.5 M 
Tris/HCl pH 7.4, 1.5 M NaCl.         
2.8.6. SDS-PAGE 
2x SDS-sample buffer was added to each sample and the mixture was heated at 95°C 
for 5 minutes.  Samples were then loaded alongside the PageRuler™ Prestained 
protein ladder (Fermentas) on a SDS-PAGE gel.  This comprised of a 3.9% (w/v) 
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stacking gel (2.5 ml 30% acrylamide/bisacrylamide, 3.75 ml 0.5 M Tris-HCl pH 6.8, 
0.15 ml 10% SDS, 8.45 ml dH2O, 0.15 ml 10% ammonium persulphate and 0.006 ml 
TEMED) and a resolving gel at the required percentage (3 ml 30% acrylamide/bis, 4 
ml 0.5 M Tris HCl pH 6.8, 2.8 ml dH2O, 0.1 ml 10% SDS, 0.1 ml 10% ammonium 
persulphate, 0.004 ml TEMED for a 10% gel).  Samples were run in 1 x running 
buffer (15g/l Tris, 72g/l glycine, 5g/l SDS pH 8.3 for 5 x). 
2.8.7. Coomassie staining and destaining  
To visualise proteins on a SDS-PAGE gel following electrophoresis, gels were 
stained in coomassie stain (0.1% coomassie brilliant blue R250, 10% glacial acetic 
acid, 40% methanol) for 30 minutes with constant shaking.  Gels were subsequently 
destained in destain solution (20% methanol, 10% glacial acetic acid) for 
approximately 2 hours, replacing with fresh destain solution frequently.     
2.8.8. Western blotting 
Proteins were transferred to nitrocellulose membrane in transfer buffer (192 mM 
glycine, 25 mM Tris, 20% (v/v) methanol) at 70 V for 2 hours, after which the 
membrane was placed in blocking solution of 3-5% non-fat milk powder in PBS-T 
(500 ml PBS containing 500 µl Tween20) for an hour with shaking.  The membrane 
was then placed in 3-5% non-fat milk in PBS-T containing the required dilution of 
primary antibody and incubated overnight at 4°C with constant shaking.  Following 3 
x 10 minutes washes with PBS-T, the membrane was transferred to 5% milk powder 
in PBS-T containing horseradish peroxidase (HRP) secondary antibody (BioRad 
blotting grade antibody at 1:3000) and incubated on a shaker at room temperature for 
an hour.  Membranes were washed as before and equal volumes of detection reagent 
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1 peroxidase and detection reagent 2 luminol enhancer solutions (Roche) were added 
for 5 minutes before exposure to film.    
2.8.9. Plaque reduction assay 
Serum samples (diluted 1 in 5 in 1% BSA (w/v) in TBS) or polyclonal sheep anti-
CHPV as a control were incubated with wild-type CHPV at a M.O.I of 0.01 pfu/cell 
for 1 hour and then inoculated onto confluent monolayers of BSC-1 cells.  After 1 
hour at 37°C, the inoculum was removed and 1% carboxymethyl cellulose (CMC)-
GMEM (supplemented with 2% FBS, 0.2 mM L-glutamine and 100 µg/ml 
penicillin/streptomycin) overlay was added to each well.  Cells were then incubated 
at 37°C.  The cells were fixed using 4% gluteraldehyde in PBS for 2 hours at room 
temperature once plaques were clearly visible followed by staining with crystal violet 
for 15 minutes.  The plates were then washed, dried and plaques counted using a 
binocular microscope.  Each serum sample was assayed in triplicate.          
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Chapter 3: The host range tdCE phenotype of Chandipura virus 
is determined by mutations in the polymerase gene 
 
3.1 Introduction  
The central requirement of host cell factors in the replication of vesiculoviruses was 
highlighted by the isolation of eighteen temperature-dependent host range (tdCE) 
mutants of CHPV (Gadkari & Pringle, 1980; Rasool & Pringle, 1986).  These 
mutants were characterised by their ability to grow at both 31ºC (the permissive 
temperature) and the restrictive temperature of 39ºC in BSC-1 cells (the permissive 
host) to comparable titres to wild-type virus yet display temperature sensitivity in 
primary avian cells (chick embryonic fibroblasts, CE).  This phenotype demonstrates 
a dependence of CHPV on undetermined host factors.  During the initial 
characterisation, analysis of in vitro transcription assays showed decreased RNA 
transcriptase activity resulting in significantly lower amounts of viral RNA 
synthesised by the tdCE mutants prepared in avian cells at the restrictive 
temperature.  Synthesis of viral proteins was also found to be either considerably 
diminished or absent in all tdCE mutants grown in avian cells at the restrictive 
temperature (Rasool & Pringle, 1986).  This led to the suggestion that the growth 
impairment is caused by reduced RNA synthesis which in turn results in decreased 
generation of viral polypeptides.   
Due to the nature of the host range mutants studying them offered a unique approach 
to uncouple the specific roles of host cell and virus proteins in the replication of this 
vesiculovirus.  Investigation of similar mutants of VSV by others has provided a 
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powerful tool to enhance understanding of vesiculovirus replication, shedding light 
on several critical amino acid residues required for the methyltransferase, MTase 
activity of the viral RNA dependent RNA polymerase (Grdzelishvili et al., 2005; 
2006; Simpson & Obijeski, 1974).  This chapter reports on the investigation of the 
underlying molecular basis of host range specificity, the CHPV tdCE phenomenon 
using a reverse genetics approach.  
 
3.2 Identifying CHPV gene(s) associated with tdCE mutant phenotype 
3.2.1 Characteristics of CHPV tdCE mutants  
CHPV strain I653514 (GenBank accession number KF468775) and temperature 
sensitive derivatives from it (Gadkari & Pringle, 1980; Rasool & Pringle, 1986) were 
used in this study.  Out of eighteen CHPV tdCE mutants isolated three were selected 
for analysis of the tdCE phenotype; namely CH112, CH157 and CH256.  The tdCE 
mutant phenotype has been defined as viruses with an efficiency of plating (E.O.P.) 
in BSC-1 cells of <0.7 and in CE cells of >2, where E.O.P. is calculated as log10 
PFU
39ºC 
subtracted from log10 PFU
31ºC
.  These E.O.P. values were selected arbitrarily 
to reflect significant growth impairment in CE cells compared to BSC-1 cells.  The 
three tdCE mutants were chosen for further characterisation during this investigation 
on the basis of their previously established range of E.O.P. values in CE cells 
(Gadkari & Pringle, 1980; Rasool & Pringle, 1986) and viability.   
Wild-type and tdCE mutant CHPV titres were determined by standard plaque assay 
in permissive (BSC-1 monkey kidney cells) and conditionally permissive (primary 
cultures of chick embryo (CE) fibroblasts) at 31°C and 39°C.  Table 3.1 shows these 
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titres alongside the E.O.P scores obtained in the original studies when the mutants 
were first isolated.  Attempts were made to utilise the permanent chicken cell line 
DF-1 as the avian host cell line, however the virus was non-cytopathic in these cells, 
possibly due to host restriction factors.      
The titres confirmed that the three mutants: CH112, CH157 and CH256 displayed the 
tdCE phenotype, i.e. all three mutants grew to a titre that was greater than 100-fold 
less at 39°C than at 31°C in CE cells.  The E.O.P. scores of the three mutants in CE 
cells were comparable with those described following the original characterisation, 
though slightly reduced by an average of approximately 15%.  Mutant CH157 had an 
E.O.P. of 0.83 in BSC-1 cells which was outside of the desired range of an E.O.P in 
BSC-1 cells of <0.7 and in CE cells of >2 (Gadkari & Pringle, 1980; Rasool & 
Pringle, 1986).  However, this was not considered a problem because the E.O.P. 
values of the mutant in the two cell types were vastly different, clearly demonstrating 
a significant difference in the growth of the mutant in avian and mammalian cells.      
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Titre in BSC-1 
(PFU/ml) 
Titre in CE 
(PFU/ml) 
Efficiency of 
plating 
(E.O.P.) 
E.O.P. original 
characterisation 
31°C 39°C 31°C 39°C BSC-1 CE BSC-1 CE 
wtCHPV 5.5x10
9 
5.1x10
9 
8.9x10
8 
6.2x10
8 
0.03 0.16   
CH112 9.2x10
8 
2.9x10
8 
4.6x10
7 
2.3x10
3 
0.50 4.30 0.57 5.20 
CH157 2.0x10
9 
3.0x10
8 
4.5x10
7 
1.1x10
5 
0.83 2.61 0.54 3.54 
CH256 1.3x10
9 
7.0x10
8 
1.4x10
7 
2.0x10
3 
0.27 3.85 0.15 4.37 
 
Table 3.1| Efficiencies of plating of wild type CHPV (wtCHPV) and tdCE mutants 
CH112, CH157 and CH256 in permissive (BSC-1) and conditionally permissive (CE) 
cells at 31°C and 39°C.   
E.O.P was calculated as log10 PFU
31ºC
 -  log10 PFU
39ºC
.  The tdCE phenotype is defined as 
clones with an E.O.P in BSC-1 cells of <0.7 and in CE cells of >2.  E.O.P. values in CE cells 
of >2 are shown in red.  Virus titres and E.O.P. values are the average from triplicate repeats.  
The last column (shaded) contains the E.O.P. scores obtained in the original characterisation 
(Rasool & Pringle, 1986).   
 
3.2.1.1. Growth of tdCE mutant viruses in a range of cultured cells  
During the initial characterisation of CHPV tdCE mutants several mutants were 
shown to have additional host cell restrictions in one or a number of the following 
cell types: hamster embryo (HE), rat embryo (RE), feline embryo (FEA), bovine 
embryo kidney (BEK), mouse embryo (NIH/3T3), mouse (L929) cells (Gadkari & 
Pringle, 1980).  Additional host cell restrictions were not investigated for CH112, 
CH157 and CH256, the mutants chosen for analysis in this study.  Therefore, wild-
type and tdCE mutant (CH112, CH157 and CH256) viruses were titrated at 31°C and 
39°C in a number of available cells types: astrocytoma U373, human embryonic 
oligodendrocyte Oligo/TL, human rhabdomyosarcoma (RD), hepatocellular 
carcinoma Hep-2 and BSR-T7 cell lines, and E.O.P. values calculated.  The results 
are shown in Table 3.2.  Viral titres in human RD cells at the two temperatures were 
determined because these cells have previously been used to study the growth 
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kinetics of CHPV (Jadi et al., 2010).  Also, due to the neuropathogenesis of CHPV 
investigation of tdCE mutant growth in two brain cell lines (astrocytoma U373 and 
human embryonic oligodendrocyte Oligo/TL) was also carried out.           
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 Titre in U373 
(PFU/ml) 
Titre in RD 
(PFU/ml) 
Titre in Hep-2 
(PFU/ml) 
Titre in BSR-T7 
(PFU/ml) 
Titre in 
Oligo/TL 
(PFU/ml) 
Efficiency of plating (E.O.P.) 
31°C 39°C 31°C 39°C 31°C 39°C 31°C 39°C 31°C 39°C U373 RD Hep-2 BSR-T7 Oligo/TL 
wtCHPV 4.6x10
8 
9.2x10
7 
1.1x10
9 
3.7x10
8 
2.2x10
9
 9.6x10
8
 5.3x10
9 
4.8x10
9 
4.8x10
9
 2.6x10
9
 0.70 0.47 0.36 0.04 0.27 
CH112 2.1x10
7 
6.9x10
6 
3.8x10
8 
2.2x10
7 
9.4x10
8
 3.2x10
8
 8.9x10
8 
3.0x10
8 
5.1x10
8
 1.6x10
8
 0.48 1.24 0.46 0.47 0.50 
CH157 3.3x10
7 
8.4x10
6 
2.1x10
8 
3.4x10
7 
9.7x10
8
 2.3x10
8
 1.7x10
9 
8.7x10
8 
6.7x10
8
 9.4x10
7
 0.59 0.79 0.63 0.29 0.85 
CH256 1.2x10
7 
2.8x10
6 
6.5x10
8 
7.8x10
7 
1.0x10
9
 3.5x10
8
 9.9x10
8 
2.4x10
8 
7.1x10
8
 2.1x10
8
 0.63 0.92 0.46 0.62 0.53 
 
Table 3.2| Efficiencies of plating of wild-type CHPV (wtCHPV) and tdCE mutants in U373, RD, Hep-2, BSR-T7 and Oligo/TL cells at 31°C and 39°C.   
E.O.P was calculated as log10 PFU
31ºC
 -  log10 PFU
39ºC
.  Virus titres and E.O.P. values are the average from duplicate repeats.  E.O.P. scores above 0.7 are 
highlighted in red.   
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None of the three tdCE mutant viruses exhibited additional host restrictions in any of 
the cell types tested as shown by E.O.P scores of less than 2 for each.  Infection of 
U373, Hep-2, BSR-T7 and Oligo/TL cells with the tdCE mutants produced viral 
titres and thus E.O.P values similar to those obtained in BSC-1 cells (all had E.O.P. 
values of less than 0.7, except for CH157 which had an E.O.P of 0.85 in Oligo/TL 
cells).  However, the E.O.P. scores of the three mutants in human RD cells were 
outside of the desired range of an E.O.P of <0.7 in permissive cells.           
3.2.2 Sequencing wild-type CHPV and tdCE mutant genomes 
To identify the genetic lesions responsible for, and therefore the virus gene(s) 
associated with, host range requirements, the entire genome of each mutant was 
sequenced.  The wild-type virus was also sequenced because the only available 
sequence at the time was assembled from several different sources.  Firstly, RNA 
was extracted from wild-type and mutant CHPV stocks and then reverse transcribed 
to generate full length cDNA using random hexanucleotide primers.  Seven PCR 
products of approximately 2 kb, which overlapped with each other by 200-400 bp 
were amplified by PCR from the full length cDNA using a high-fidelity DNA 
polymerase, as detailed in Figure 3.1a.  PCR products were separated on agarose gels 
(Figure 3.1b) and the correct size fragment of each reaction was purified, to eliminate 
the minor products generated as a consequence of non-specific primer binding.  The 
sequences of primers which were used to construct PCR products 1-7 are shown in 
Appendix 1.   
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Figure 3.1| Generation of PCR products for DNA sequencing wtCHPV and mutant 
genomes 
A. The positions of the amplified PCR products along the genome are shown in blue.  The 
forward and reverse primer used to amplify each of the PCR products are shown in green.   
B. Agarose gel (0.7%) electrophoresis of PCR products 1 to 7 (1901, 2039, 2347, 2000, 
2074, 1352 and 1708 bp, respectively) amplified from wtCHPV, CH112, CH157 and 
CH256.  The position of size markers are shown on the left.  The gels were stained with 
ethidium bromide.      
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Each PCR product was amplified in duplicate and sequenced.  Contigs for wild-type 
CHPV, CH112, CH157 and CH256 were constructed and the entire length of each 
contig was covered by at least three sequences generated using different primers.  
The mutant nucleotide sequences were then aligned with the wild-type virus 
sequence using ClustalW software and the point mutations identified.  Each mutant 
contained only a very small number of mutations, detailed in Table 3.3.  The 
GenBank accession numbers for wtCHPV, CH112, CH157 and CH256 are 
KF468775, KF468772, KF468773, KF468774, respectively.  All of the tdCE mutants 
contained coding changes in the RNA polymerase (L) gene and mutants CH112 and 
CH256 contained additional mutations in the attachment (G) protein gene.  
Additionally, two of the tdCE mutants contained a further silent point mutation(s).  
Mutant CH112 contained the point mutation U1980→C in the P gene and U9958→C in 
the L gene which altered the codon sequences for amino acid residues 206 and 1732 
from AAU (asn) to AAC (asn) and GAU (asp) to GAC (asp), respectively.  Mutant 
CH157 contained a U9022→C mutation in the L gene causing an AAU (asn) to AAC 
(asn) codon change.  
The presence of the mutations resulting in coding changes in the polymerase gene is 
consistent with the observation of reduced RNA transcriptase activity in vitro at 
39°C in 10 of 12 CHPV tdCE mutants relative to wtCHPV, with CH112, CH157 and 
CH256 exhibiting efficiencies of transcription at 39°C of 14%, 56% and 37% of the 
wild-type virus (Rasool & Pringle, 1986). 
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tdCE 
mutant 
E.O.P. 
In CE cells 
Point 
mutation 
Gene Codon change Amino acid 
change 
CH112 4.30 U3941 → C G UCA to CCA Ser297 to Pro 
  C5691 → U L UCG to UUG Ser310 to Leu 
  C5760 → U L CCU to CUU Pro333 to Leu 
  C7217 → U L CCA to UCA Pro819 to Ser 
  U9958 → C L GAU to GAC Non coding 
  U1980 → C P AAU to AAC Non coding 
CH157 2.61 G9735 → U L GGG to GUG Gly1658 to Val 
  U9022 → C L AAU to AAC Non coding 
CH256 3.84 U4034 → C G UAU to CAU Tyr328 to His 
  G7694 → A L GCC to ACC Ala978 to Thr 
 
Table 3.3| Nucleotide positions and coding changes identified in recombinant CHPV 
tdCE mutants. 
 
3.2.3 Generation of recombinant viruses containing the identified point 
mutations 
To confirm which of the point mutations identified in the mutants were responsible 
for the tdCE phenotype recombinant viruses containing each point mutation, and 
combinations of the L mutations in the case of mutant CH112, were generated.  
Quickchange site directed mutagenesis using mutagenic oligonucleotide primers 
(refer to Appendix 1 for sequences) was used to individually produce the C5691→U, 
C5760→U, C7217→U, G9735→U, G7694→A, U3941→C, U4034→C point mutations in the 
full length anti-genomic clone of CHPV (pT7CV: See Appendix 2 for the plasmid 
map of pT7CV).  An example of this strategy is shown in Figure 3.2a for the 
generation of C5691→U.  The methylated, non-mutated parental DNA templates were 
digested with DpnI restriction endonuclease and remaining mutated, nascent DNA 
transformed into competent E.coli DH5α cells.  Several colonies were grown in 
overnight cultures and plasmid DNA was purified.  Combinations of mutations were 
made by sequential Quickchange reactions with the appropriate mutagenic primers.   
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DNA fragments containing the point mutations were re-cloned into pT7CV.  To 
achieve this, fragments containing the point mutations were subsequently digested 
out of the plasmid using two restriction endonucleases that had unique sites in the 
plasmid, the correct size fragment extracted from agarose gels and ligated into wild 
type pT7CV that had been previously digested with the same restriction enzymes.  
This was done to reduce the length of DNA needed to be sequenced and problems 
due to other point mutations being inadvertently generated during the Quickchange 
reaction.   
Figure 3.2b shows agarose gel images of the digested fragments.  pT7CV containing 
either C5691→U, C5760→U and C5691 and 5760→U were digested with the restriction 
endonucleases PmlI and KpnI to give 3086 and 11035 base pair products, the smaller 
of which contained the point mutation and was therefore extracted from the agarose 
gel.   The pT7CV C7217→U and G7694→A plasmids were cut with KpnI and SphI, 
C5691, 5760 and 7217→U, C5760 and 7217→U and C5691 and 7217→U with PmlI and SphI and 
G9735→U with SphI and RsrII.  These restriction digestion reactions generated 
fragments of 2409 and 11712, 5495 and 8626, and 1670 and 12451 base pairs 
respectively.  In each case the smaller of the two products was then purified from an 
agarose gel (the fragment containing the point mutation) and ligated into identically 
digested pT7CV vector DNA.  The ligation reactions were then transformed into 
bacteria, resultant clones cultured and plasmid DNA extracted.   
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Figure 3.2| Quickchange site directed mutagenesis to generate the host range mutations 
within the L gene  
A. Diagrammatic representation of the strategy used to generate the point mutations, using 
pT7CV C5691→U as an example.     
B. 1% (w/v) agarose gels of pT7CV (containing one or more specific point mutations) after 
digestion with two restriction enzymes.   
 
 
A similar strategy was used to generate the two point mutations which were 
identified within the G gene of two of the tdCE mutants.  Mutagenic oligonucleotide 
primers (Appendix 1) were used in Quickchange site directed mutagenesis to 
produce the U3941→C and U4034→C mutations in pT7CV.  Any non-mutated DNA 
was removed by DpnI digestion and remaining mutated, nascent DNA was 
transformed into competent E.coli DH5α cells.  Several colonies were grown in 
overnight cultures and plasmid DNA was purified.  pT7CV containing the U3941→C 
and U4034→C mutations were digested with BsiwI and PmlI or PmlI and KpnI 
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respectively and the 2124 and 3086 bp fragments (Figure 3.3) were ligated into wild-
type pT7CV (previously digested with the same restriction enzymes).  As before, the 
ligation reactions were transformed into bacteria, resultant clones cultured and 
plasmid DNA extracted.   
 
Figure 3.3| Re-cloning DNA fragments containing the point mutations within the G gene 
into pT7CV  
1% (w/v) agarose gel of pT7CV (containing a specific point mutation) after digestion with 
two restriction enzymes  
 
The plasmid DNA was analysed by restriction digestions with BamHI, yielding 
fragments of 349, 915, 2557, 5806 base pairs in length as expected (Figure 3.4a).  To 
confirm that the correct point mutations were produced and other point mutations, 
additions or deletions had not been inadvertently made during the Quickchange 
reaction all of the insert sequences were verified by DNA sequencing.  A partial 
chromatogram from the DNA sequencing results of the insert containing the 
C5691→U change, as an example, is shown in Figure 3.4b.            
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Figure 3.4| Confirmation of the presence of the specific mutations 
A. An example of an analytical restriction digest (BamHI digestion) to check for other 
alterations to the full length CHPV vector following the ligation of the insert (containing 
point mutation(s) into pT7CV 
B. Partial chromatogram of the DNA sequencing results of pT7CV C5691→U using the CV-
L16 primer.  The point mutation is shown by an arrow.   
 
 
 
3.2.4 Recovery of recombinant viruses containing the point mutations associated 
with host range 
Rescue of recombinant infectious virus was carried out for the wild type virus as 
control and for each of the nine combinations of point mutations generating coding 
changes in the virus RNA dependent RNA polymerase (L) gene or one of the two 
mutations in the attachment (G) protein gene using the CHPV reverse genetics 
system previously described (Marriott & Hornsey, 2011).  The genomic plasmid 
(containing the point mutation(s)) and support plasmids pT7N, pT7P and pT7L were 
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transfected into BSRT-7/5 cells (refer to Appendix 2 for plasmid maps).  After 48 
hours, the supernatant was inoculated onto confluent monolayers of BSC-1 cells and 
virus was harvested when the cytopathic effect was extensive (approximately 24 
hours post infection).  The CHPV reverse genetics system is illustrated in Figure 3.5. 
   
 
Figure 3.5| A diagram summarising the plasmid requirements for rescue of infectious 
CHPV from plasmid DNA 
 
All recovered viruses were titrated in BSC-1 and CE cells at both 31°C and 39°C and 
E.O.P. scores calculated for each condition to confirm the tdCE phenotype (Table 
3.4).  The data show that a single amino acid change in the virus RNA polymerase (L 
protein) of each mutant was solely responsible for the tdCE host range dependent 
phenotype.  All recombinant viruses containing the C7127→U mutation in the L gene 
of mutant CH112 conferred the tdCE phenotype while any combination of the 
C5691→U and C5760→U point mutations in the L gene alone or together did not (Table 
3.4).  The latter was demonstrated by E.O.P. scores for the respective recombinant 
viruses of less than two in CE cells.  Furthermore, the results showed that the 
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mutations identified in the G gene of CH112 and CH256 were not involved in the 
tdCE mutant phenotype.  Similarly, only the presence of the G7694→A mutation in 
the L gene of mutant CH256 and G9735→U in the L gene of mutant CH157 conferred 
the tdCE phenotype.
93 
 
 
 
Gene with 
mutation(s) 
Recombinant virus Titre in BSC-1 cells 
(pfu/ml) 
Titre in CE cells 
(pfu/ml) 
Efficiency of 
plating 
  31°C 39°C 31°C 39°C BSC-1 CE 
n/a rCV (wt) 9.9 x 10
8
 3.1 x 10
8
 3.0 x 10
7
 1.3 x 10
7
 0.50 0.36 
L gene rCV 112 (C5691 → U) 9.3 x 10
8
 1.5 x 10
8
 4.9 x 10
7
 1.5 x 10
7
 0.79 0.51 
rCV 112 (C5760 → U) 3.1 x 10
8
 2.8 x 10
8
 2.5 x 10
7
 1.3 x 10
7
 0.04 0.28 
rCV 112 (C7217 → U) 3.8 x 10
8
 8.9 x 10
7
 2.3 x 10
7
 7.5 x 10
2
 0.63 4.49 
rCV 112 (C5691,5760 → U) 4.2 x 10
8
 7.6 x 10
7
 3.9 x 10
7
 9.8 x 10
6
 0.74 0.60 
rCV 112 (C5691,7217 → U) 1.8 x 10
8
 7.6 x 10
7
 1.7 x 10
7
 1.3 x 10
2
 0.37 5.12 
rCV 112 (C5760,7217 → U) 1.1 x 10
8
 2.4 x 10
7
 9.8 x 10
6
 2.8 x 10
2
 0.66 4.54 
rCV 112 (C5691,5760,7217→U) 1.7 x 10
8
 6.3 x 10
7
 1.2 x 10
7
 3.1 x 10
2
 0.43 4.59 
rCV 157 (G9735 → U) 9.3 x 10
7
 1.4 x 10
7
 2.3 x 10
7
 1.0 x 10
4
 0.82 3.36 
rCV 256 (G7694 → A) 1.1 x 10
9
 2.5 x 10
8
 3.8 x 10
7
 1.8 x 10
5
 0.64 2.32 
G gene rCV 112 (U3941 → C) 7.8 x 10
8
 1.7 x 10
8
 7.8 x 10
7
 1.8 x 10
7
 0.66 0.64 
rCV 256 (U4034 → C) 3.5 x 10
8
 1.2 x 10
8
 3.1 x 10
7
 1.8 x 10
7
 0.46 0.24 
 
Table 3.4| Efficiencies of plating of mutated rCHPV viruses in BSC-1 and CE cells 
Viruses with E.O.P. values >2 in CE cells and therefore display the tdCE phenotype are highlighted in red.  Virus titres and E.O.P. values are the averages 
from triplicate repeats      
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3.3 Discussion 
Host restricted and conditional host range mutants have been powerful tools for 
dissecting vesiculovirus replication, with the characterisation of several dual  
conditionally temperature sensitive/host restricted (ts/hr) mutants of VSV Indiana 
leading to the elucidation of amino acid residues that are essential for the 
methyltransferase (MTase) activities of the L protein (Grdzelishvili et al., 2005; 
2006; Simpson & Obijeski, 1974).  A series of tdCE mutants have been described for 
VSV (Pringle, 1978) and CHPV (Gadkari & Pringle, 1980; Rasool & Pringle, 1986) 
in which the viruses are capable of growth in mammalian cells at 31°C and 39°C but 
cannot grow at 39°C in primary avian cells.  These mutants exhibit a greater than 
100-fold reduction in viral titre at 39°C when grown in CE cells, emphasising the 
essential role of host cell factors in vesiculovirus replication.   
The initial study reported reduced RNA transcriptase activity during in vitro 
transcription assays resulting in significantly lower amounts of viral RNA 
synthesised in the tdCE mutants grown in avian cells at the restrictive temperature 
and viral protein synthesis was also found to be either considerably depressed or non-
existent in all tdCE mutants grown in avian cells at the restrictive temperature 
(Rasool & Pringle, 1986).  This indicated that the growth restriction is caused by 
diminished RNA synthesis which in turn results in decreased production of viral 
polypeptides.  In vitro RNA methylation activity of the virus RNA dependent RNA 
polymerase and heat shock protein induction were found to occur at similar levels as 
the wild type virus in all tdCE mutants (Rasool & Pringle, 1986).  Thus, these 
mutants contain lesion(s) affecting a different aspect of L protein function than the 
hr1 VSV Indiana dual ts/hr mutant (Simpson & Obijeski, 1974) which was shown to 
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contain an amino acid substitution within the MTase domain of its L protein giving 
rise to deficiencies in mRNA cap methylation (Grdzelishvili et al., 2005; 2006).        
This research aimed to determine the molecular basis of CHPV host range.  The data 
presented here demonstrate that for each of three tdCE mutants, CH112, CH157 and 
CH256 the lesions responsible for the severe growth defect resides in the gene 
encoding the catalytic component of the virus RNA dependent RNA polymerase (L 
protein).  The point mutations identified result in the following amino acid changes 
in the L protein: Pro819 to Ser, Gly1658 to Val and Ala978 to Thr in tdCE mutants 
CH112, CH157 and CH256 respectively.  The presence of the mutations resulting in 
coding changes in the polymerase gene is consistent with the observation of reduced 
RNA transcriptase activity in vitro at 39°C in 10 of 12 CHPV tdCE mutants relative 
to wtCHPV, with CH112, CH157 and CH256 exhibiting efficiencies of transcription 
at 39°C of 14%, 56% and 37% of the wild-type virus (Rasool & Pringle, 1986).  
The large protein of Rhabdoviruses is multifunctional and is comprised of 6 
functional domains containing regions of greater amino acid conservation and highly 
variable intra domains (Poch et al., 1990).  The molecular interrelationship between 
the domains in the VSV L protein have also been established with conserved blocks 
I-IV arranged into a ring structure containing the RNA polymerase activity and an 
appendage of domains V and VI responsible for capping 
(polyribonucleotidyltransferase, PRNTase) and methylation (MTase) respectively 
(Rahmeh et al., 2010).  Specifically, domain III was found to confer the RNA-
dependent RNA polymerase activity of the L protein.  The pre-A and GDN motifs, 
which are highly conserved in the domain III of non-segmented negative sense 
(NNS) RNA viruses and related to other viral RNA-dependent RNA polymerases, 
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have been shown to be essential for RNA synthesis (Muller et al., 1994; Sleat & 
Banerjee, 1993). 
The locations of the point mutations responsible for the tdCE phenotype within the 
CHPV L protein are shown in Figure 3.6.  The point mutations conferring the host 
range phenotype of the tdCE mutants are located between domains III and IV 
(CH112 C7217 → U) or within domain IV (CH256 G7694 → A) or VI (CH157 G9735 → 
U) of the L gene.  The G9735 → U change within domain VI lies in a stretch of highly 
conserved amino acids and immediately precedes a GXGXG motif (GDGSG 
sequence) which is 19 amino acids upstream of a lysine residue, which jointly have 
been implicated in polyadenylation or protein kinase functions (Cherian et al., 2012).  
The GXGXG motif has a predicted S-adenosyl-L-methionine-binding site required 
by the virus encoded methyltransferase (Rahmeh et al., 2009).   While the 
methyltransferase activity of the L protein has been proposed to also lie within 
domain VI the CH157 mutant polymerase displays a normal mRNA capping function 
(Rasool & Pringle, 1986).  The functions of protein sequence within close proximity 
to the locations of the CH112 and CH256 coding changes are unknown.    
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Figure 3.6| Diagram of the CHPV L gene and location of the L protein coding sequences 
The nucleotide positions within the 11,119 nt genome are indicated.  The location of the 6 
domains of the vesiculovirus L protein are indicated (I to VI) and the locations and nature of 
the tdCE mutants in the L gene and protein are shown.  The locations of the RNA dependent 
RNA polymerase (RdRp), polyribonucleotidyltransferase, (PRNTase) and methyltransferase 
(MTase) activities are also indicated. 
 
 
In conclusion, the data presented in this chapter demonstrate that the conditional 
growth defect for each of three CHPV tdCE mutants, CH112, CH157 and CH256 is 
caused by single amino acid changes in the virus RNA polymerase protein.   
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CHAPTER 4 
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Chapter 4: The construction and characterisation of tagged wild 
type CHPV and tdCE mutant replication complex proteins 
 
4.1 Introduction  
The location of the tdCE lesions within the polymerase protein gene described in 
chapter 3 coupled with the defect in virus RNA synthesis in the mutants (Rasool & 
Pringle, 1986) suggest that in CE cells the formation of functional replication 
complexes may be affected.  Replication complexes are located throughout the 
cytoplasm of infected cells and are the sites of viral RNA synthesis, containing the 
viral RNA, viral replicative machinery: the catalytic component of the virus RNA 
dependent RNA polymerase (L protein), cofactor of the polymerase (P protein), 
nucleocapsid (N) protein and an intimately associated array of host cell proteins, 
required by the virus for replication.  Studies in VSV have shown that infection leads 
to the induction of stress granule-like complexes, comprised of viral RNA, 
replicative proteins and several cellular antiviral proteins in the cytoplasm of infected 
cells.  This has led to the hypothesis that the formation of inclusions is host-cell 
mediated and that they are in fact the replication complexes described previously 
(Dinh et al., 2013a).     
The nature of the host range phenotype indicates that the mutations in the viral 
polymerase affect an essential interaction with certain cellular factor(s) which are 
different in CE compared to BSC-1 cells.  Thus, in order to further investigate the 
effects of the tdCE mutations on CHPV replication, the intracellular localisation of 
components of the RNP complex (especially the two constituents of the viral 
polymerase: L protein and the P protein cofactor) was determined for wild-type 
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versus mutant L viruses in mammalian and chick cells at 31°C and 39°C.  The 
differences in the host proteins bound by wild-type L viruses during an infection in 
BSC-1 and CE cells were also investigated.     
Currently, there are no antibodies to specific CHPV proteins and thus in order to 
study the intracellular localisation and cellular binding partners of individual virus 
proteins, tagged proteins were used.  Using the CHPV reverse genetics system 
(Marriott & Hornsey, 2011) (Figure 3.5) recombinant viruses containing tagged L 
and/or P proteins (constituents of virus replication complexes) were generated and 
used in this investigation.  The L protein was tagged because the coding changes 
responsible for the host range defect in the tdCE mutants resides within their L 
proteins.  Tagged P proteins were also generated because as a component of the viral 
polymerase the phosphoprotein closely associates to the L protein and it has 
previously been used as a surrogate to study replication complex localisation in 
VSV-infected cells (Das et al., 2006).  A recombinant CHPV in which red 
fluorescent protein (RFP) was fused in-frame within a putative hinge region of the 
CHPV phosphoprotein, between residues 213 and 214 of P (rCV-P/RFP) had been 
previously made by Dr A.C. Marriott.  Single-step growth curve analysis of this virus 
in BSC-1 cells showed a very similar virus yield (8.09 ± 0.07 log10 pfu/ml) to the 
recombinant wild-type virus (8.22 ± 0.02 log10 pfu/ml) indicating that the RFP 
insertion had minimal effect on virus growth in cell culture (Dr A.C. Marriott 
personal communication).  The P-RFP fusion protein is stable and the resulting 
recombinant virus grows well in both mammalian and avian cells.  Therefore rCV-
P/RFP was utilised in this study to examine P protein localisation and binding 
partners.       
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4.2. Generation of recombinant viruses containing tagged proteins  
4.2.1. Recombinant CHPV encoding eGFP in the variable region upstream of 
domain VI of L protein could not be recovered 
The literature contains several examples where a large reporter gene has been 
inserted within the polymerase gene of a morbillivirus.  The more distantly related L 
proteins of the Morbillivirus genus have 3 conserved domains separated by 2 highly 
variable hinge regions.  A functional virus with the eGFP gene inserted within hinge 
region 2 of the measles virus L protein (corresponding to a region between blocks V 
and VI in rhabdoviruses) was successfully generated, which exhibited only slightly 
reduced polymerase activity (Duprex et al., 2002).  Similar insertions in rinderpest 
virus and canine distemper virus L proteins resulted in severely attenuated growth in 
vivo (Brown et al., 2005).  Rhabdoviruses do not contain hinge region 2, however, 
insertion of the eGFP ORF into a comparable position in the genome of VSV (55 
residues upstream of the catalytic tetrad K-D-K-E of the MTase in L) was also 
tolerated, although produced a temperature sensitive phenotype (Ruedas & Perrault, 
2009).  The positions of the 6 domains within the CHPV L protein amino acid 
sequence including the location of the K-D-K-E motif is shown in Figure 1.7.   
The demonstration that the polymerases of these NNS RNA viruses are able to 
accommodate such large insertions of sequence in this region highlights the 
functional independence of domain VI to the rest of the L protein in Rhabdoviruses 
(domain 2 and 3 of morbillivirus L).  Attempts were made to engineer a recombinant 
CHPV encoding eGFP in this region of the polymerase protein.  The insertion site 
chosen was 4 amino acids upstream of that used to generate the VSV recombinant 
102 
 
(Ruedas & Perrault, 2009) (i.e. 59 residues upstream of the MTase) because the VSV 
produced was temperature sensitive.       
The open reading frame (ORF) of eGFP (without the stop codon) was amplified from 
pCVeGFP, a full length anti-genomic clone of CHPV with eGFP inserted between 
the M and G genes (constructed by Dr A.C. Marriott) using primers containing sites 
for the restriction endonuclease SalI.  A SalI site, 5’GTCGAC3’, was then introduced 
into pT7CV at nucleotide 9502 by Quickchange site directed mutagenesis using 
mutagenic oligonucleotides to generate pT7CVsalI (refer to Appendix 1 for primer 
sequences).  The PCR product containing the eGFP sequence flanked with SalI sites 
was ligated into pTCVsalI following digestion of both vector and insert with SalI 
restriction enzyme.  The resultant plasmid: pT7CVLeGFP was subsequently transfected 
into BSR-T7 cells alongside the support plasmids pT7N, pT7P and pT7L.  However, 
virus could not be recovered suggesting that the resulting polymerase protein was 
non-functional.   
4.2.2. Construction of Flag tagged virus proteins                   
Due to the unsuccessful attempts to insert large marker sequences within the CHPV 
L gene in a recombinant virus and because others have reported the generation of a 
temperature sensitive VSV encoding eGFP within the polymerase protein (Ruedas & 
Perrault, 2009) other tagging options were considered.  Having such a large protein 
fused to the amino or carboxy terminus of the protein of interest frequently alters the 
properties of that protein including its folding, localisation and function and there are 
no examples in the literature of C- or N-terminally tagged L polymerase proteins.  
Therefore, the introduction of a fluorescent marker protein at these positions was also 
ruled out.  Proteins often have higher tolerance to shorter epitope insertions and for 
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this reason the eight amino acid flag tag (amino acid sequence DYKDDDDK) was 
selected to be added to the carboxy terminus of CHPV L in the support plasmid 
(pT7L) and L in the full length virus clone (pT7CV) (for recovery of recombinant 
viruses containing L/Flag).       
4.2.2.1. Construction of pT7L Flag plasmid  
There are a limited number of suitable unique restriction enzyme sites within the 
11,684 bp CHPV L gene and no restriction enzyme site directly after the L-ORF stop 
codon for use in insertion of additional sequences  so an overlapping PCR strategy 
was used to insert the 24 nucleotide Flag sequence in pT7L (Figure 4.1 a).  
Overlapping portions of the L-ORF were amplified by PCR from pT7L using the L F 
and L Flag R primers in one reaction and the L Flag F and L R oligonucleotides in a 
second reaction to produce 268 and 175 bp PCR products (Figure 4.1 b).  The outer 
primers (LF and L R) were subsequently used in a PCR reaction to join the two PCR 
products obtained in the previous step together, yielding a 405 bp product (Figure 4.1 
c).  This product was digested by SalI and NsiI releasing a 340 bp fragment (Figure 
4.1 c) which was then ligated into a pT7L vector also digested with SalI and NsiI.  
The ligation reaction was transformed into competent E.coli DH5α cells and plated 
out.  Colonies were grown overnight and plasmid DNA was extracted.  As expected, 
fragments of 1253, 3394 and 7037 bp were produced when pT7L Flag was digested 
with HincII (Figure 4.1 d), thus identifying the plasmid and DNA sequencing with 
the L30 primer showed the Flag sequence had been inserted in the correct location 
(Figure 4.1 e).          
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Figure 4.1| Construction of carboxy-terminus Flag tagged pT7L (pT7LFlag) 
A. Map of pT7LFlag plasmid (vector backbone not shown) 
B. 2% (w/v) agarose gel stained with ethidium bromide of the LF and LFlagR PCR product 
(268 bp) and LFlagF and LF PCR product (175 bp)  
C. 2% (w/v) agarose gel electrophoresis of the LF and LR PCR product (405 bp) and the 
same PCR product after digestion with SalI and NsiI (340 bp) 
D. Analytical 1% agarose gel to confirm the identity of pT7L Flag (HincII digest) 
E. Partial chromatogram of the DNA sequencing results of pT7L Flag using the L30 primer 
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4.2.2.2. The L/Flag protein is functional in minigenome assays 
To establish whether the Flag protein remains stably associated with the L protein, a 
minigenome assay using an eGFP reporter minigenome was performed (see 
Appendix 2 for plasmid maps).  In the minigenome reverse genetics system of CHPV 
(Marriott & Hornsey, 2011) the minimum requirements for viral transcription and 
replication: L, P and N proteins are each expressed from a separate plasmid which 
are under the control of T7 promoter and an encephalomyocarditis virus (EMCV) 
internal ribosome entry site (IRES) sequences.  Upon transfection of the three 
plasmids into BSR-T7 cells, which constitutively express the bacteriophage T7 RNA 
polymerase, the L, P and N proteins are expressed and are able to transcribe and 
replicate a GFP minireplicon (an analogue for genomic RNA).  GFP expression was 
analysed 24 hours after transfection.  Slightly reduced but comparable amounts of 
GFP expression were present in pT7LFlag transfected cells in comparison with cells 
transfected with the wild type L vector (pT7L) (Figure 4.2).  While this indicates that 
the L/Flag can substitute for L in the minigenome rescue, GFP expression was low in 
both conditions.      
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Figure 4.2| Minigenome rescue with pT7L/Flag 
Confluent monolayers of BSR-T7 cells were transfected with 0.6 µg pT7N, 0.1 µg pT7P, 0.1 
µg pT7L or pT7L/Flag and 0.2 µg mgT7GFP.  24 hours post transfection, GFP expression 
was analysed by fluorescence microscopy.  The panels on the left hand side show GFP 
fluorescence and those on the right hand side are transmission images of the cells overlaid 
with GFP fluorescence.     
 
4.2.2.3. Insertion of C-terminal Flag tag to L in wild type and tdCE mutant pT7CV 
using overlapping PCR 
Since the L/Flag protein was shown to be functional in minigenome assays, the 
reverse genetics system was utilised to generate a recombinant virus encoding the 
L/Flag protein.  In order to rescue virus containing L/Flag the flag epitope tag was 
inserted at the 3’ of mutant and wild-type L genes in the full length clone of the virus 
(pT7CV) (Figure 4.3 a).  This was achieved by overlapping PCR.  It was not possible 
to use primers L F and L R primers that were used to generate pT7LFlag because 
NsI1 and Sal1 are not unique in the pT7CV plasmid.   
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Overlapping portions of the L-ORF were amplified by PCR from pT7CV and 
pT7CV G9735→U using the L F2 and L Flag R primers in one reaction and the L Flag 
F and L R2 oligonucleotides in a second reaction to produce 1605 and 198 bp PCR 
products (Figure 4.3 b).  The PCR was also carried out with pT7CV G9735→U as the 
template because the PCR product contains the nucleotide which is mutated in the 
tdCE mutant CH157.  The outer primers (LF2 and L R2) were subsequently used in a 
PCR reaction to join the two PCR products obtained in the previous step together, 
yielding a 1783 bp product (Figure 4.3 c).  This product was digested by SphI and 
Rsr11 resulting in a 1679 bp fragment (Figure 4.3 c) which was then ligated into a  
pT7CV or pT7CV G9735→U vector also digested with SphI and RsrII.  The ligation 
reaction was transformed into competent E.coli DH5α cells and plated out.  Colonies 
were grown overnight and plasmid DNA was extracted.  As expected, fragments of 
373, 915, 2557, 5806 bp were produced when pT7CVLFlag was digested with 
BamHI (Figure 4.3 d), thus identifying the plasmid and DNA sequencing with the 
L30 primer showed the Flag sequence had been inserted in the correct location.       
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Figure 4.3| Introduction of a 3’ Flag tag in L in wild type and mutant genome clones 
A. Strategy for adding a flag tag to the L gene in the full length vector  
B. 2% (w/v) agarose gel stained with ethidium bromide of the L F2 (A) and L Flag R (B) 
PCR product (1605 bp) and L Flag F (C) and L R2 (D) PCR product (198 bp)  
C. 2% (w/v) agarose gel electrophoresis of the LF2 (A) and L R2 (D) PCR product after 
digestion with SphI and Rsr11 (1679 bp).   
D. Analytical 1% agarose gel to confirm the identity of pT7CV LFlag (BamHI digest).  The 
expected fragments of 373, 915, 2557, 5806 base pairs in length were detected.   
 
4.2.3. Construction of pT7CV-PRFP containing the tdCE mutations with and 
without L/Flag            
In order to investigate any effects of the tdCE point mutations on the intracellular 
localisation and activity of the phosphoprotein (P protein), the L gene of the P/RFP 
virus was mutated to produce three tdCE mutants, r7217P/RFP (C7217→U), 
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r157P/RFP (G9735→U) and r256P/RFP (G7694→A) corresponding to tdCE mutants 
CH112, CH157 and CH256, respectively.  This was achieved by cloning DNA 
fragments containing one of the three critical tdCE point mutations into pT7CV-
PRFP (see Appendix 2 and Figure 4.4 a for plasmid map).  Four dual tagged 
recombinant viruses: containing wild-type L or one of the three tdCE mutations as 
well as both the L/Flag and P/RFP proteins were also generated.  These were 
designated rCVL/FlagP/RFP, r7217L/FlagP/RFP (C7217→U), r157L/FlagP/RFP (G9735→U) and 
r256L/FlagP/RFP (G7694→A) for tdCE mutants CH112, CH157 and CH256, respectively.  
Details of the cloning strategies are given below.        
Mutant and wild-type L genes with and without a Flag tag were inserted into the 
pT7CV-PRFP backbone (Figure 4.4 a).  To generate pT7CV-PRFP containing the 
112 C7217→U, 157 G9735→U and 256 G7694→A point mutations, the full length 
vectors with these mutations were digested with PmlI and SphI (112) or SphI and 
RsrII (157 and 256) and ligated into identically digested pT7CV-PRFP.   
pT7CV-Flag/PRFP and Flag/PRFP plasmids with the 157 G9735→U point mutation 
were made by ligating the wild type or mutation-containing 1679 bp SphI and RsrII 
digested PCR products with a 3’ Flag tag (from the second stage of the overlapping 
PCR using LF2 and L R2 primers, see 4.2.2.3) into the pT7CV-PRFP backbone, also 
digested with SphI and RsrII restriction endonucleases.  T7CV/Flag 112 C7217→U 
and 256 G7694→A (construction explained in 4.2.2.3) were digested with PmlI and 
RsrII or KpnI and RsrII respectively and the resultant 1670 and 4103 bp fragments 
ligated into T7CV-PRFP.  This produced the T7CV-Flag/PRFP plasmid containing 
the specific point mutations.   
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As before, all the plasmids that were generated were transformed into competent 
E.coli DH5α cells.  Colonies were grown and plasmid DNA was isolated.  Analytical 
BamHI digestions of the plasmids producing fragments of 349 (373 for vectors 
containing flag), 1599, 2557, 4497, 5806 bp (Figure 4.4 b) confirmed the plasmid 
contained the RFP gene and had not undergone any large rearrangements.  DNA 
sequencing confirmed the correct alterations had been made.          
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Figure 4.4| Inserting mutant L and L/flag into PRFP backbone  
A) Plasmid map of pT7CV-PRFP 
B) Analytical restriction digest of T7Flag/PRFP digested with BamHI on a 1% (w/v) agarose 
gel 
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4.2.4. Recovery and growth of P/RFP, L/Flag and dual recombinant viruses 
4.2.4.1. Titres of the recovered recombinant viruses 
The purified mutant PRFP, Flag and Flag/PRFP plasmids (described in sections 
4.2.2.3 and 4.2.3) were subsequently used in full-length transfection experiments to 
recover infectious viruses containing the Flag, PRFP or Flag/PRFP linked with the 
tdCE mutations.  The recombinant viruses were then inoculated onto BSC-1 cells and 
incubated at 33°C until cytopathic effects were extensive.  The virus stocks were 
harvested and the titres determined by plaque assay (Table 4.1).  The recombinant 
viruses containing L/Flag epitope tags had extremely low titres compared with wild 
type CHPV and therefore could not be used at the M.O.I. required for the intended 
experiments.  Therefore the viruses were grown at 33°C (which increased the viral 
titres by approximately 2 logs) and then at 31°C which resulted in a further log 
increase in titres, sufficient for the investigation.  It was not possible to rescue the 
157Flag/PRFP virus. 
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Recombinant virus 
Titre at 
37ᴼC 
(pfu/ml) 
Titre at 
33ᴼC 
(pfu/ml) 
Titre at 
31ᴼC 
(pfu/ml) 
rCV-L/Flag 2.48 x 10
4
 9.25 x 10
6
 7.15 x 10
7
 
r7217L/Flag (C7217→U) 6.25 x 10
2
 3.92 x 10
6
 6.58 x 10
7
 
r112L/Flag (C5691, 5760, 7217→U) 7.50 x 10
1
 7.42 x 10
6
  4.81 x 10
7
 
r157L/Flag (G9735→U) 9.50 x 10
2
 9.25 x 10
4
 7.39 x 10
5
 
r256L/Flag (G7694→A) 1.27 x 10
4
 1.47 x 10
7
 6.85 x 10
7
 
rCVeGFP 1.40 x 10
9
 
  rCV-P/RFP 3.80 x 10
7
 
  r7217P/RFP (C7217→U) 2.28 x 10
7
 
  r112P/RFP (C5691, 5760, 7217→U) 2.58 x 10
7
 
  r157P/RFP (G9735→U) 2.35 x 10
5
 5.99 x 10
6
 6.53 x 10
6
 
r256P/RFP (G7694→A) 6.45 x 10
7
 
  rCV-L/FlagP/RFP 7.68 x 10
4
 8.77 x 10
5
 2.05 x 10
6
 
r7217L/FlagP/RFP (C7217→U) 2.50 x 10
2
 5.34 x 10
5
 7.83 x 10
7
 
r112 L/FlagP/RFP (C5691, 5760, 7217→U) 7.5 x 10
1
 6.92 x 10
4
 1.01 x 10
5
 
r157L/FlagP/RFP (G9735→U) X X X 
r256L/FlagP/RFP (G7694→A) 1.78 x 10
3
 5.50 x 10
5
 1.25 x 10
6
 
 
Table 4.1| Titres of recombinant CHPV in BSC-1 cells at different temperatures 
Recombinant viruses were grown in BSC-1 cells at 31°C, 33°C and 37°C and harvested 
when CPE was extensive.  The resultant viruses were titrated on BSC-1 cells.  X denotes 
virus not able to be rescued.      
 
4.2.4.2. Single-cycle growth analysis of P/RFP and L/Flag recombinant viruses 
The growth characteristics of recombinant CHPV (rCHPV), rCV-R/RFP and rCV-
L/Flag were examined by single step growth analysis and the titre of virus present in 
the supernatant from 0 to 8 hours post-infection is shown in Figure 4.5.  The growth 
curves show that both of the recombinant viruses containing tagged proteins are 
impaired in their growth in comparison with the wild-type virus, with rCV-L/Flag the 
most severely impaired.  rCV-P/RFP reached the maximum titre of 7.3 log10  pfu/ml
-1 
7 hours post-infection whereas rCHPV grew to a maximum titre of 9.3 log10  pfu/ml
-1 
by the same time point, i.e. approximately a 100-fold  difference in growth.  The 
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rCV-L/Flag virus lagged behind the other two viruses, with virus first detectable in 
the supernatant at 5 hours post-infection compared with 3 hours post-infection for 
CHPV and rCV-P/RFP.  rCV-L/Flag reached a titre of 4.7 log10  pfu/ml
-1 
, which was 
approximately 500 and 50,000-fold lower than rCV-P/RFP and rCHPV, respectively.  
However, the stock of rCV-L/Flag virus which was grown at 31°C was 7.15 x 10
7 
pfu/ml (Table 4.1).   
 
 
Figure 4.5| Growth curve of wild-type and recombinant CHPV in BSC-1 cells at 37°C 
BSC-1 cells were inoculated with rCHPV (blue), rCV-P/RFP (red) or rCV-L/Flag (green) at 
an M.O.I. of 10.  Virus supernatant was collected at 0, 1, 2, 3, 4, 5, 6, 7 and 8 hours post-
infection and titrated.  Infections were carried out in duplicate.   
 
4.2.4.3. Fluorescence of P/RFP recombinant viruses  
To confirm the presence of the fluorescent RFP reporter construct BSC-1 cells were 
infected with the wild-type and tdCE mutant P/RFP viruses at an M.O.l. of 3 pfu/cell 
and RFP visualised using epifluorescence microscopy.  Discrete loci of RFP 
expression within the cytoplasm of infected cells were first observed 4 hours post-
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infection (Figure 4.6).  The initial signs of CPE were also seen at this time point, as 
shown in Figure 4.6 by several rounded infected cells.  24 hours after infection of the 
P/RFP viruses, the CPE was extensive and most of the remaining cells were 
fluorescing.     
 
 
Figure 4.6| RFP fluorescence in BSC-1 cells infected with wild-type and tdCE mutant 
rCV-P/RFP 
BSC-1 cells were inoculated with rCV; rCV CH112(C7217 to U); rCV CH157; rCV CH256 
P/RFP viruses at an M.O.I. of 3.  Cells were incubated at 37°C and fluorescence was 
visualised using a fluorescence microscope at 4 and 24 hours post-infection.   The top panel 
for each time point shows RFP fluorescence and the lower panel shows a transmission image 
of the cells for each condition.       
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4.2.4.4. L/Flag could not be detected in infected cells by immunofluorescence   
To confirm the presence of functional L/Flag protein BSC-1 cells were infected with 
wild-type (rCV-L/Flag) and tdCE mutation-containing L/Flag viruses (r7217L/Flag 
(C7217→U), r157L/Flag (G9735→U), r256L/Flag (G7694→A)) at an M.O.I. of 3 
pfu/cell.  Cells were fixed at 4, 8 and 24 hours post-infection, permeabilised and 
stained with anti-Flag M2 antibody (Sigma).  Following incubation with a secondary 
antibody conjugated to a fluorophore emitting green light, the cells were examined 
using confocal fluorescence microscopy.  No fluorescence was detected in cells 
infected with any of the four recombinant viruses.  A positive control for the anti-
Flag antibody was used.              
 
4.2.5. The P/RFP protein can be detected in infected cells by Western blot 
To confirm the presence of the P/RFP protein in P/RFP virus-infected cells BSC-1 
cells were infected with the P/RFP recombinant virus at a M.O.I of 5 pfu/cell.  5 
hours post-infection, cell lysates were harvested and the P/RFP protein was detected 
by western blot (Figure 4.7).  P/RFP is approximately 62.6 kDa in size (CHPV P 
protein is 32.6 and RFP is 30 kDa). 
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Figure 4.7| Western blot of P/RFP protein expression in BSC-1 cells 
Whole cell lysates of wild type CHPV or P/RFP virus infected BSC-1 cells were 
electrophoresed on a 10% SDS-PAGE gel, transferred onto a Hybond ECL membrane and 
blotted with rabbit polyclonal anti-RFP antibody.  A molecular mass marker protein was 
used to determine the approximate sizes of the protein.      
 
4.2.6. The Flag-tagged CHPV L protein is stable  
In order to demonstrate that the L proteins of the wild-type L protein Flag virus 
contain a C-terminal Flag tag BSC-1 cells were infected with rCV-L/Flag at a M.O.I 
of 5 and whole cell lysates harvested 12 hours post-infection.  The expression of 
L/Flag in rCV-L/Flag infected BSC-1 cells was then analysed by western blot, using 
the anti-Flag M2 primary antibody (Figure 4.8).  A 238.5 kDa band (the molecular 
weight of CHPV L protein) is present in cell lysates that had been inoculated with 
rCV-L/Flag but not in wild type CHPV infected lysates.  This indicates that the 
L/Flag protein is functional during virus infection.  The L/Flag protein was also 
detected in pelleted L Flag viruses (wild type L and tdCE L mutant viruses), 
providing further confirmation that the Flag tags are stably attached to the L proteins 
of these viruses (Figure 4.8).      
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Figure 4.8| Western blot of L/Flag protein expression in BSC-1 cells and pelleted virus 
Whole cell lysates of wild type CHPV or rCV-L/Flag infected BSC-1 cells and pelleted 
wtCHPV and L Flag viruses (wild type control and tdCE mutant viruses) were 
electrophoresed on a 7% SDS-PAGE gel, transferred onto a Hybond ECL membrane and 
blotted with mouse anti-Flag M2 antibody.   
 
 
4.3. The location of CHPV tdCE mutant replication complexes in 
permissive and non-permissive conditions 
The presence of the amino acid substitutions conferring the tdCE phenotype within 
the polymerase protein and the diminished RNA synthesis in the mutants suggest that 
the generation of functional replication complexes in CE cells may be disrupted.  To 
determine whether the tdCE point mutations disrupt the intracellular localisation of 
the P protein in the replication complexes the P/RFP recombinant viruses: 
r7217P/RFP (C7217→U), r157P/RFP (G9735→U), r256P/RFP (G7694→A) and the 
control (wild-type L protein) CVP/RFP virus were used to infect cells at an M.O.I of 
1 pfu per cell.  Cells were fixed with 10% formaldehyde in PBS when fluorescence 
was clearly visible.  There was no visible RFP expression in CE cells infected with 
P/RFP mutant L viruses at 39°C until 24 hours post-infection, whereas RFP was 
clearly visible after just 8 hours when the cells were incubated at 31°C (the latter was 
also true for CE cells inoculated with the wild type L virus at either temperature and 
BSC-1 cells under any condition). 
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The distribution of P/RFP in wild type and mutant L viruses in BSC-1 and CE cells 
at 31°C and 39°C determined by confocal fluorescence microscopy is shown in 
Figure 4.9.  In infected BSC-1 cells at either temperature P/RFP was present in large 
bright cytoplasmic foci located primarily near the cell periphery (Figure 4.9 a-h).  
Several smaller punctate regions of fluorescence were also visible as well as very 
faint diffuse staining throughout the cell cytoplasm (Figure 4.9 a-h).  A similar 
pattern of fluorescence was also observed with the P/RFP mutant L viruses in CE 
cells grown at 31°C and in wild type virus-infected CE cells grown at both 
temperatures (Figure 4.9 i-m).  However, CE cells incubated at 31°C showed a 
slightly brighter diffuse cytoplasmic staining of P/RFP than BSC-1 cells.  All three 
mutant L gene viruses showed a significantly different pattern in CE cells infected at 
39°C, generating only a very diffuse pattern of RFP/P fluorescence (Figure 4.9 n-p) 
suggesting that the formation of replication complexes was significantly impaired in 
non-permissive conditions.   
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Figure 4.9| Intracellular localisation of mutated rCV-P/RFP viruses in BSC-1 and CE 
cells.   
BSC-1 (a-h) and CE (i-p) cells infected with rCV (a, e, i, m); rCV CH112(C7217 to U) (b, f, j, 
n); rCV CH157 (c, g, k, o); rCV CH256 (d, h, l, p) P/RFP viruses at an M.O.I. of 1.  Cells 
were incubated at 31°C (a-d, i-l) or 39°C (e-h, m-p) and fixed in 4% formaldehyde when 
RFP fluorescence was clearly visible.  This was 8 hours post-infection for BSC-1 cells, CE 
cells incubated at 31°C and CE cells infected with rCV and incubated at 39°C.  CE cells 
incubated with the mutant viruses at 39°C were fixed 48 hours post-infection.  Nuclei were 
stained with DAPI. 
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4.4. Identification of cellular factors associated with CHPV L protein in 
mammalian and avian cells 
4.4.1. Introduction and strategy  
Host cell factors are essential to the life cycles of all viruses and the isolation of tdCE 
mutants of CHPV emphasised their importance in the replication of vesiculoviruses.  
The critical host factors for CHPV are largely unknown, however, a recent RNAi 
screen identified 72 mammalian genes as essential for VSV infection (Panda et al., 
2011).  Table 1.3 gives details of the cellular proteins shown to be involved in VSV 
replication.  The objective of this research was to identify cellular proteins that 
associate with the catalytic component of the CHPV polymerase, the L protein.  The 
strategy used to identify crucial cellular binding partner(s) was co-
immunoprecipitation and the L protein binding partners were then characterised by 
mass spectrometry (University of Liverpool).     
 
4.4.2. Determination of cellular binding partners of the CHPV L protein  
BSC-1 and CE cells were infected with rCV-L/Flag at an M.O.I. of 5 pfu/cell and 
incubated at 31°C.  Whole cell lysates were prepared at 8 hours post-infection.  This 
time point was guided by the presence of RFP fluorescence from wild-type P/RFP 
virus infection of BSC-1 and CE cells (as L/Flag could not be detected in 
immunofluorescence).  L/Flag fusion proteins were immunoprecipitated using anti-
Flag M2 magnetic beads (Sigma) and eluted in 0.1M glycine HCl pH3.  Lysates of 
rCHPV infected BSC-1 and CE cells were also prepared and immunoprecipitated.  
These were used as controls for the non-specific binding of proteins to the anti-flag 
M2 magnetic beads.  Following neutralisation in Tris base, samples containing the 
122 
 
L/Flag fusion proteins were analysed by mass spectrometry at the University of 
Liverpool using the methodology outlined below.  The immunoprecipitated samples 
were concentrated, digested with trypsin and peptide mixtures were analysed by 
online nanoflow liquid chromatography using the nanoACQUITY-nLC system 
(Waters MS technologies, Manchester, UK) coupled to an LTQ-Orbitrap Velos 
(ThermoFisher Scientific, Bremen, Germany) mass spectrometer.  Progenesis LC-
MS (version 4.1. nonlinear dynamics) software was used for the analysis and tandem 
mass spectrometry data were searched against the monkey, chicken and CHPV 
predicted proteomes.     
Tables 4.2 and 4.3 show the proteins which were identified in the mass spectrometry 
analysis of immunoprecipitated L/Flag samples during mammalian and avian cell 
infection, respectively, and therefore are possible cellular binding partners of CHPV 
L protein.  The cellular proteins are ranked highest to lowest according to maximum 
fold change, which takes into account the number of peptides used to identify the 
protein and the number used to quantify the protein.  The greater the maximum fold 
change value the more peptides used to identify and quantify the protein and 
therefore the higher the probability that the interaction is correct.  Only proteins with 
a maximum fold change value of 3 or greater were considered potential cellular 
interacting partners of L/Flag (126 proteins in mammalian cell samples and 25 
proteins in avian cell samples) and thus were included in the tables, whereas those 
with values of less than 3 were considered to be non-specifically bound to L/Flag.  
The value of 3 was chosen as the cut-off point as it corresponds to the value seen 
with the CHPV G protein which has not been shown to specifically associate with 
the CHPV L protein, was identified with a maximum fold value of 2.9.   
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Mass spectrometry analysis of the cellular binding partners of the L/Flag fusion 
protein in mammalian cells identified all three members of the viral 
ribonucleoprotein (RNP) complex: L, P and N proteins (highlighted in yellow in 
Table 4.2) with high maximum fold change values.  As the P and N proteins are 
known to interact with the L protein their detection provided confidence that the pull 
down was successful.  The other two virus proteins, G and M were also identified but 
at significantly lower frequencies which can be attributed to background, non-
specific interaction.  The M protein was identified at a very high frequency in the 
mass spectrometry analysis of the L/Flag protein pull down in avian cells 
(highlighted in yellow in Table 4.3).  This finding might be incorrect as the L and M 
proteins of vesiculoviruses have not been previously shown to interact.        
 
124 
 
Max fold 
change 
Protein identified Cellular functions 
200.42 V-type proton ATPase subunit d 1 A constituent of the vacuolar ATPase (V-ATPase), an enzyme 
required for the acidification of eukaryotic intracellular 
organelles.  Essential for receptor mediated endocytosis   
55.75 Keratin, type I cytoskeletal 16  Intermediate filament protein 
39.63 Vimentin  Intermediate filament protein 
36.76 Actin, alpha cardiac muscle 1  Cell motility 
27.75 Keratin, type I cytoskeletal 17  Intermediate filament protein 
27.28 Keratin, type II cytoskeletal 7  
Interacts with eukaryotic translation initiation factor 3 (eIF3), 
induces DNA synthesis 
23.17 Coronin-1C, Actin Binding Protein  Cytokinesis, cell motility 
21.95 Drebrin  Actin-binding protein 
20.35 40S ribosomal protein S12  Component of the 40S ribosomal subunit 
18.67 Phosphoprotein   
18.17 60S ribosomal protein L37  Component of the 60S ribosomal subunit 
17.97 Keratin, type I cytoskeletal 18  Intermediate filament protein 
17.41 Cystatin-A  Cysteine protease inhibitor with roles in cell-cell adhesion 
17.36 Corneodesmosin  Cell-cell adhesion 
15.41 Keratinocyte proline-rich protein  ND 
14.96 Fatty acid-binding protein, epidermal  Fatty acid metabolism 
14.03 Plectin  
Connects immediate filaments with microtubules and 
microfilaments 
13.42 Peptidyl-prolyl cis-trans isomerase A  
Protein folding.  Also binds cyclosporin and may be involved in 
cyclosporin-dependent immunosuppression.   
12.76 Keratin, type II cytoskeletal 8  Intermediate filament protein 
12.12 Transgelin-2  May function as a tumour suppressor 
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12.06 RNA-directed RNA polymerase L   
12.05 Actin, cytoplasmic 1  Cell structure and motility  
9.89 Keratin, type I cytoskeletal 14  Intermediate filament protein 
9.25 Small nuclear ribonucleoprotein Sm D1  
Member of the small nuclear ribonucleoprotein (snRNP) family, 
RNA-binding protein    
9.21 Protein arginine N-methyltransferase 1  
Belongs to the protein arginine N-methyltransferase family, 
roles in post translational modifications 
9.14 Histone H1.2  
Required for the condensation of chromatin, roles in chromatin 
remodelling 
9.05 Keratin, type II cytoskeletal 5  Structural constituent of the cytoskeleton 
8.73 T-complex protein 1 subunit epsilon  
Chaperone protein that facilitates the folding of proteins 
(including actin and tubulin) in an ATP-dependent manner 
8.64 Mitochondrial inner membrane protein  Regulates mitochondrial cristae architecture 
8.11 40S ribosomal protein S7  Component of the 40S ribosomal subunit 
7.60 Putative RNA-binding protein 3  Stimulates protein synthesis, cold-inducible 
7.59 Glial fibrillary acidic protein  Intermediate filament protein 
7.43 Ubiquitin-40S ribosomal protein S27a  
S27a is a component of the 40S ribosomal subunit.  Ubiquitin is 
required for targeting proteins for degradation by the 
proteasome 
7.37 60S ribosomal protein L29  Component of the 60S ribosomal subunit 
7.14 DBIRD complex subunit ZNF326  
Major constituent of the DBIRD complex required for 
integrating elongation with alternative splicing  
7.07 Hornerin  Intermediate-filament associated protein, binds calcium ions 
7.02 Tropomyosin alpha-3 chain  Actin-binding protein, roles in stability of the cytoskeleton  
6.81 60S ribosomal protein L27a  Component of the 60S ribosomal subunit 
6.76 Nucleoprotein   
6.62 Small nuclear ribonucleoprotein- Member of the snRNP family, involved in pre-mRNA 
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associated protein N  processing 
6.44 Protein FAM98A  Roles in cell division 
6.34 
Transitional endoplasmic reticulum 
ATPase  
Interacts with clathrin and heat shock protein 70 (Hsc70), roles 
in vesicle transport 
6.26 Dermcidin  Peptidase activity 
6.25 60S ribosomal protein L21  Component of the 60S ribosomal subunit 
6.21 Ras-related protein Rab-1B  
GTPase required for the transport of vesicles between the 
endoplasmic reticulum and Golgi 
6.12 
Eukaryotic translation initiation factor 3 
subunit C  
Constituent of the eukaryotic translation initiation factor 3 (eIF-
3) complex, essential for the initiation of protein synthesis 
6.10 Myosin regulatory light chain 12B  Cell migration and cytokinesis 
6.05 60S ribosomal protein L13  Component of the 60S ribosomal subunit 
5.91 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
Carbohydrate metabolism 
5.90 
Heterogeneous nuclear 
ribonucleoprotein D-like  
Member of the heterogeneous nuclear ribonucleoprotein 
(hnRNP) family of RNA-binding proteins.  Stimulates 
transcriptional repression  
5.75 
KRR1 small subunit processome 
component homolog  
Roles in the biogenesis of the 40S ribosomal subunit and 
ribosome assembly  
5.72 Junction plakoglobin Roles in cytoskeletal arrangement and transcriptional activation 
5.65 Ubiquitin-60S ribosomal protein L40  
L40 is a component of the 60S ribosomal subunit.  Ubiquitin is 
required for targeting proteins for degradation by the 
proteasome 
5.47 Keratin, type II cytoskeletal 1  Structural component of the cytoskeleton  
5.41 Nucleolar protein 14  
Roles in pre-18S RNA processing and export of the 40S subunit 
to the cytoplasm 
5.26 Caveolin-1  
Scaffolding protein in caveolae plasma membranes, stimulates 
cell cycle progression 
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5.21 Desmoplakin 
Formation of desmosomes, associates with intermediate 
filaments  
5.17 Alpha-enolase  
Glycolysis, represses transcription, stimulates the generation of 
immunoglobulins 
5.14 60S ribosomal protein L35  Component of the 60S ribosomal subunit 
5.12 40S ribosomal protein S18  Component of the 40S ribosomal subunit 
5.09 Protein PRRC2A  Involved in pre-mRNA splicing 
4.88 Keratin, type I cytoskeletal 9  Structural constituent of the cytoskeleton 
4.81 Heat shock protein HSP 90-beta  
Chaperone that facilitates protein folding, constitutively 
expressed 
4.80 T-complex protein 1 subunit alpha  
Chaperone protein that facilitates the folding of proteins 
(including actin and tubulin) in an ATP-dependent manner 
4.65 60S ribosomal protein L34  Component of the 60S ribosomal subunit 
4.62 40S ribosomal protein S25  Component of the 40S ribosomal subunit 
4.61 Protein LTV1 homolog  
RNAi screening identified an involvement in cell cycle arrest at 
the G2 checkpoint 
4.60 40S ribosomal protein S24  Component of the 40S ribosomal subunit 
4.59 Splicing factor U2AF 65 kDa subunit  Splicing 
4.58 
Arf-GAP with coiled-coil, ANK repeat 
and PH domain-containing protein 2  
A GTPase-activating protein (GAP) for ADP ribosylation factor 
6 (ARF6), regulates vesicular trafficking  
4.57 Peptidyl-prolyl cis-trans isomerase B  Stimulates protein folding 
4.57 Tropomyosin alpha-1 chain  
Binds to actin filaments, structural component of the 
cytoskeleton 
4.50 60S ribosomal protein L39  Component of the 60S ribosomal subunit 
4.47 Malate dehydrogenase, mitochondrial  
Catalyses the oxidation of malate to oxaloacetate in the citric 
acid cycle 
4.43 
Thyroid hormone receptor-associated 
protein 3  
Roles in pre-mRNA splicing, implicated in the coactivation of 
transcription 
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4.39 
6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 3  
Generation and degradation of fructose 2,6-bisphosphate 
4.31 
Heterogeneous nuclear 
ribonucleoprotein A1 
Member of the heterogeneous nuclear ribonucleoprotein 
(hnRNP) family of RNA-binding proteins.  Involved in 
exporting mRNA from the nucleus to the cytoplasm and 
packaging of pre-mRNA into hnRNP complexes 
4.28 Chromatin target of PRMT1 protein  Implicated role in cell cycle progression 
4.26 60S ribosomal protein L24  Component of the 60S ribosomal subunit 
4.25 Cytosolic purine 5'-nucleotidase  Hydrolyses purine nucleotides (nucleic acid metabolism) 
4.25 Calmodulin  
Regulates a large number of kinases, phosphatases and ion 
channels 
4.24 60S ribosomal protein L7a  Component of the 60S ribosomal subunit 
4.17 Zinc finger protein 706  ND 
4.14 
Heterogeneous nuclear 
ribonucleoprotein H  
Member of the heterogeneous nuclear ribonucleoprotein 
(hnRNP) family of RNA-binding proteins.  Involved in the 
modulation of alternative splicing 
4.10 
TATA-binding protein-associated factor 
2N  
Involved in transcription initiation 
4.06 Interleukin enhancer-binding factor 3  
Post-transcriptional regulator of gene expression, inhibits the 
initiation of translation 
4.03 Myosin light polypeptide 6  Constituent of the ATPase myosin motor protein 
4.02 60S ribosomal protein L23a  Component of the 60S ribosomal subunit 
4.01 Desmoglein-1  Component of desmosomes, facilitates cell to cell adhesion 
4.00 Keratin, type II cytoskeletal 2 epidermal  Structural constituent of the cytoskeleton 
4.00 Annexin A1  
Calcium-dependent phospholipid binding protein which has 
roles in exocytosis and inhibiting inflammation 
3.99 T-complex protein 1 subunit beta  
Chaperone protein that facilitates the folding of proteins 
(including actin and tubulin) in an ATP-dependent manner 
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3.95 60S ribosomal protein L36a  Component of the 60S ribosomal subunit 
3.95 14-3-3 protein zeta/delta  
Adaptor protein which is responsible for regulating a large 
number of signalling pathways 
3.78 Unconventional myosin-Ic  Involved in the transport of vesicles and transcription initiation 
3.73 Annexin A4  
Calcium-dependent phospholipid binding protein which has 
roles in endocytosis and exocytosis 
3.70 40S ribosomal protein S10  Component of the 40S ribosomal subunit 
3.67 
Eukaryotic translation initiation factor 3 
subunit I  
Constituent of the eukaryotic translation initiation factor 3 (eIF-
3) complex, essential for the initiation of protein synthesis 
3.54 40S ribosomal protein S28  Component of the 40S ribosomal subunit 
3.52 
Serine/arginine repetitive matrix protein 
1  
Constituent of splicing mRNA complexes, regulates pre-mRNA 
processing  
3.47 Small nuclear ribonucleoprotein Sm D3  
Major component of the spliceosome which is essential for pre-
mRNA processing  
3.47 RNA-binding protein 28  
Member of the snRNP family, involved in pre-mRNA 
processing 
3.46 
PHD finger-like domain-containing 
protein 5A  
Member of the snRNP family, involved in pre-mRNA splicing 
and transcriptional upregulation of connexin 43 
3.44 
Eukaryotic translation initiation factor 3 
subunit B  
Constituent of the eukaryotic translation initiation factor 3 (eIF-
3) complex, essential for the initiation of protein synthesis 
3.44 Cellular nucleic acid-binding protein  
Binds single stranded DNA and RNA and is involved in the 
cap-independent translation of ornithine decarboxylase mRNA 
3.43 40S ribosomal protein S6  
Component of the 40S ribosomal subunit.  Promotes cell 
proliferation by preferentially translating specific mRNAs 
3.42 RRP12-like protein  ND 
3.39 Serine/threonine-protein kinase 38-like  Associated with the cytoskeleton 
3.34 
Eukaryotic translation initiation factor 4 
gamma 1  
Component of the EIF4F complex which is responsible for 
recruiting mRNA to ribosomes, 5’ cap recognition and removal 
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of secondary structure from templates during translation 
initiation 
3.33 Serum albumin  Major component of plasma 
3.24 Alpha-centractin  
Constituent of dynactin which is a multisubunit complex that 
binds to microtubules and dynein to mediate vesicular transport 
3.21 40S ribosomal protein S29  Component of the 40S ribosomal subunit.   
3.20 General transcription factor II-I Regulates transcription 
3.18 Serine/threonine-protein kinase 38-like 
Inhibits apoptosis upon association with microtubule associated 
monooxygenase 1 (MICAL1) 
3.18 40S ribosomal protein S23  Component of the 40S ribosomal subunit.   
3.17 THO complex subunit 4  
A chaperone protein which modulates dimerisation and 
activation of basic leucine zipper-containing transcription 
factors.  Also involved in mRNA splicing and nuclear export 
3.16 Nucleophosmin 
Roles include modulating the tumour suppressor proteins ARF 
and p53, cell proliferation, generation of ribosomes, duplicating 
centrosomes and histone remodelling  
3.15 40S ribosomal protein S30  S30 is a component of the 40S ribosomal subunit.   
3.14 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 3, 
mitochondrial  
Inhibits the transcription of the anti-apoptotic Bcl-2-binding 
protein BAG1 and is required to preserve the mitochondrial 
structure  
3.13 60S ribosomal protein L28  Component of the 60S ribosomal subunit 
3.08 Transcription factor BTF3  
Binds to RNA polymerase 11, required for the initiation of 
transcription 
3.07 Protein arginine N-methyltransferase 5  
Inhibits cell proliferation, blocks EGF signalling and has roles 
in snRNP complex assembly 
3.07 
Eukaryotic translation initiation factor 
4H  
Constituent of the translation initiation complex, promotes 
EIF4A helicase activity 
3.06 Heterogeneous nuclear Member of the heterogeneous nuclear ribonucleoprotein 
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ribonucleoprotein K  (hnRNP) family of RNA-binding proteins.  Involved in the 
modulation of alternative splicing and the DNA damage 
response 
3.04 60S ribosomal protein L27  Component of the 60S ribosomal subunit 
3.03 Src substrate cortactin  
Involved in the organisation of the actin cytoskeleton, cell 
migration 
3.01 
Peptidyl-prolyl cis-trans isomerase-like 
3  
Enhances protein folding 
3.01 Galectin-1  Modulates cell proliferation and apoptosis 
3.00 Bcl-2-associated transcription factor 1  Represses transcription, stimulates apoptosis 
 
Table 4.2| Proteins identified in immunoprecipitated L/Flag samples during mammalian cell infection 
BSC-1 cells were infected with rCV-L/Flag at an M.O.I. of 5 pfu/cell, incubated at 31°C and whole cell lysates prepared at 8 hours post-infection.  Proteins 
bound to L/Flag were immunoprecipitated using anti-flag M2 magnetic beads (Sigma) and eluted in 0.1M glycine HCl pH3.  Samples were analysed by LC-
MS.  The identified proteins are listed in order of maximum fold change highest to lowest, which takes into account the number of peptides used to identify 
the protein and the number used to quantify the protein.  Cellular interacting proteins with maximum fold values of 3 or greater (126 proteins) were considered 
potential specific cellular binding partners of L/Flag and therefore were included in this table whereas those with values of less than 3 were considered to be 
background or non-specifically bound proteins.  The cut-off value of 3 was selected because the CHPV G protein, which has not been shown to bind the 
CHPV L protein specifically, was identified with a maximum fold value of 2.9.  Viral proteins are highlighted in yellow.    
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Max fold 
change 
Protein identified Cellular functions 
5964.39 Matrix protein   
153.96 Annexin A1 
Calcium-dependent phospholipid binding protein which 
has roles in exocytosis and inhibiting inflammation 
153.13 Tropomyosin alpha-1 chain 
Binds to actin filaments, structural component of the 
cytoskeleton 
21.07 Collagen alpha-2(I) chain  Structural constituent of the extracellular matrix 
10.48 40S ribosomal protein S13  Component of 40S ribosomal subunit 
9.36 Non-histone chromosomal protein HMG-17  Modulates DNA-histone interaction 
9.03 Nucleolin  
Promotes chromatin condensation, formation of 
ribosomes  
8.84 Histone H2A.Z  Constituent of nucleosomes 
6.94 Keratin, type I cytoskeletal 19  Intermediate filament protein 
5.02 Nucleophosmin  Chaperone for the core histones, ribosome assembly 
4.88 Myosin light polypeptide 6  Constituent of the ATPase myosin motor protein 
4.82 Cathepsin L1  Degrades proteins in lysosomes 
4.62 Collagen alpha-1(I) chain  Major component of the extracellular matrix   
4.44 Heat shock 70 kDa protein  Involved in protein folding in response to stress  
4.38 Myosin-9  Cytokinesis, cytoskeleton remodelling  
4.10 Ubiquitin-40S ribosomal protein S27a  
S27a is a component of the 40S ribosomal subunit.  
Ubiquitin is required for targeting proteins for 
degradation by the proteasome 
4.06 60S ribosomal protein L15  Component of 60S ribosomal subunit 
3.94 Actin, cytoplasmic 2  Structural constituent of the cytoskeleton 
3.94 40S ribosomal protein S4  Component of 40S ribosomal subunit 
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3.94 Fibronectin  Cell-cell adhesion, cell motility 
3.76 78 kDa glucose-regulated protein  
Member of the heat shock protein 70 family, assists in 
the formation of multimeric protein complexes in the 
endoplasmic reticulum 
3.72 Elongation factor 1-alpha 1  
Required in protein synthesis to stimulate the attachment 
of aminoacyl-tRNA to the A site of ribosomes  
3.22 Annexin A2  Involved in exocytosis and cytoskeleton architecture 
3.11 Ubiquitin-60S ribosomal protein L40  
L40 is a component of the 60S ribosomal subunit.  
Ubiquitin is required for targeting proteins for 
degradation by the proteasome 
3.08 Keratin, type I cytoskeletal 14  Intermediate filament protein 
3.01 Vimentin  Intermediate filament protein 
 
Table 4.3| Proteins identified in immunoprecipitated L/Flag samples during avian cell infection 
CE cells were infected with rCV-L/Flag at an M.O.I. of 5 pfu/cell, incubated at 31°C and whole cell lysates prepared at 8 hours post-infection.  Proteins bound 
to L/Flag were immunoprecipitated using anti-flag M2 magnetic beads (Sigma) and eluted in 0.1M glycine HCl pH3.  Samples were analysed by LC-MS.  The 
identified proteins are listed in order of maximum fold change highest to lowest.  Cellular proteins with maximum fold values of 3 or greater (25 proteins) 
were included in this table and considered potential specific cellular binding partners of L/Flag.  Proteins with values of less than 3 were considered to be non-
specific, background proteins.  The cut-off maximum fold value of 3 was chosen because the CHPV G protein, which has not been shown to specifically bind 
the CHPV L protein, was identified with a value of 2.9.  Viral proteins are highlighted in yellow.  Cellular proteins which were also identified in the 
mammalian cell samples to be associated with L/Flag are highlighted in purple.     
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The potential protein binding partners of L/Flag during mammalian and avian cell 
infection were classified based on their cellular functions and the proportions of each 
of the functional groups which are represented are illustrated in Figure 4.10.  The 
functional diversity of proteins identified in the mammalian cell samples was greater 
than in the avian cell samples, which is reflected in the number of functional groups, 
14 for mammalian cell and 6 for avian cell samples.  39% and 42% of the potential 
L/Flag interacting proteins in mammalian and avian cells respectively which were 
identified during this analysis are involved in cellular gene expression and comprised 
the largest functional group in both datasets.  Many proteins with roles in the 
cytoskeleton, protein folding, vesicular transport and the cell cycle were also 
identified as L/Flag binding partners in both mammalian and avian cells.  Proteins 
that function in RNA post-transcriptional modification were isolated as potential 
L/Flag interacting proteins during infection in mammalian cells, accounting for 11% 
of the co-immunoprecipitated proteins.  The remaining 13% of L/Flag fusion 
proteins detected in the mammalian cell samples was comprised of proteins involved 
in carbohydrate metabolism, cell to cell interaction, lipid metabolism, post-
translational modification, amino acid metabolism, nucleic acid metabolism, cell 
signalling and apoptosis.             
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Figure 4.10| Cellular functions of potential L/Flag interacting proteins   
The 126 mammalian and 25 avian proteins which were identified as potential L/Flag binding 
partners were categorised into groups based on their cellular functions.  The proportions of 
each category of protein are depicted in pie charts for mammalian (a) and avian (b) cells.      
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4.5 Discussion 
Studies have shown that the L proteins of the morbilliviruses are able to withstand 
the insertion of large reporter genes within hinge regions, intra domain regions of 
relatively low amino acid sequence conservation, with negligible effects on virus 
growth in vitro (Duprex et al., 2002).  This has sought to highlight both the 
conformational and functional independence of the conserved blocks.  However, 
insertion of the eGFP ORF into a comparable position in the genome of VSV (55 
residues upstream of the catalytic tetrad K-D-K-E of the MTase in L) produced a 
temperature sensitive phenotype (Ruedas & Perrault, 2009).  In this study, the rescue 
of a recombinant CHPV containing GFP at a similar position between domains V 
and VI of CHPV L (4 amino acids upstream of the insertion site in the VSV 
recombinant) was unsuccessful, indicating that the engineered polymerase was non-
functional.  Addition of the 8 amino acid Flag epitope tag to the carboxyl terminus of 
the CHPV L protein was tolerated in the recovered virus, although viruses containing 
this insertion had reduced growth kinetics, growing to titres which were 
approximately 2 logs lower than the parental recombinant wild-type virus (Figure 
4.5).    
The replication cycle of CHPV occurs at RNP complexes within the cytoplasm of 
infected cells.  Studies in VSV have shown RNP complexes are distributed 
throughout the cytoplasm but at early stages of infection these are located 
predominantly adjacent to the nucleus during nucleocapsid synthesis.  Subsequently 
newly synthesised complexes are seen to traffic in a microtubule-dependent manner 
towards the cell membrane for virion assembly prior to progeny release (Das et al., 
2006).  Thus, it is likely that the images in Figure 4.9 demonstrate the late stages of 
CHPV infection, as the P/RFP protein is primarily localised to the cell membrane.  
137 
 
Aggregations of VSV RNP complexes have been observed within infected cells (Das 
et al., 2006).  The data presented here supports this finding, large dots of 
fluorescence representing groups of RNP complexes were visualised upon infection 
of cells with rCV-P/RFP (Figure 4.6, 4.9).  While replication complexes were 
initially thought to be virus induced, recently the presence of stress granule-like 
complexes comprised of viral RNA, replicative proteins and several cellular antiviral 
proteins were detected in VSV-infected cells leading to the suggestion that these are 
in fact the replication complexes and that their formation is host-cell mediated (Dinh 
et al., 2013a).    
The location of the tdCE point mutations within the polymerase protein gene 
together with the significantly lower amounts of viral RNA synthesised by the 
mutants indicate that in CE cells at 39°C the generation of functional replication 
complexes may be disrupted.  The P/RFP fusion protein mutants showed a striking 
difference in P protein distribution in CE cells infected with L mutant viruses 
compared with the wild type L virus at 39°C but not 31°C (Figure 4.9 panels m-p).  
At 31°C most P protein was organised into discrete localised clusters in replication 
complexes within the infected cell and especially near to the cell membrane.  This 
organisation was lost at 39°C with the L gene mutant viruses in CE cells.  Under 
these conditions the P protein showed a diffuse distribution throughout the cytoplasm 
with only very few and extremely indistinct foci present.  The lack of P/RFP-
containing foci in CE cells at the restrictive temperature, taken together with 
previous data showing defects in in vitro RNA transcriptase activity and polypeptide 
synthesis, supports the hypothesis that the defects in the mutant L proteins lead to 
disruption of replication complexes, reduced viral RNA synthesis and hence reduced 
viral protein synthesis in non-permissive conditions. The three point mutations 
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examined produce similar phenotypes, despite the amino acid changes being located 
in separate domains of the CHPV L protein (Figure 3.6). 
The existence of host range (hr) and tdCE mutants highlight the essential role of 
cellular proteins in the replication of CHPV.  The nature of the tdCE phenotype is 
suggestive that the coding changes within the L protein alter its relationship with 
specific cellular factor(s) that are not present in CE cells and are required to hold the 
polymerase in an active conformation at 39°C.  By immunoprecipitating wild-type 
and tdCE mutant P and L fusion proteins from mammalian and avian cells at 31°C 
and 39°C and analysing their binding partners by mass spectrometry it would be 
possible to decipher the effect(s) of the tdCE lesions on the ability of the L protein to 
interact with host cell factors.  This approach would facilitate the isolation of cellular 
protein(s) that interact with the virus replication complex in a manner that is 
absolutely essential for successful virus propagation.  The first step was to establish 
whether this methodology works by identifying potential wild type L/Flag interacting 
proteins.     
Vesiculoviruses are intimately associated with host cell factors.  There is limited 
information about these cellular factors for CHPV, however, the known cellular 
interactions with VSV RNA or proteins are listed in Table 1.3.  72 mammalian genes 
were shown to be integral for VSV infection in a recent RNAi screen (Panda et al., 
2011).  Using co-immunoprecipitation in conjunction with mass spectrometry 126 
mammalian and 25 avian potential binding partners of the CHPV L protein, the 
catalytic component of the CHPV polymerase were identified (Tables 4.2, 4.3).  
However, the experimental approach used does not allow discrimination between 
direct and indirectly bound proteins and therefore many of these host cell proteins 
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may only associate with the CHPV L protein indirectly via interactions with one or 
several specifically bound cellular proteins.  In addition, cellular proteins interacting 
with CHPV L protein at low concentrations may not be detected by this approach.   
The majority of the potential cellular binding partners of the L protein have cellular 
functions in gene expression or cytoskeleton structure (39% and 21% of the total 
identified proteins in mammalian cells and 42% and 29% of the total in avian cells).  
Several L interacting proteins were identified from both mammalian and avian cells 
including actin, which has also been shown to be required for clathrin-mediated 
endocytosis of VSV (Cureton et al., 2009).  Cytoskeletal proteins are used by a range 
of viruses predominantly at the stage of virus entry and egress, although a number of 
non-segmented negative sense (NNS) RNA viruses utilise these proteins for viral 
RNA synthesis.  Examples of NNS RNA viruses that require actin for the efficient 
transcription of their mRNA include RSV (Burke et al., 1998) and human 
parainfluenza virus 3 (Gupta et al., 1998b), while VSV (Heinrich et al., 2010), 
measles and Sendai (Moyer et al., 1986) viruses have been demonstrated to use 
tubulin for viral mRNA synthesis.  Therefore, the identification of actin as a possible 
cellular interacting partner of the CHPV L protein in this study is the first example of 
actin associating with a vesiculovirus protein.  To provide further evidence for this 
interaction the immunoprecipitated L/Flag sample should be immunoblotted using an 
anti-actin antibody.     
 
Tubulin has been shown to have several functions during VSV infection, for 
transcription (Moyer et al., 1986)
 
and microtubules are required to transport the viral 
mRNA from replication complexes to the cell membrane and this is essential for 
efficient translation (Heinrich et al., 2010).  Despite the important roles tubulin plays 
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in VSV replication direct interaction of the VSV RNP complex proteins with the 
cytoskeleton has not been demonstrated and tubulin was not identified as a possible 
CHPV L binding partner in this investigation.  However, tubulin has been shown to 
interact with the VSV M protein to stimulate cell rounding, suggestive of a role in 
the cytopathic effect of the virus (Melki et al., 1994).          
 
CHPV L protein was found to interact with the intermediate filament proteins 
vimentin and keratin during infection of mammalian and avian cells.  Previous 
studies have shown that other virus proteins also interact and modulate vimentin 
including the HIV-1 protease, which has been shown to digest vimentin resulting in 
its substantial reorganisation within host cells (Honer et al., 1991).  In addition, 
African swine fever virus stimulates the aggregation of vimentin and then localises to 
those sites for replication and assembly of virus particles (Stefanovic et al., 2005).  
Conversely, disruption of the vimentin network prevents human cytomegalovirus 
infection (Miller & Hertel, 2009).  VSV M protein-mediated changes in vimentin 
distribution have also been reported in VSV-infected cells (Lyles & McKenzie, 
1997).  Keratin 8, implicated as a CHPV L interacting protein in this investigation, 
has been shown to enhance hepatitis B virus (HBV) replication (Zhong et al., 2013).    
 
This research identified two members of the heat shock protein (Hsp) family of 
stress-inducible cellular chaperones, Hsp90 and Hsp70 as potential interacting 
partners of the L protein during infection in mammalian and avian cells, respectively.  
Hsp90, which has a specific set of protein substrates including some transcription 
factors and kinases, is postulated to be essential for the replication of a diverse range 
of viruses including rhabdoviruses, orthomyxoviruses (Momose et al., 2002), 
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paramyxoviruses and bunyaviruses due to its crucial role in the correct folding of 
viral polymerases (Connor et al., 2007).  Specifically, Hsp90 has been shown to be 
involved in VSV replication and maintaining L protein stability via an interaction 
with the N protein (Connor et al., 2007).  Therefore, Hsp90 may also indirectly 
associate with the CHPV L protein by binding to the N protein.  The involvement of 
Hsp70 in the replication of a number of viruses has also been demonstrated with the 
protein enhancing the replication of some viruses and inhibiting others.  Expression 
of Hsp70 is crucial in suppressing VSV (Kim et al., 2013) and measles virus 
(Carsillo et al., 2006) neurovirulence in vivo due to Hsp70-dependent induction of 
the type I IFN response despite its role in slightly enhancing virus gene expression 
(Kim et al., 2013).  Furthermore, Hsp70 directly binds to the RNP proteins of 
influenza A virus PB1 and PB2, inhibiting the replication of the virus (Li et al., 
2011).  In contrast, Hsp70 was shown to upregulate flavivirus replication through 
direct interactions with HCV replicative proteins NS5A, NS3 and NS5B (Chen et al., 
2010) and JEV NS5 (Ye et al., 2013).   
 
The other major functional group of host cell proteins implicated as possible CHPV 
L protein partners in this study have cellular roles in gene expression and include 
ribosomal proteins, eukaryotic translation initiation factors (eIF4G, H and eIF3B, C, 
I), members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family of 
RNA-binding proteins (hnRNP D, K, A1, H) and transcription factors.  These 
findings are consistent with the dependency of vesiculoviruses on the host cell 
replicative machinery for viral polypeptide synthesis.  The scaffolding protein eIF4G 
is a constituent of the eIF4F complex, which is required for the initiation of cellular 
protein synthesis.  VSV infection alters the phosphorylation state of the eIF4F 
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complexes, impairing host cell translation (Connor & Lyles, 2002).  eIF4H 
stimulates eIF4A, a component of the eIF4F complex with ATP-dependent helicase 
activity responsible for unwinding secondary RNA structures to facilitate ribosome 
binding.  The eIF3 complex regulates the assembly of the pre-initiation complex and 
scanning for the AUG start codon for the initiation of protein synthesis and the eIF3 
subunits A, G, I have been shown to be essential for VSV infection during RNAi 
screening experiments (Panda et al., 2011).            
 
The hnRNP RNA-binding proteins have a range of cellular functions in gene 
expression, mRNA metabolism, chromatin re-modelling, nuclear export of mRNA, 
mRNA processing and the cell cycle.  These proteins are principally localised to the 
nucleus, however, in cells infected with VSV an increase in cytoplasmic hnRNPs has 
been documented (Pettit Kneller et al., 2009).  One of the hnRNP proteins identified 
as a possible CHPV L interacting protein in this study, hnRNP K, has been suggested 
to be essential for VSV infection by inhibiting apoptosis, enhancing virus replication 
and release by modulating the expression of several host cell proteins including the 
upregulation of alanine deaminase like (ADAL), ARF1, Bcl-Xl, Bcl-2 and BagI and 
downregulation of Bcl-Xs and Bik (pro-apoptotic factors) (Dinh et al., 2013b).  
hnRNP K has been shown to support the replication of a number of other viruses 
such as Sindbis virus through an interaction with nonstructural protein 2 (Burnham et 
al., 2007), HCV by directly binding to the core protein of the virus (Hsieh et al., 
1998) and Epstein Barr virus through an interaction with EBNA2 (Gross et al., 
2012).  The involvement of hnRNP A1 protein (identified as a potential CHPV L 
interacting partner in this analysis) in supporting norovirus replication by facilitating 
the circularisation of the viral genome has also been demonstrated (Lopez-Manriquez 
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et al., 2013).  hnRNP D has also been shown to play several roles in viral infections, 
supporting the translation of HCV mRNA (Paek et al., 2008) and inhibiting Nipah 
virus transcription (Hino et al., 2013).  In addition, hnRNP U was postulated to 
inhibit cellular mRNA synthesis through an interaction with leader RNA in VSV-
infected cells (Gupta et al., 1998a).       
 
In this chapter, the lesions responsible for the severe growth defect of three CHPV 
tdCE mutants, CH112, CH157 and CH256 were shown to severely affect the ability 
of the viruses to assemble large replication complexes in the cytoplasm of cells in the 
non-permissive conditions.  The identification of 126 mammalian and 25 avian 
proteins with cellular roles predominantly in gene expression and cytoskeleton 
structure which may associate with the CHPV L protein was also described, 
providing the first analysis of potential CHPV L binding partners.  Further 
investigation will be required to validate the potential interactions identified.     
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Chapter 5: The pathogenesis of Chandipura virus-induced 
encephalitis 
 
5.1 Introduction 
CHPV causes a neurological disease in humans and there have been several 
epidemics of CHPV-induced encephalitis in children (Chadha et al., 2005; Gurav et 
al., 2010; Tandale et al., 2008).  The virus also causes a neurological disease in 
experimentally infected young mice by any route of administration, while infection 
leading to encephalitis of adult mice is only achieved by intracranial injection of 
CHPV (Jortner et al., 1973).  In young mice the disease is exhibited as a progressive 
paralysis prior to death.  Further information about the mouse model of CHPV 
pathogenesis including details about the range of symptoms observed is given in 
section 1.6.2.  One report into CHPV pathology described extensive regions of 
necrosis in the internal and external granular layers of mouse cerebellum 96 hours 
after intraperitoneal inoculation of CHPV (Jortner et al., 1973), implicating the 
cerebellum as an important site of CHPV replication in the brain.   
While there has been some increase in our understanding of the immunological 
response to CHPV very little is currently known about the underlying aspects of 
pathogenesis of any vesiculovirus.  Specifically in the case of CHPV, there is limited 
information about the progress of CHPV disease in the mouse model.  Moreover, the 
site(s) of infection within the brain, the pattern of spread with time after infection and 
any host range specificities in terms of the cell tropism of CHPV are all unknown.  
Mice are recognised as the standard model for studying virus pathogenesis and are 
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the only species used to date to study CHPV and IFHV-induced encephalitis.  There 
is a small but growing literature on the immunology of CHPV infection and all of the 
work to date has been performed in mice.  Therefore mice were chosen to investigate 
the process of neurological disease caused by CHPV in this study in order to 
generate data that is comparable with other information in the literature.  Suckling 
mice between the ages of 7-11 days old were used as animals at this age present with 
neurological symptoms following infection through any route of virus 
administration. 
Additionally, there is limited information about the brain cell types susceptible to 
CHPV infection.  Currently, neurones are the only brain cell type that have been 
shown to be permissive to CHPV infection and apoptotic and necrotic CHPV-
infected neuronal cells have been observed following infection of several neuronal 
cell lines and in vivo infection of mice (Ghosh et al., 2013; Jortner et al., 1973).  
Viruses often have a tropism for certain cell types and this is fundamental to the 
disease they induce.  For example, the neuropathogenic Alphavirus Semliki Forest 
virus (SFV) (family Togaviridae), a positive sense single stranded RNA virus, 
exhibits a strong tropism for neurones and oligodendrocytes, while SFV infection of 
astrocytes has not been demonstrated (Fazakerley, 2004).   
 Ex vivo cultures of brain tissue including cerebellum, hippocampus, cerebral cortex 
and retina have been utilised in the neuroscience community for studies of brain cell 
function and development, as well as in research into a wide range of neurological 
diseases such as Parkinson’s disease, Alzheimer’s disease, stroke and epilepsy.  
These cultures are able to retain the physiological proportions of brain cell types and 
normal tissue architecture for several weeks after preparation and therefore have the 
advantage that they can be used in experiments that take longer than 6 hours, the 
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maximum survival time of acute brain slices.  Cultures of brain tissue have been used 
to investigate viral tropism for several systems.  Cerebella and hippocampal slice 
cultures were employed in a study of Borna disease virus (BDV) (Friedl et al., 2004), 
coronal brain slice cultures were used in a model of reovirus pathogenicity (Dionne 
et al., 2011) and the brain site involved in cytomegalovirus latency (Tsutsui et al., 
2002) and herpes simplex virus type 1 (HSV-1) neurotropism (Braun et al., 2006) 
were investigated using cultures of brain tissue.  Organotypic cultures of mouse 
cerebellar were employed to investigate the cell tropism of CHPV in this study.  This 
chapter reports on the investigation of CHPV-induced neurological disease using ex 
vivo and in vivo approaches.       
For guidance labelled diagrams of superior and sagittal views of the mouse brain are 
shown in Figure 5.1.   
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Figure 5.1| The mouse brain 
A. Superior view of a mouse brain 
B. Diagram of a sagittal section through the mouse brain (obtained from the GENSAT 
mouse brain atlas, sagittal section 07, 
http://www.gensat.org/imagenavigator.jsp?imageID=13507) 
   
 
5.2 Ex vivo investigation of the cell tropism of CHPV 
5.2.1 rCVeGFP-infection of cerebellar slice cultures  
To determine whether CHPV was able to proliferate in mouse cerebellar slice 
cultures the recombinant virus  rCVeGFP, which contains a GFP gene inserted 
between the M and G genes of CHPV (Marriott & Hornsey, 2011) (Figure 5.2)  was 
used as it allowed the progress of CHPV infection to be followed in real time with 
samples fixed at appropriate times post-infection.  
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Figure 5.2| Diagram of rCVeGFP genome  
 
In a preliminary experiment cerebellum slice cultures from seven day old mice were 
prepared by Dr Daniel Fulton and cultured for seven days to allow time for the loss 
of any dead cells.  The slices were inoculated with 1x10
6 
pfu per slice of rCVeGFP 
and observed using an epifluorescence microscope.  GFP fluorescence was first 
observed at approximately 6 hours post-infection and at this time the appearance of 
GFP was restricted to several small regions at the periphery of the slices (not shown).  
This restriction may be due to variation in the thickness of the cultured brain slices 
with the edges tending to be thinner and thus more accessible to virus.  At 12 hours 
post-infection GFP expression remained confined to the edges of the slices (although 
the infection had spread further inwards compared to at 6 hours post-infection).  24 
hours after the tissue was infected with virus, rCVeGFP-infected cells were detected 
in the cerebellar slices, with the fluorescence found in specific regions only.                    
Having demonstrated that cerebellar slice cultures support CHPV replication and that 
infection was restricted within the slices, the location of virus-infected cells within 
the histology of the cerebellum was examined.  A labelled photomicrograph 
illustrating the structure of the cerebellum is shown in Figure 5.3 a.  Slices of mouse 
cerebella were infected with rCVeGFP, as above.  24 hours post infection the slices 
were fixed and stained with anti-MBP (myelin basic protein), an antibody specific 
for oligodendrocytes that stains the white matter or myelin component of the 
cerebellum, thus facilitating the identification of specific regions of the tissue 
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containing virus.  Further details about the specificity of this and other brain cell 
markers used in this research is shown in Table 5.1.  The sections were 
counterstained with a secondary antibody coupled to a fluorophore emitting red light 
and examined using a 10 x microscope objective (Figure 5.3 b).  Using a low 
magnification it was possible to visualise the majority of each slice in one field of 
view and the anti-MBP stain allowed the cerebellum histology to be clearly 
observed.  A striking restricted localisation of the virus was observed and virus-
infected cells were found in large numbers in the internal and external granule layers, 
consistent with other research which reported extensive localised necrosis in these 
regions (Jortner et al., 1973).  Limited co-localisation of rCVeGFP-infected cells and 
white matter and little penetration of virus into the molecular layer was observed.        
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Figure 5.3 | rCV-eGFP-infected mouse cerebellum stained for myelin 
A. Labelled photomicrograph of mouse cerebellum stained with haematoxylin and eosin.  
Obtained from http://pictures.doccheck.com/en/photos/54843/12440/cerebellum/. 
B. Cultures of mouse cerebellar were infected with rCVeGFP and incubated for 24 hours at 
37°C.  The slices were then fixed, blocked and stained using anti-MBP antibody in order to 
visualise the architecture of the cerebellum (red).  The virus-infected cells are shown in 
green.  Fluorescence was observed using a Leica SP5 confocal fluorescence microscope.  
The images are 5µM thick Z stacks.   
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Antibody Specificity 
Anti-MBP (myelin basic 
protein) 
Developing and adult myelin, developing 
oligodendrocytes 
Anti-NG2 NG2 Chondroitin Sulfate Proteoglycan on 
oligodendrocyte precursor cells (O-2A progenitor cells).  
The stain appears as clusters on the cell surface.  The 
antibody does not stain differentiated oligodendrocytes 
well 
Anti-ccI Adenomatous polyposis coli (APC) protein found on 
oligodendrocyte cell bodies.  The antibody also labels 
some astrocytes and purkinje cells.   
Anti-Olig2 Oligodendrocyte marker, transcription factor 
Anti-CD11b Integrin alpha-M/beta-2 is predominantly expressed in 
monocytes and granulocytes  
Anti-MAP2 Microtubule associated protein 2 is expressed only in the 
cytoplasm of neuronal cells (predominantly in perikarya 
and dendrites).  It is also found in neurone-restricted 
progenitors  
Anti-NeuN (NEUronal 
Nuclei) 
An RNA-binding protein expressed in differentiated post-
mitotic neuronal nuclei, perikarya and some proximal 
neurone processes in fetal and adult brain (although some 
neurones including Purkinje cells, dentate nucleus 
neurones and inferior olivary cells are not recognised at 
all development stages).   
Anti-β-III tubulin Class II β tubulin (intracellular microtubules) is 
expressed specifically in mature neurones 
Anti-calbindin Purkinje cell bodies and fibers 
Anti-GABA-A receptor α 6 Mature cerebellar granule cells from  ~post-natal day 14 
Anti-GFAP Glial fibrillary acidic protein is a class III intermediate 
filament which is the main constituent of intermediate 
filaments in astrocytes.  It is a cell specific marker for 
differentiated astrocytes 
Table 5.1| Specificities of brain cell markers 
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5.2.2 Elucidating the identity of rCVeGFP-positive cells using brain cell marker 
proteins  
The CHPV-infected brain cell types were investigated using a range of brain cell 
marker proteins which are listed in Table 5.1.  Each cell type specific stain was used 
on at least three different cerebellum slices and the percentage of cells with co-
localising signals calculated from five fields of view for each slice.  rCVeGFP-
infected cerebellum slice cultures were fixed at 12 and 24 hours post infection and 
subjected to immunohistochemistry to detect brain cell-specific markers and 
immunofluorescence to detect the GFP reporter present in the recombinant CHPV.  
Morphologically, the virus-infected cells detected by GFP fluorescence were similar 
to interneurons or granule cells, a type of small neuron.  Granule cells account for 
approximately half the neurones in the CNS and are densely packed within the 
cerebellar granule layer, as were the CHPV-infected cells (Figure 5.3 b).  The 
rCVeGFP-infected cells are also similar to granule cells in size (approximately 10 
µm) and abundance in mouse cerebellum.  An anti-GABA-A receptor α6 antibody, 
specific for granule cells was used in immunofluorescent analysis of the infected 
cerebellar slices.  The results showed that approximately only 1% of virus-infected 
cells co-localised with those stained with the granule cell specific antibody: anti-
GABA-A receptor α6 though the remainder did not (Figure 5.4).   
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Figure 5.4| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP 
and stained for granule cells 
rCVeGFP-infected cells fluoresce green and cell marker proteins were stained with anti-
GABA-A receptor α6 primary antibody followed by a red alexa secondary antibody.  
Fluorescence was visualised using a Leica SP5 confocal fluorescence microscope.  The 
images are 5µM thick Z stacks.  Scale bar of 20 µm is shown on each image.  Several 
GABA-A receptor α6-positive cells infected with rCVeGFP are highlighted with 
arrows.       
 
As previous studies have reported CHPV infection of neurones (Ghosh et al., 2013; 
Jortner et al., 1973) and the morphological similarity between the virus-infected cells 
and small neurones, granule cells, and also the restricted localisation of CHPV-
infected cells within regions of the cerebellum where granule cells are abundant (i.e. 
the internal and external granule layers) has been observed in this investigation, two 
other neurone-specific antibodies were used in the analysis of the rCVeGFP-infected 
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cerebellar sections.  Immunohistochemistry was performed using anti-MAP2 and 
anti-NeuN antibodies, which recognise neurone-restricted progenitors and 
differentiated post-mitotic neuronal cells, respectively.  Approximately 80% of virus-
infected and MAP-2-positive cells were shown to co-localise (Figure 5.5 a, b), while 
there was no co-labelling of virus-infected and NeuN-stained cells (Figure 5.5 c, d).  
These results indicate that CHPV preferentially infects neurone-restricted progenitor 
cells which have not yet fully differentiated.    
 
 
Figure 5.5| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP, 
fixed at 12 hours post-infection and stained for neurones 
rCVeGFP-infected cells fluoresce green and cell marker proteins were stained with either 
anti-MAP2 (a, b) or anti-neuN (c, d) primary antibodies followed by a red alexa secondary 
antibody.  Fluorescence was visualised using a Leica SP5 confocal fluorescence microscope.  
The images are 5µM thick Z stacks.  Scale bar shown.         
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The spread of CHPV infection in the cultures of cerebellar slices was also 
investigated by fixing the cerebellar sections 24 hours post-infection.  The neuronal 
cell markers MAP2, neuN and βIII-tubulin (which is expressed in mature neurones) 
in rCVeGFP-infected tissue were stained and the slices examined by confocal 
fluorescence microscopy (Figure 5.6).  As seen at 12 hours post-infection there was 
co-localisation of virus-infected and MAP2-expressing cells, but at a slightly lower 
level (approximately 55%) at this later time point (Figure 5.6 a, b, c).  However, in 
contrast to the situation at 12 hours post-infection, a few NeuN-positive cells were 
infected, as shown by several yellow regions in Figure 5.6 d, e, f.  A very small 
number of cells stained for βIII-tubulin were also infected with rCVeGFP (Figure 5.6 
h).  Thus, by 24 hours post-infection mature neurones (as well as immature neurones) 
were infected with CHPV, although the levels of co-localisation were consistently 
low (approximately 2%).          
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Figure 5.6| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP, 
fixed at 24 hours post-infection and stained for neurones 
rCVeGFP-infected cells fluoresce green and cell marker proteins were stained with anti-
MAP2 (a, b, c), anti-neuN (d, e, f) or anti-βIII tubulin (g, h) primary antibodies followed by a 
red alexa secondary antibody.  Fluorescence was visualised using a Leica SP5 confocal 
fluorescence microscope.  The images are 5µM thick Z stacks.  Scale bar of 20 µm shown on 
each image.  Several infected cell marker-positive cells are highlighted with arrows.           
 
To further define the types of neurone infected with CHPV an antibody specific for 
calbindin, a marker for Purkinje neurones, was used to stain the cultures fixed at 24 
hours post-infection.  Purkinje neurones have a large cell body (approximately 20 
µm) and an elaborate array of branching dendrites which extend into the cortex of the 
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cerebellum.  They are fundamental to the function of the cerebellum as they serve as 
the only route for signals from the cerebellum to the rest of the brain.  No co-
localisation between CHPV-infected and calbindin-positive cells was observed 
(Figure 5.7).   
 
Figure 5.7| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP, 
fixed at 24 hours post-infection and stained for purkinje neurones 
rCVeGFP-infected cells fluoresce green and cell marker proteins were stained with anti-
calbindin primary antibody followed by a red alexa secondary antibody.  Fluorescence was 
visualised using a Leica SP5 confocal fluorescence microscope.  The images are 5µM thick 
Z stacks.  Scale bar of 20 µm is shown on each image.     
159 
 
Microglia are the immunocompetent cells of the CNS, transforming into active 
phagocytic macrophages in response to pathogen invasion.  Thus, it was important to 
investigate their potential role in CHPV-induced pathology.  Cerebellar slice cultures 
infected with rCVeGFP and fixed 12 and 24 hours post-infection were also 
immunostained for the microglia marker CD11b.  Co-localisation of virus-infected 
and anti-CD11b immunostained cells was not observed at 12 hours post-infection, as 
shown by the absence of overlapping signals in Figure 5.8 a, b.  However, at 24 
hours post-infection approximately 15% of cells infected with rCVeGFP were 
microgila (determined by a positive signal with anti-CD111b; Figure 5.8 c, d).     
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Figure 5.8| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP 
and stained for microglia 
Cerebellar slice cultures were infected with rCVeGFP and fixed at 12 and 24 hours post-
infection.  rCVeGFP-infected cells fluoresce green and cell marker proteins were stained 
with anti-CD11b primary antibody followed by a red alexa secondary antibody.  
Fluorescence was visualised using a Leica SP5 confocal fluorescence microscope.  The 
images are 5µM thick Z stacks.  Scale bar shown.  
 
The infection of oligodendrocytes, a further type of glial cell, by CHPV has not been 
investigated, although a tropism for the cells has been demonstrated by the 
neuropathogenic virus SFV, a widely used model to study viral encephalitis 
(Fazakerley, 2004).  The major function of oligodendrocytes is to generate myelin 
which is essential for the efficient conduction of nerve impulses.  The rCVeGFP-
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infected tissue sections were stained with primary antibodies against NG2 
chondroitin sulfate proteoglycan, Adenomatous polyposis coli protein (CCI) and the 
transcription factor Olig2.  NG2 serves as a marker for oligodendrocyte precursor 
cells, CCI is predominantly expressed on the cell bodies of differentiated 
oligodendrocytes and Olig2 is a transcription factor expressed in oligodendrocytes at 
all stages of development.  The slices were then incubated with a secondary antibody 
conjugated to a red Alexa Fluor® (either 568 or 594).  Analysis of the slices by 
confocal fluorescence microscopy showed only a few of the virus infected cells were 
stained for oligodendrocyte marker proteins at 12 hours post-infection (Figure 5.9). 
Two Olig2-positive cells which had been infected with rCVeGFP are highlighted 
with arrows in Figure 5.9 i.   
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Figure 5.9| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP, 
fixed at 12 hours post-infection and stained for oligodendrocytes 
Slices were fixed 12 hours post-infection.  rCVeGFP-infected cells fluoresce green and cell 
marker proteins were stained with anti-NG2 (a, b, c), anti-cc1 (d, e, f) or anti-Olig2 (g, h, i) 
primary antibodies followed by a red alexa secondary antibody.  Fluorescence was visualised 
using a Leica SP5 confocal fluorescence microscope.  The images are 5µM thick Z stacks.  
Scale bar shown.  Co-localisation of virus-infected and oligodendrocyte cell marker-positive 
cells is illustrated by arrows.     
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There was an increase in the number of rCVeGFP-infected oligodendrocytes at 24 
hours post-infection compared with 12 hours post-infection, as shown by a rise in 
virus-infected NG2-, ccI and olig2-positive cells (Figure 5.10).  
 
 
Figure 5.10| Confocal micrographs of mouse cerebellar slices inoculated with CVeGFP, 
fixed at 24 hours post-infection and stained for oligodendrocytes 
CVeGFP-infected cells fluoresce green and cell marker proteins were stained with anti-NG2 
(a, b, c), anti-cc1 (d, e, f) or anti-Olig2 (g, h) primary antibodies followed by a red alexa 
secondary antibody.  Fluorescence was visualised using a Leica SP5 confocal fluorescence 
microscope.  The images are 5µM thick Z stacks.  Scale bar shown.      
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Astrocytes, another class of glial cell, perform a variety of important functions in the 
brain including supporting neurones, maintaining brain homeostasis by removing 
glutamate and regulating the levels of potassium, connecting neurones with the 
vascular system and controlling synapse formation and maintenance (Nedergaard et 
al., 2003).  The presence of rCVeGFP-infected astrocytes was investigated using 
immunohistochemistry with an anti-glial fibrillary acidic protein (GFAP) antibody, 
which is specific for differentiated astrocytes.  A small number of GFAP-
immunoreactive astrocytes were infected with virus, demonstrating that these cells 
are also permissive to CHPV infection (Figure 5.11).   
 
 
Figure 5.11| Confocal micrographs of mouse cerebellar slices inoculated with rCVeGFP, 
fixed at 24 hours post-infection and stained for astrocytes 
rCVeGFP-infected cells fluoresce green and cell marker proteins were stained with anti-
GFAP primary antibody followed by a red alexa secondary antibody.  Fluorescence was 
visualised using a Leica SP5 confocal fluorescence microscope.  The images are 5µM thick 
Z stacks.  Scale bar shown.        
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5.3 Establishing an in vivo model of CHPV-induced encephalitis  
5.3.1. Dose-dependent induction of encephalitis in mice by CHPV 
5.3.1.1. Titration of CHPV in mice 
Wild type CHPV strain I653514 was used in the early studies in mice and therefore 
was selected for use in this investigation to allow comparison with previously 
published data.  A recombinant wild-type virus, designated rCHPV derived from 
strain 1653514 was generated and also tested.  The initial step in this investigation 
was to establish the appropriate dose of wild type CHPV and rCHPV to elicit clear 
signs of infection between 2-5 days post-infection.  This was necessary as variation 
in the infectious dose required to initiate disease with different strains is well 
recognised.  This virus strain and the initial infectious dose used in the titration study 
(refer to section 2.3.2 for the method) was guided by these.  The ability to observe 
the clinical symptoms of CHPV infection between 2-5 days post-infection was 
considered ideal as it provided a sufficient window in which to study the progression 
of neurological disease in the mouse model.  A staged approach was used in the 
titration experiments with three mice being tested with the initial dose and then 
observed.  The dose was altered as appropriate (lowered if the initial dose tested 
resulted in rapid disease onset) and another group of three animals tested.  This 
process was repeated until a dose of virus was identified that caused observable 
disease in all three animals with paralysis in two limbs seen on or near day three after 
infection.  This staggered approach was taken to reduce the numbers of animals 
required for the experiments, in accordance with the Home Office licence.  The study 
did not require that the animals progress to the most advanced stage of disease before 
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analysis and therefore any animals presenting with paralysis in two limbs were 
immediately culled.           
 
Three ICR (CD1) mice (7-11 days old) were infected by the intraperitoneal route 
with the initial dose of 1.0 x 10
4
 pfu of wild-type CHPV per mouse.  The mice were 
observed twice daily from the time of infection for signs of disease and the total 
weight of the group was measured daily.  The group weight of the mice was 
measured as an additional monitor of general health.  The progress of disease was 
recorded using a quantitative scoring system which is explained in section 2.3.1.  The 
results are shown in Figure 5.12.  The 1.0 x 10
4
 pfu dose of virus resulted in a very 
rapid onset of disease with the first observable symptoms at day 2 post-infection.  By 
day 3 post infection the disease had progressed further with one of the mice 
exhibiting paralysis of two limbs (which is the end point of the experiment, a score 
of 4 in the clinical scoring system) and the other two mice showing paralysis in one 
of the hind limbs (the side adjacent to the site of inoculation).  Following an initial 
increase at day 1 post infection the weight of the mice declined rapidly over the 
observation period, with the group weight at day 3 post-infection almost 10% lower 
than on the day of virus inoculation and lower than their initial group weight.  A 
domed appearance to the head of the most severely affected mouse on day 3 post-
infection with CHPV was also observed, suggestive of an accumulation of fluid 
surrounding the brain.      
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Figure 5.12| Progress of wild-type CHPV infection at different doses 
Groups of three mice were inoculated intraperitoneally with either 1x10
4
, 1x10
3
 or 1x10
2
 pfu 
of wild type CHPV.  For each dose the progress of disease is shown as the collective average 
weight (calculated as the percentage difference compared to day 0) (A) and the average 
clinical score (B).     
 
The progress of disease produced by 1.0 x 10
4
 pfu CHPV was considered too rapid 
for practical study and therefore a lower dose was required to study the progress of 
disease.   A 10-fold lower dose (1.0 x 10
3 
pfu per mouse) was used to inoculate a 
second group of three mice and disease monitored as before (Figure 5.12).  The first 
symptoms of disease were observed at day 3 post-infection (a day later than seen at 
the higher dose), however, disease progression remained too rapid for use in the 
study.   The average weight profiles of the infected animals were very similar at the 
two doses.  The study was repeated using an inoculum containing 1 x 10
2 
pfu of 
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CHPV per mouse, the results of which are shown in Figure 5.12.  This dose elicited a 
more gradual disease progression.  The initial clinical signs of infection were 
observed 3 days post-inoculation.  However, unlike with the case at the higher doses, 
none of the three mice inoculated with 1.0 x 10
2 
pfu of CHPV displayed the most 
severe symptoms (score of 4) until day 4 post-infection.  Furthermore, the reduction 
in weight compared to the uninfected control mice was less marked, not falling 
below the starting average weight, and occurred more gradually.  There was a slight 
increase (6%) in group weight at day 4 post-infection compared with the initial group 
weight, despite all of the mice displaying symptoms.  Taken together, these results 
indicated that a dose of 1.0 x 10
2 
pfu per mouse was appropriate for the next stage of 
the investigation as it was sufficient to elicit symptoms in each of the mice and 
provided a suitable window in which to study the progression of CHPV-induced 
encephalitis.              
 
The clinical signs of disease progression of seven out of the nine mice used in the 
pilot study were consistent with descriptions in the literature: unilateral paralysis of 
the hind limb nearest the injection site followed by bilateral hind limb paralysis (after 
which would be forelimb paralysis and death if the mice were allowed to progress to 
this stage) (Jortner et al., 1973).  However, the other two mice displayed paralysis in 
one of the forelimbs (the same side of the body as the inoculation) following the 
initial unilateral hind limb paralysis.  Thus, the disease progression of CHPV after 
intraperitoneal inoculation of the virus in young mice is variable and does not always 
follow the previously documented stages.                     
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5.3.1.2. Virus was detected in the brains (but not lungs or liver) of infected mice 
In order to investigate the site(s) of CHPV replication in the mouse model, the 
brains, lungs and livers were removed from six of the mice which were culled 
following infection with wild-type CHPV (two from each of the doses used in the 
pilot study above, section 5.3.1.1.).  The tissues were homogenised in PBS and virus 
was titrated in BSC-1 cells.  The titres obtained are shown in Table 5.2.  Virus was 
detected at high titre (with an average of 4.78 x10
9 
pfu/ml) in each of the six brain 
samples tested.  No virus was found in any of the other organs, indicating that less 
than 200 pfu/ml of virus was present in these samples (i.e. 200 pfu/ml was the 
detection limit of the assay used).       
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Sample Average titre 
(pfu/ml) 
Mouse 1 brain 4.78 x10
6 
Mouse 1 lungs <200 
Mouse 1 liver <200 
Mouse 2 brain 3.50 x10
9 
Mouse 2 lungs <200 
Mouse 2 liver <200 
Mouse 3 brain 1.15 x10
10
 
Mouse 3 lungs <200 
Mouse 3 liver <200 
Mouse 4 brain 7.10 x10
9
 
Mouse 4 lungs <200 
Mouse 4 liver <200 
Mouse 5 brain 2.45 x10
9 
Mouse 5 lungs <200 
Mouse 5 liver <200 
Mouse 6 brain 4.10 x10
9 
Mouse 6 lungs <200 
Mouse 6 liver <200 
 
Table 5.2| Titre of virus present in the brain, lungs and liver after infection with wild-
type CHPV 
Brain, lungs and liver were extracted from six mice showing symptoms of infection with 
CHPV (scoring 4 on the clinical assessment scale).  The homogenised samples were 
subsequently used in plaque assays in BSC-1 cells.  The detection limit for the assay was 200 
pfu/ml virus.          
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5.3.2. Progression of wild-type CHPV infection in vivo 
5.3.2.1. Weight change and clinical assessment 
A dose of 50 pfu was used to elicit clear signs of infection between 2-5 days post-
infection.  Four groups of six 7-11 day old mice were inoculated intraperitoneally 
with 50 pfu of wild type CHPV and 5 mice (two from one group and one from each 
of the other groups) were sacrificed on 1, 2 and 3 days post-infection.  The brains 
were removed and divided along the midsagittal plane.  One half of each brain was 
homogenised for virus titration (section 5.3.2.2) and the other half was fixed for 
pathological examination (section 5.3.2.3).  PBS was inoculated into the peritoneal 
cavity of a group of 6 uninfected control mice.  All infected and uninfected mice 
were observed at daily intervals for signs of disease and the weight of the animals in 
each group and the clinical scores were recorded.  The number of mice used in the 
experiment was the minimum number of animals necessary to provide statistically 
robust data.  The collective weight of each group at each time point was expressed as 
percentage change compared to day 0 and the average of the 6 groups was then 
calculated.  The clinical scores for each time point were summed and an average 
calculated.      
The average weight changes and clinical scores (the mean of groups A-D) are shown 
in Figure 5.13 A and B respectively.  The uninfected control group showed a steady 
increase in weight, gaining an average of 9% in weight each day over the 3 day 
observation period.  Infection with wild-type CHPV severely inhibited weight gain in 
the suckling mice and the clinical scores obtained closely reflected the weight change 
data.  The first symptoms of CHPV disease occurred at day 2 post-inoculation of 50 
pfu of wild-type CHPV.  Day 2 post-infection is also the time point where the 
infected mice separate from the trajectory of the uninfected control mice in terms of 
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weight, with a 2% average decrease in body weight in the experimental groups 
compared with a 9% increase in weight in the uninfected control group.  There was a 
further 2% average reduction in weight by the following day in the infected mice, by 
which point the average score was 4 (i.e. paralysis in two limbs) in the clinical 
assessment system, the end point in this experiment.  The differences between the 
mean group weights of the uninfected and infected animals were shown to be 
significantly different on day 2 and 3 post-infection (one tailed unpaired Student’s t-
test, p≤0.05). 
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Figure 5.13| In vivo timecourse of wild-type CHPV infection  
Suckling CDI mice (7-9 days old) were inoculated with 50 pfu of wild-type CHPV (red) or 
PBS (blue) by the intraperitoneal route.  Weight data are expressed as a percentage change 
compared to the group weight at day 0.  The change in mean weight (A) and average clinical 
scores (B) are given.  The statistical significance of body weight changes on any one day was 
determined by a one tailed unpaired Student’s t-test and is indicated by an asterisk (p≤0.05).          
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5.3.2.2. Virus was detected in the mouse brain 24 hours post-infection with wild-type 
CHPV 
Five mice were sacrificed at 1, 2 and 3 days post infection with wild-type CHPV 
(above in section 5.3.2.1).  Mice which showed paralysis of two limbs (i.e. the 
endpoint of the experiment) were culled and also sampled.  Brains were removed 
from all of the sacrificed animals to be sampled and divided into two down the 
midsagittal plane.  One half of each brain was homogenised in 500 µl of PBS and 
virus titrated in BSC-1 cells.  The virus titres are shown in Table 5.3.  Virus was 
present in the brain samples of each animal tested by 24 hours after intraperitoneal 
infection and the mean titre increased rapidly by 48 hours post-inoculation and 
decreased slightly by 72 hours post-inoculation.  At 24 and 48 hours post-infection 
there was a 392-fold and 10 million-fold increase in viral titre in the brains of 
infected mice, respectively, compared to the 50 pfu starting inoculum.     
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Time post-
infection (hours) 
Average titre 
per sample  
(pfu/ml) 
Average titre 
(pfu/ml) 
24 
1.40x10
4
  
7.15x10
3
  
1.38x10
4
 1.96x10
4
 
8.75x10
3
  
2.40x10
5
  
48 
2.02x10
8
  
1.50x10
9
  
4.75x10
8
  
9.13x10
7
  
4.55x10
9
 5.22x10
8
 
8.68x10
9
  
1.43x10
8
  
-  
1.09x10
7
  
3.60x10
9
  
72 
7.39x10
7
  
8.47x10
8
  
1.00x10
10
  
2.72x10
4
  
6.13x10
3
 1.05x10
8
 
2.83x10
8
  
1.74x10
9
  
4.93x10
9
  
6.00x10
9
  
       
Table 5.3| Titre of virus present in the brain after infection with wild-type CHPV strain 
I653514 
At daily intervals 1 mouse from each experimental group was sacrificed using a schedule 1 
method.  Eight mice were culled because they displayed paralysis in two limbs and one had 
died (highlighted in pink and red respectively).  The brains were removed from all of the 
sacrificed animals and divided into two down the midsagittal plane and one half was assayed 
for virus.  Virus titres are the averages from duplicate repeats (column 2) and the overall 
average titre at each time point (i.e. the mean titre of the samples).  The titre data from the 
fatal infection was not included in the average titre for the time point.  The average titres 
given are the geometric mean across the groups.               
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Large variations were seen in the individual viral titres obtained per sample at the 72 
hour time point, approximately a two million-fold difference between the lowest and 
highest titre.  However, seven out of nine mice that were culled at the 72 hour time 
point had a titre greater than 7.0x10
7 
pfu/ml.   
 
5.3.2.3. Pathological examination of brains from mice infected with wild-type CHPV 
showed pronounced damage to the cerebellum 
The brains were removed from all of the sacrificed animals in the wild-type CHPV 
timecourse (section 5.3.2.1) and divided along the midsagittal plane.  As detailed 
above in section 5.3.2.2 one half of each brain was used in titration experiments on 
BSC-1 cells, in order to determine the titre of virus present in the brain at each stage 
of infection.  The other half was fixed in 4% paraformaldehyde in PBS.  Sagittal 
sections were prepared and stained with haematoxylin and eosin (H&E) (University 
of Edinburgh).   
Analysis of the brain sections infected with CHPV strain I653514 at post-infection 
day 1 appeared comparable to the uninfected samples (post-infection day 1 samples 
not shown).  The first signs of virus infection in the brain were observed at day 2 
post-infection (Figure 5.14).  The histopathological lesions were restricted to the 
cerebellum and included neuronal damage including cell shrinkage and purkinje 
neurones with pyknotic nuclei (Figure 5.14 f) and substantial areas of cell death 
(Figure 5.14 d-f).  There was also evidence of inflammation and infiltration of 
mononuclear infiltrates, indicative of an active immune response.  At day 3 post-
infection the histopathologic changes in the cerebellum were even more pronounced 
with severe neuronal vascular degeneration, large regions of cell death (Figure 5.14 
g, h) and large numbers of mononuclear cells (Figure 5.14 i).  On day 3 post-
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infection cell death was also observed in the hippocampus (Figure 5.15 b, c) and 
there were several regions of vacuolation in the cortex (Figure 5.15 d).        
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Figure 5.14| Sagittal brain sections stained with haematoxylin and eosin from mice inoculated with CHPV strain I653514  
5µM paraffin processed sagittal sections from control samples (a-c) and mice infected with CHPV and sampled at post-infection day 2(d-f) or post-infection 
day 3 (g-i).  A pyknotic nucleus  is indicated by an arrow in panel f.       
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Figure 5.15| Sagittal brain sections stain with haematoxylin and eosin from mice inoculated with CHPV strain I653514  
The 5µM sections were processed in paraffin.  Representative photomicrographs of hippocampus in control (a) and in virus-infected mice at post-infection day 
3 (b, c) and cortex from a CHPV-infected section at post-infection day 3 (d).  
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5.3.3. The dose of recombinant wild-type CHPV required to cause encephalitis 
The availability of the CHPV reverse genetics system (Marriott & Hornsey, 2011) 
provided a unique opportunity to explore the site of CHPV infection in the mouse 
brain and the cell types permissive to infection, by enabling the generation of a 
number of recombinant viruses containing reporter genes.  It was important, 
therefore, to firstly compare the pathogenesis of the genetically modified viruses 
with the wild type virus in mice to validate the biological significance of work using 
the recombinant viruses.  Viruses grown extensively in tissue culture can have a 
different pathogenicity to the parental virus, either due to point mutations which have 
accumulated in the parental virus as a consequence of repeated passages in cell lines 
or non-coding, epigenetic alterations.  rCHPV does not contain any mutations with 
respect to CHPV strain I653514 but there may be epigenetic changes including 
differences in glycosylation. For this reason a rCHPV was used as the comparison 
with the tagged recombinant viruses.  Section 4.1.4 contains details of the recovery 
of rCHPV.   
 
5.3.3.1. A ten-fold higher dose of rCHPV (500
 
pfu) was required to induce 
encephalitis compared with wild-type CHPV strain I653514 
A group of six 8 day old ICR (CDI) mice were inoculated with 50 pfu of rCHPV by 
the intraperitoneal route.  This was the dose of wild-type CHPV (strain I653514) 
capable of inducing fatal encephalitis.  The group weight and clinical assessment 
scores for the mice over a 9 day observation period are shown in Figure 5.16 A and 
B respectively.  The weight of the animals in the experimental group remained 
similar to the uninfected control mice, increasing steadily throughout the duration of 
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the experiment, despite 2 out of 6 mice becoming sick.  The first symptoms were 
observed on day 6 post-infection, as shown by the increase in clinical score in Figure 
5.16 B.  These results indicated that the rCHPV was considerably less pathogenic 
than the wild-type virus where intraperitoneal inoculation of 50 pfu resulted in an 
average clinical score of 3.92 at day 3 post-infection and a highly significant 
reduction in mean weight at both day 2 and 3 post-infection with respect to the 
control group.      
To establish the dose of rCHPV required to produce a disease progression equivalent 
to that of the wild-type virus another group of six 8 day old ICR (CDI) mice were 
inoculated with the 10-fold higher dose of 500 pfu of rCHPV.  At this dose all six of 
the infected mice developed disease and reached the end point 5 days post-infection 
(Figure 5.16 B).  Moreover, the relative percentage increase in group weight from 
day 0 to 5 was 20% lower in the rCHPV-infected group than the mock group (Figure 
5.16 A).  Despite being a lethal dose, there was a delay in the onset of clinical 
disease of 1-day and a 2-day delay in the progression of disease compared with the 
wild-type virus (Figure 5.13).                     
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Figure 5.16| Progress of recombinant wild-type CHPV infection at different doses 
Groups of six mice were inoculated intraperitoneally with either 50 pfu or 500 pfu of 
recombinant wild type CHPV (rCHPV) or PBS.  For each dose the progress of disease is 
shown as the collective average weight (calculated as the percentage difference compared to 
day 0) (A) and the average clinical score (B).      
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5.3.4. Progression of recombinant wild-type CHPV infection in vivo 
5.3.4.1. Weight change and clinical assessment 
rCHPV (500 pfu per mouse) was administered intraperitoneally to 6 groups of 8 day 
old ICR (CDI) mice (6 mice per group) and group weights and clinical scores were 
measured daily.  PBS was inoculated into the peritoneal cavity of a group of 6 
control mice.  6 mice were sacrificed at each of 1, 2, 3, 4 and 5 days post infection.  
The brains were removed and divided as described previously.  One half of each 
brain was homogenised for virus titration (section 5.3.4.2) and the other half was 
fixed for pathological examination (section 5.3.4.3).   
The average relative percentage weight change and clinical scores for the virus-
infected and uninfected mice throughout the timecourse are shown in Figure 5.17.  
The onset of clinical symptoms in the virus-infected group occurred on day 3 post-
infection and the mean clinical score of the virus group on the last day of the 
experiment was 1.7 (as the majority of the mice did not develop disease).  This was 
reflected in the mean weight changes, which remained similar for the rCHPV-treated 
and uninfected animals throughout the experiment (Figure 5.17 A).                             
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Figure 5.17| In vivo timecourse of recombinant wild-type CHPV infection (500 pfu) 
Suckling CDI mice (8 days old) were inoculated with 500 pfu of rCHPV or PBS by the 
intraperitoneal route.  The average daily percentage change in weight for the virus-infected 
and the mock group is shown in A, whilst the average clinical disease assessment for is given 
in in B.   
 
As very few of the mice developed encephalitis upon intraperitoneal injection of 500 
pfu of rCHPV the experiment was repeated using a dose of 1000 pfu of virus per 
mouse (Figure 5.18).  There was a reduction in percentage weight gain (relative to 
the mock) at day 4 post-infection, followed by a further decrease in weight at day 5 
post-infection) in the rCHPV-infected group (Figure 5.18 A).  The onset of 
symptoms began on day 3 post-infection of rCHPV and progressed rapidly thereafter 
(Figure 5.18 B).  By post-inoculation day 5 severe disease was observed in the virus 
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group and the end point was reached.  Thus this dose of rCHPV is lethal and 
therefore would provide tissue samples with which to study the pathology of CHPV-
induced encephalitis.  The average weight change of the rCHPV-infected group at 
day 2 post-infection was found to be significantly higher than the mean mock weight 
at this timepoint, a shown by an asterisk in Figure 5.18 A.  The animals in both 
groups then resumed weight gain at similar levels until day 4 post-infection when the 
infected mice showed a highly significant loss of weight.  The infected mice showed 
another significant weight loss on day 5.   
 
Figure 5.18| In vivo timecourse of recombinant wild-type CHPV infection (1000 pfu)  
Suckling CD1 mice (8 days old) were inoculated with 1000 pfu of wild-type CHPV (red) or 
PBS (blue) by the intraperitoneal route.  The average daily percentage change in weight for 
the virus-infected and the uninfected groups are shown in A, whilst the clinical disease 
assessment for each is given in B.  The statistical significance of body weight changes on 
any one day was determined by a one tailed unpaired Student’s t-test and is indicated by an 
asterisk (p≤0.05).              
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5.3.4.2. Virus was detected at high titre in the mouse brain 3 days post-infection with 
rCHPV 
6 mice per time point from the 1000 pfu rCHPV timecourse (above in section 
5.3.4.1) were sacrificed at 1, 2, 3, 4 and 5 days post-infection.  The brains were 
removed and divided into two as before with one half assayed for virus.  The virus 
titres are shown in Table 5.4.  Mice which showed paralysis in two limbs (i.e. the 
endpoint of the experiment) were culled but not sampled because including them 
would have skewed the data so that the mice which experienced a more gradual 
disease progression were sacrificed for sampling at the later time points (as they were 
the only ones left).  These mice may have had a lower than average brain viral titre if 
the animals that were culled were allowed to progress to the most advance stage of 
disease had been included in the average.   
Virus was detected in the brain at post-inoculation day 1 in 5 out of 6 mice tested 
with an average titre of 4.30x10
2
 pfu/ml.  At day 2 post-infection the level of virus 
present in the majority of brain samples (5 out of 6) remained fairly low, although 
the average titre was high because of the 1.54x10
6 
pfu/ml of virus in one of the 
samples.  All of the mice sampled had high levels of virus in the brain at day 3 post-
infection, an approximately 80,000-fold increase in comparison with the 1000 pfu 
starting inoculum which was introduced into the peritoneal cavity.  The average viral 
titre in the brain increased further by day 4 post-infection (200,000-fold higher than 
the virus administered).  There was a slight reduction in virus titre on day 5 
compared with the previous day.  This was probably because the majority of mice 
displayed the most severe symptoms by day 4 post-infection and so were culled and 
therefore the mice sampled on day 5 were those that experienced a slower than 
average disease progression. 
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There was a 2-day delay in the appearance of virus at high titre in the mouse brain 
after intraperitoneal inoculation of 1000 pfu rCHPV compared with when 500 pfu of 
wild-type CHPV strain I653514 was administered.  This is consistent with an 
identical delay in the onset of clinical symptoms.       
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Time post-infection 
(days) 
Average titre per 
sample  (pfu/ml) 
Average titre 
(pfu/ml) 
1 
0 
4.30x10
2
 
1.03x10
3
 
1.20x10
3
 
5.00x10
1
 
2.75x10
2
 
2.50x10
1
 
2 
2.50x10
1
 
 
2.57x10
5
 
 
1.54x10
6
 
7.50x10
1
 
1.75x10
2
 
0 
7.50x10
1
 
3 
8.25x10
7
 
8.02x10
7
 
6.75x10
3
 
2.55x10
7
 
1.73x10
8
 
2.00x10
8
 
3.10x10
4
 
4 
2.53x10
8
 
 
2.14x10
8
 
 
1.73x10
6
 
9.00x10
7
 
4.93x10
8
 
3.25x10
8
 
1.20x10
8
 
5 
1.38x10
6
  
8.11x10
7
 
 
2.23x10
8
 
2.00x10
5
 
1.00x10
8
 
 
Table 5.4| Titre of virus present in the brain after infection with recombinant wild-type 
CHPV 
At daily intervals 1 mouse from each virus group was sacrificed using a schedule 1 method.  
The brains were removed from all of the sacrificed animals and divided into two down the 
midsagittal plane.  One half of each brain was homogenised in 500 µl of PBS and titrated on 
BSC-1 cells.  Virus titres are the averages from duplicate repeats (column 2) and the overall 
average titre at each time point (i.e. the mean titre from the samples).            
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5.3.4.3 Pathological examination of brains from mice infected with rCHPV 
The other half of the brains from the rCHPV-infected mice, which were sampled 
daily from 1 to 5 days post-infection and uninfected control mice (section 5.3.4.1) 
were fixed in 4% paraformaldehyde in PBS for pathological analysis.  Sagittal 
sections from these samples were prepared and then stained with haematoxylin and 
eosin (H&E) (University of Edinburgh).  Figure 5.19 contains representative 
photomicrographs from the analysis of the sections.   
In line with the virus titre data and the clinical scores, the initial pathological changes 
were first observed on day 3 post-infection, a day later than following inoculation of 
CHPV strain I653514.  These changes included some neuronal damage including cell 
shrinkage and pyknotic nuclei (Figure 5.19 c) and mononuclear infiltrates (Figure 
5.19 d) in the cerebellum.  At days 4 and 5 post-infection the pathology was more 
striking with large zones of complete cell death in the cerebellum (Figure 5.19 f-k).  
Some cell death was also observed in the hippocampus and cortex at days 4 and 5 
post-infection (not shown).   
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Figure 5.19| Brain sections stained with haematoxylin and eosin from mice inoculated 
with 1000 pfu of rCHPV 
5µM sections were prepared and processed in paraffin.  Representative photomicrographs 
showing regions of the cerebellum from control (a, b) and virus-infected mice at post-
infection day 3 (c, d, e), 4 (f, g, h) and 5 (i, j, k).  Pyknotic nuclei and neurones with central 
chromatolysis are shown by arrows.   
 
5.3.5. The dose of a GFP-tagged CHPV (CVeGFP) required to cause 
encephalitis 
To investigate the site(s) of infection and the cellular tropism of CHPV in the brain 
the recombinant CHPV, rCVeGFP (Marriott & Hornsey, 2011) was used.  A diagram 
of the rCVeGFP genome is shown in Figure 5.2.  The pathogenicity of this virus in 
mice was compared to that of rCHPV to confirm that the genetically modified virus 
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behaved in the same way as the wild-type tissue culture-derived virus. Introduction 
of the eGFP gene had little observable effect on the growth of the virus in tissue 
culture. 
5.3.5.1. A dose of 1000
 
pfu of CVeGFP was required to induce encephalitis  
6 8 day old mice were inoculated intraperitoneally with 50 pfu of CVeGFP.  This 
dose had no effect on the observed weight relative to the uninfected animals but did 
induce disease, as illustrated in Figure 5.20.  The initial symptoms were observed on 
day 5 post-infection.  A 10-fold increase in the dose of CVeGFP administered (500 
pfu per mouse) led to more severe disease; showing the first signs of infection on 
post-infection day 4 and progressing to the experimental endpoint on day 6 (Figure 
5.20).  Intraperitoneal injection of 1000 pfu resulted in severe disease in all of the 
mice with the initial signs evident on day 3 and the endpoint reached on day 6 post-
infection.  Thus, 1000 pfu was deemed a suitable dose to further investigate the 
progression of CHPV-induced encephalitis.  In vivo infection with CVeGFP (at any 
of the three doses) did not lead to weight loss (as observed for CHPV strain I653514 
and rCHPV) and levels remained comparable to the uninfected mice throughout the 
study.  
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Figure 5.20| Progress of CVeGFP infection at different doses 
Groups of six mice were inoculated intraperitoneally with either 50 pfu, 500 pfu or 1000 pfu 
of CVeGFP or PBS.  For each dose the progress of disease is shown as the collective average 
weight (A) (calculated as the percentage difference compared to day 0) and the average 
clinical score (B).    
        
5.3.6. Progression of CVeGFP infection in vivo 
5.3.6.1. Weight change and clinical assessment 
6 groups of 6 8 day old mice were infected with 1000 pfu CVeGFP via the 
intraperitoneal route and observed for signs of clinical disease.  PBS was inoculated 
into the peritoneal cavity of a group of 6 control mice.  Each day 5 mice were culled 
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and the brain removed.  Brains were divided along the midsagittal plane.  One half of 
each brain was homogenised for virus titration (section 5.3.6.2) and the other half 
was fixed for pathological examination (section 5.3.6.3).  The group body weight 
changes (relative to day 0) for the virus-infected group was comparable to the 
uninfected group throughout the study, despite the mice exhibiting severe symptoms 
of disease (Figure 5.21).  Symptoms were first observed on day 5 post-infection.   
 
Figure 5.21| In vivo timecourse of CVeGFP infection (1000 pfu) 
Suckling CD1 mice (8 days old) were inoculated with 1000 pfu of CVeGFP (green) or PBS 
(blue) by the intraperitoneal route.  The change in mean weight for the virus-infected and the 
uninfected group is shown in A, whilst the average clinical scores are given in B.     
  
194 
 
5.3.6.2. There was a two day delay in the onset of CVeGFP-induced encephalitis 
compared with rCHPV  
To allow comparison, the mean group weights and clinical scores of mice infected 
with 1000 pfu of rCHPV (Figure 5.18) and 1000 pfu of rCVeGFP (Figure 5.21) are 
given in Figure 5.22.  The results indicate that the insertion of eGFP in the CHPV 
genome between the M and G genes produced a virus that had different 
characteristics in vivo.  There was a 2-day delay in disease onset and progression 
compared to infection with rCHPV.  The summed clinical scores for rCHPV-infected 
mice were significantly higher than rCVeGFP-infected mice from post-inoculation 
day 3, as determined by one tailed Mann-Whitney U tests (Figure 5.22 B).  
Intraperitoneal injection of 1000 pfu of rCHPV produced a fatal encephalitis in all 
mice by day 5 post-infection.  Animals given this dose of rCHPV also showed 
significant weight loss compared to the non-infected control group on days 4 and 5.  
In contrast, relative weight change was unaffected by infection with rCVeGFP, as 
shown by values comparable to the controls in Figure 5.21.   However, Figure 5.22 A 
shows the mean weights of mice infected with rCVeGFP being significantly higher 
than the mock from day 3.  This is because the mock values in this figure were 
derived from the average weights of uninfected mice, which were substantially lower 
than the mock group in the rCVeGFP experiment (Figure 5.21).   
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Figure 5.22| Comparison of rCHPV and rCVeGFP pathogenesis (1000 pfu) 
Changes in mean weight (A) and average clinical score (B) after intraperitoneal inoculation 
of 1000 pfu of rCHPV (red) or 1000 pfu of rCVeGFP (green).  Weight data are expressed as 
a percentage change compared to the group weight at day 0.  Statistical significance of 
summed clinical scores for day 3 was determined by a one tailed Mann-Whitney U test, 
indicated by p value.  The differences between the clinical scores for rCHPV and rCVeGFP 
for days 4 and 5 post-infection were highly significant, indicated by an asterisk.     
 
 
5.3.6.3. Virus was detected at high titre in the mouse brain four days post-infection 
with CVeGFP 
One mouse from each group in the 1000 pfu CVeGFP timecourse study (section 
5.3.6.1) was sacrificed each day following virus inoculation.  The brains were 
removed and one half of each brain was homogenised in 500 µl of PBS and virus 
was titrated in BSC-1 cells.  The titres of virus obtained in the brain after 
intraperitoneal inoculation of 1000 pfu of CVeGFP are shown in Table 5.5.   
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The earliest time point virus was detected in the brain at this dose was day 1 post-
infection although only in 2 out of the 6 samples.  In these samples the titres were 
very low and may represent contamination by virus in the blood resulting from 
viraemia though this was not tested directly.  The average titre increased on day 2 
post-infection to 4.55 x10
3
 pfu/ml, however, only 2 out of 6 samples tested positive 
for virus and one of those only had a titre of 2.50x10
1 
pfu/ml.  By day 3 post-
infection, the average titre had increased further to 1.51x10
4
 pfu/ml and virus was 
found in half of the samples.  The average viral titre continued to rise at day 4 and 5 
post-infection and virus was detected in the brains of each of the mice sampled at day 
5 post-infection.  The titre data after intraperitoneal inoculation of 1000 pfu of 
CVeGFP varied considerably between the samples at each of the time points. 
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Time post-
infection (days) 
Average titre per 
sample  (pfu/ml) 
Average titre 
(pfu/ml) 
1 
0 
3.33x10
1
 
0 
0 
5.00x10
1
 
1.50x10
2
 
0 
2 
0 
4.55x10
3
 
2.50x10
1
 
0 
0 
0 
2.73x10
4
 
3 
2.50x10
1
 
1.51x10
4
 
7.43x10
4
 
0 
0 
0 
1.65x10
4
 
4 
0 
8.88x10
5
 
0 
0 
2.50x10
1
 
5.22x10
6
 
1.14x10
5
 
5 
2.25x10
6
 
2.13x10
6
 
4.50x10
4
 
2.00x10
2
 
1.00x10
3
 
1.05x10
7
 
7.50x10
1
 
6 
0 
4.86x10
5
 
1.83x10
6
 
2.50x10
3
 
1.10x10
5
 
Table 5.5| Titre of virus present in the brain after intraperitoneal inoculation of 1000 
pfu of rCVeGFP 
At daily intervals 1 mouse from each experimental group was sacrificed using a schedule 1 
method.  The brains were removed from all of the sacrificed animals and divided into two 
down the midsagittal plane.  One half of each brain was homogenised in 500 µl of PBS and 
titrated in BSC-1 cells.  Virus titres are the averages from duplicate repeats (column 2) and 
the overall average titre at each time point (i.e. the mean titre of the samples).            
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5.3.6.4. Significantly lower levels of virus was present in the brains of CVeGFP-
infected mice compared to rCHPV-infected mice at days 3 and 4 post-inoculation    
The average viral titres detected in the brain after intraperitoneal inoculation of 1000 
pfu of rCHPV or rCVeGFP are shown in Figure 5.23.  Mice infected with rCVeGFP 
were found to have significantly lower levels of virus present in the brain than 
rCHPV-infected mice at 3 and 4 days post-infection.  This was determined using a 
two tailed Mann-Whitney U test.      
 
 
Figure 5.23| Virus titre in rCHPV and rCVeGFP brain samples 
Average virus titre determined from brain samples from mice inoculated with 1000 pfu 
rCHPV (red) and rCVeGFP (green).  Error bars show the standard error of the mean.  
Statistical significance of each day was determined by a two tailed Mann-Whitney U test.  
Statistically significant differences are indicated by p value for days 3 and 4.   
 
5.3.6.5. rCVeGFP passaged in the mouse brain contains functional GFP 
Plaques obtained from the titration of brain samples taken from mice inoculated with 
rCVeGFP (section 5.3.6.1) were visualised using epifluorescence microscopy, to 
confirm the expression of GFP (not shown).   
In addition, RNA was extracted from 5 of the homogenised brain samples and 
reverse transcribed to generate cDNA using random hexanucleotide primers.  The 
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GFP sequence was amplified from the cDNA by PCR using the MGFPF and 
GGFPR oligonucleotides which correspond to the end of the M gene and start of the 
G gene for the forward and reverse primer, respectively (Appendix 1).  The PCR 
product was visualised on an agarose gel and the fragment was purified and 
sequenced using the MGFPF and GGFPR primers (in separate reactions).  The GFP 
sequence was confirmed to be present in each of the samples tested.      
 
5.3.6.6. Pathological examination of brains from mice infected with rCVeGFP 
Half of each brain taken from the animals in the rCVeGFP timecourse (section 
5.3.6.1) were fixed in 4% paraformaldehyde in PBS for pathological examination by 
collaborators at the Pirbright Institute.  Sagittal sections were prepared and stained 
with haematoxylin and eosin (H&E).  No evidence of pathology was observed in 
sections of brain from rCVeGFP-infected mice at day 1 post-infection and the 
sections were comparable to the uninfected control samples.  Representative 
micrographs of the virus-infected brain samples at day 2 and 3 post-infection and 
uninfected samples at day 3 are shown in Figures 5.24 and 5.25.     
Sections of brain from mice infected with rCVeGFP at day 1 (not shown) and 2 post-
infection looked comparable to the mock non-infected counterparts (Figure 5.24).  
The first signs of virus infection in the brain were observed at day 3 post-infection 
(Figure 5.25).  These changes included indications of inflammation including some 
perivascular cuffing and infiltrating mononuclear cells in the cerebellum (Figure 5.25 
a) and also inflammation in the rostral migratory stream in the subventricular zone.  
In addition, there were regions of neuronal damage in the cerebellum including 
Purkinje neurones with pyknotic nuclei (Figure 5.25 g) and areas of complete cell 
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death.  Some vacuolation in the cortex accompanied with eosinophilia was also 
observed (not shown) and limited inflammation in white matter tracts was observed.  
The hippocampus, and the dentate gyrus appeared normal in all mice. 
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Figure 5.24| Brain sections stained with haematoxylin and eosin from mice inoculated with 1000 pfu of rCVeGFP 
5µM sections were prepared and processed in paraffin.  Representative photomicrographs showing regions of the cerebellum from control (a, b, c) and virus-
infected mice at post-infection day 2 (d, e, f).
100 μm 50 μm
50 μm100 μm
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Figure 5.25| Brain sections stained with haematoxylin and eosin from mice inoculated 
with 1000 pfu of rCVeGFP 
5µM sections were prepared and processed in paraffin.  Representative photomicrographs 
showing regions of the cerebellum from virus-infected mice at post-infection day 3.  
Pyknotic nuclei and neurones with central chromatolysis are indicated with white 
arrowheads and a perivascular cuff by an arrow.  An area containing large scale cell death is 
indicated by a dashed line.       
 
5.3.7. Brain cell types infected with rCVeGFP following intraperitoneal 
inoculation of mice with the virus 
Brains from suckling mice injected with 1000 pfu CVeGFP via the intraperitoneal 
route (section 5.3.6) and sacrificed at day 5 post-infection were removed and divided 
along the midsagittal plane.  One half of each brain was used to determine the titre of 
virus present in the brain at each stage of infection (section 5.3.6.3).  The other half 
was fixed in 4% paraformaldehyde in PBS, paraffin embedded and sagittal sections 
prepared by collaborators at the Pirbright Institute.  The tissue sections were studied 
using immunohistochemistry to detect GFP present in recombinant CVeGFP and/or 
100 μm100 μm 100 μm
50 μm 50 μm 50 μm
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brain cell-specific markers.  This was carried out for comparison with the data from 
the ex vivo slice cultures (section 5.2), which if gave comparable results would 
indicate that cerebellar slice cultures provide a suitable model with which to study 
CHPV pathogenesis.  In addition, this approach allowed the sites of CHPV infection 
throughout the mouse brain to be studied, rather than the analysis being limited to the 
cerebellum.   
The saggital sections were stained with anti-GFP (counterstained with a secondary 
antibody coupled to green Alexa Fluor® 488) and an antibody against one of the 
following brain cell specific markers: GABA-A receptor α 6, MAP2, NeuN, 
calbindin, CD11b, cc1, GFAP (counterstained with a secondary antibody conjugated 
to a red Alexa Fluor® either 568 or 594).  The results are shown in Figure 5.26.  
Consistent with the histopathological examination virus-infected cells were 
predominantly restricted to the cerebellum (Figure 5.26 a-g), though low levels of 
GFP expression were found in the hippocampus in some of the samples with high 
virus titres (Figure 5.26 h).  In the cerebellum, approximately 65% of cells were 
positive for both GFP and the granule cell marker protein GABA-A receptor α 6 
(Figure 5.26 a).  This is in contrast with the results from the ex vivo analysis of 
cerebellar slice cultures infected with rCVeGFP which found that approximately 
only 1% of virus-infected cells co-localised with those stained with the granule cell 
specific antibody (Figure 5.4).  However, it was noted during the analysis that 
morphologically rCVeGFP-infected cells were similar to granule cells and that they 
were localised to the granule cell layers (Figure 5.3).   
Approximately 1% of virus-infected cells co-localised with the two other neurone-
specific antibodies anti-MAP2 and anti-NeuN, which are specific for neurone-
restricted progenitors and differentiated post-mitotic neuronal cells, respectively 
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(Figure 5.26 b, c).  No evidence of rCVeGFP infection of purkinje neurones was 
observed, as demonstrated by the absence of co-localisation in Figure 5.26 d.  A 
small number of GFAP-immunoreactive astrocytes (Figure 5.26 g) and cc1-positive 
mature oligodendrocytes (Figure 5.26 f) were infected with virus, demonstrating that 
these cells are also permissive to CHPV infection, although are infrequently infected.  
In addition, approximately 15% of virus-infected cells were microglia (as shown by 
dual GFP and CD11b positivity) (Figure 5.26 e).                 
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Figure 5.26| Confocal micrographs of brain sections from mice infected with rCVeGFP 
and stained for brain cell-specific marker proteins 
Images are of the cerebellum (a-g) and the hippocampus (h).  CVeGFP-infected cells stained 
with anti-GFP and a secondary green alexa antibody and cell marker proteins were stained 
with either anti-GABA-A receptor α6 (a), anti-MAP2 (b), anti-neuN (c), anti-calbindin (d), 
anti-CD11b (e), anti-cc1 (f), or anti-GFAP (g) primary antibodies followed by a red alexa 
secondary antibody.  Panel H shows GFP-expressing cells in the hippocampus.  
Fluorescence was visualised using a Leica SP5 confocal fluorescence microscope.  Scale bar 
shown.      
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5.4 The effect of tdCE point mutations on the pathogenesis of infection 
 
The three temperature-dependent host range mutants (tdCE) of CHPV characterised 
in this study contain a single point mutation in the gene encoding the L protein which 
severely inhibits their growth at 39°C in primary avian cells (but not at 31°C or at 
either temperature in mammalian cells).  The objective was to determine whether 
these mutations have a direct effect on the pathogenesis of CHPV in vivo. 
Groups of 6 ICR CD1 mice (8 days old) were intraperitoneally inoculated with tdCE 
rCV 112 (C7217 → U) and rCV 157 (G9735 → U) at a dose of 50 and 1000 pfu per mouse.  
Only two of the three tdCE mutant viruses were used to limit the number of animals 
required in experiments.  None of the mice became unwell or showed symptoms of 
CHPV-induced encephalitis following infection with 50 or 1000 pfu of either virus 
(Figure 3.27 a, b, d, e).  When the dose of rCV 112 (C7217 → U) was increased to 5000 
pfu 2 out of 6 mice developed disease with the first symptoms observed on day 5 
post-infection and paralysis of two limbs on day 7 post-infection.  Therefore, there 
was a 2-day delay in the onset of symptoms and a 2-day delay in the progression of 
disease to the experimental endpoint compared with the wild-type control virus 
(rCHPV).  Furthermore, this dose was 5-fold higher than the dose of rCHPV which 
induced disease.  In line with the clinical assessment, the group weight of the rCV 
112 (C7217 → U) -infected mice decreased at day 5 post-infection in comparison with 
the uninfected group.  These results indicate that the host range mutations 
substantially attenuate (but do not prevent) the pathogenesis of CHPV in mice.         
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Figure 5.27 Progress of tdCE mutant virus infection at different doses 
Groups of six mice were inoculated intraperitoneally with either 50 pfu, 1000 pfu or 5000 pfu of rCV 112 (C7217 → U) (A,B), rCV 157 (G9735 → U) (C,D) or 
PBS (shown in blue).  For each dose the progress of disease is shown as the collective average weight (calculated as the percentage difference compared to 
day 0) (A, C) and the average clinical score (B, D).   
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5.5 Discussion 
Experimental infection of young mice with CHPV produces a fatal neurological 
disease (Jortner et al., 1973) and there have been a number of outbreaks of CHPV-
induced neurological disease, referred to as encephalitis, in humans between 9 
months and 16 years old (Chadha et al., 2005; Gurav et al., 2010; Tandale et al., 
2008).  Early studies in mice showed that the virus is able to cross the blood brain 
barrier to infect the CNS (after intraperitoneal or intravenous administration) 
resulting in a dose-dependent encephalitis by haematogenous spread in suckling mice 
but not in adults (Balakrishnan & Mishra, 2008; Jortner et al., 1973).  The data 
presented here support these findings.  Intraperitoneal inoculation of 8 day old ICR 
(CD1) mice with 50 pfu of CHPV strain I653514, which was also used in the early 
studies in mice, was shown to induce neurological disease.  The first symptoms of 
CHPV disease were typically uncoordinated movements and unilateral paralysis of 
the hind limb nearest the injection site and weight loss at day 2 post-infection.  
Paralysis progressed rapidly and paralysis of two limbs (usually bilateral hind limb 
paralysis) and a further reduction in weight occurred at day 3 post-infection.  Initial 
studies found that forelimb paralysis occurred in the final stages of disease after 
which the mice succumbed to infection (Jortner et al., 1973).  Paralysis of two limbs 
was taken as the humane end point used in this study.  The collective weight of the 
virus-infected group was shown to be significantly lower than the uninfected group 
on day 2 and 3 post-infection (one tailed unpaired Student’s t-test, p≤0.05).   
 
There was a 392-fold and 10 million-fold increase in viral titre in the brains of 
CHPV-infected mice at day 1 and 2 post-infection respectively, compared to the 
initial inoculum.  Virus was not detected in the lungs or liver of infected animals 
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(Table 5.2).  This contrasts with previous research which detected the presence of 
low levels of virus in the blood, skeletal muscle, liver, lung and spleen and 
subsequently at high titres in the brain (Jortner et al., 1973) which was taken to 
indicate that peripheral infection of CHPV in suckling mice induces viraemia and 
haematogenous spread ensures the dissemination of virus throughout the body.  One 
study demonstrated the rapid generation of anti-CHPV IgM antibodies upon 
experimental peripheral infection of young mice which may reduce viral titres 
present in the blood and other organs (Balakrishnan & Mishra, 2008).  A recent study 
detected rising levels of CHPV RNA in nervous tissue progressively further away 
from the site of inoculation during the course of infection indicating that CHPV may 
also spread from the peripheral nerves to the brain via axonal transport (Anukumar et 
al., 2013).  Infection of mice with the Alphavirus Semliki Forest virus (SFV) (family 
Togaviridae), a positive sense single stranded RNA virus, is a well-established model 
to study the pathogenesis of viral encephalitis (Fazakerley, 2004).  While SFV and 
CHPV have considerably different molecular organisations and replicative cycles 
they are similar in the disease they induce.  When inoculated in the periphery SFV 
causes transient plasma viraemia and once in the circulation SFV is able to invade 
the CNS through cerebral endothelial cells and replicate, initially at perivascular foci 
(Fazakerley, 2004).  A similar process has been proposed for CHPV infection. 
 
CHPV-induced encephalitis in adult mice is only achieved by direct intracranial 
injection (Sokhei & Obukhova, 1984).  The mechanism of age-dependent 
susceptibility of CHPV disease has not been clarified, however, important 
contributory factors are likely to include an immature host immune response and 
immature nervous system in young mice (Balakrishnan & Mishra, 2008).  A range of 
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other neurotropic viruses have also been shown to produce age-related CNS disease 
including Japanese encephalitis (JE), Yellow fever, St Louis encephalitis, West Nile, 
Sindbis, measles, Semliki Forest and herpes viruses (Oliver & Fazakerley, 1998).  
Different strains of SFV exhibit different levels of virulence and the disease outcome 
is often strongly age related.  Intraperitoneal inoculation of mice with the L10 strain 
of SFV results in panencephalitis, regardless of the age of the mice.  On the other 
hand, although SFV strain A7(74) is able to initiate infection at perivascular foci in 
all mice, dissemination of virus infection throughout the brain and thus fatal 
encephalitis is only achieved in mice aged 11 days old or less on the day of 
inoculation (Oliver & Fazakerley, 1998).  This is irrespective of the route of virus 
administration and therefore the same is true following intracerebral inoculation of 
the virus.  Restriction of SFV strain A7(74) replication in the CNS of adult mice is 
not a result of a maturing immune system because virus infection in nude (athymic, 
without T lymphocytes) and SCID (severe combined immunodeficiency, impaired in 
their ability to produce B and T cells) mice remains localised (Fazakerley et al., 
1993).  However, a subclinical, persistent SFV infection ensues in mice deficient in 
T-lymphocytes.  The data suggest that the age-dependent nature of SFV strain 
A7(74) virulence is a product of neuron maturity with mature neurons unable to 
support productive infection and induce apoptosis to facilitate the dissemination of 
virus progeny to adjacent cells (Fazakerley et al., 1993).  The underlying molecular 
basis for the restriction of SFV strain A7(74) in mature neurones has not been 
characterised.  The age-related pattern of disease associated with CHPV infection 
may involve one or more of these factors and remains to be explored. 
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A number of studies have used ex vivo cultures of brain tissue to investigate viral 
tropism (Braun et al., 2006; Dionne et al., 2011; Friedl et al., 2004; Tsutsui et al., 
2002), balancing a need for normal tissue architecture and physiological proportions 
of brain cell types while minimising the number of in vivo experiments conducted.  
This study is the first example of ex vivo cultures of brain tissue used to investigate 
the cellular tropism of a vesiculovirus.  Using a recombinant virus rCVeGFP which 
expressed the eGFP reporter protein cerebellar slice cultures were demonstrated to 
support CHPV replication with GFP expression first visible approximately 6 hours 
post-infection.   
Analysis of the cerebellar slices by confocal fluorescence microscopy, fixed at 12 
hours post-infection demonstrated that a large proportion (approximately 80%) of 
rCVeGFP-infected cells were neuron-restricted progenitor cells, as shown by the 
high level of co-localisation of virus-infected and MAP-2-positive cells in Figure 5.4 
a, b.  Strikingly, cells positive for both neuN, a marker protein specific for 
differentiated post-mitotic neurones, and virus were not observed at this time point 
(Figure 5.4 c, d).  Analysis of rCVeGFP-infected cerebellar slices fixed at 24 hours 
post-infection showed a slight reduction in the number of virus-infected neurone-
restricted progenitor (MAP-2-positive) cells (Figure 5.7).  In contrast to at 12 hours 
post-infection, a small proportion of mature neurones, as determined by NeuN and 
βIII-tubulin positivity were infected with virus at 24 hours post-infection.  However, 
only approximately 1% of CHPV-infected cells in the cerebellum were MAP2 or 
NeuN positive in brain samples following in vivo CHPV infection (Figure 5.26 b, c).  
No evidence for CHPV infection of purkinje neurones was demonstrated by 
immunohistochemistry in the ex vivo samples, though there was evidence of damage 
to these cells detected in the in vivo analysis described below.        
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Using an anti-MBP antibody to highlight the cerebellum structure, virus infected 
cells from ex vivo infection were shown to be present in large numbers in the granule 
layers of the cerebellum.  Small neurones called granule cells are abundant in these 
regions of the tissue and the rCVeGFP-infected cells have similar morphologies to 
this type of neurone.  During in vivo infection of rCVeCHPV, approximately 65% of 
virus infected cells in the cerebellum were shown to be granule cells (Figure 5.26 a).  
This is in contrast with the results from the ex vivo analysis of cerebellar slice 
cultures infected with rCVeGFP which found limited co-localisation of virus infected 
and GABA-A receptor α6 (granule cell specific marker protein)-positive cells 
(Figure 5.3), although there have been reports that the GABA-A receptor α6 subunit 
is only expressed on cerebellar granule cells at approximately post-natal day 14 (Dr 
D. Fulton personal communication).  The brain samples from the in vivo infections 
were from slightly older mice (11 days old) than the slices used in the ex vivo 
analysis (7 days old), which may be an important factor regarding the detection of 
granule cells by this antibody and therefore may explain the differences in the 
numbers of granule cells shown to be infected with virus by the two methodologies.  
Thus, infection of granule cells cannot be discounted on the basis of the ex vivo 
results.   
While CHPV infection of microglia was not demonstrated at 12 hours post-infection 
of cerebellar slice cultures, 15% of virus-infected cells expressed the microglia 
specific protein at 24 hours post-infection (Figure 5.10).  Moreover, 15% of virus-
infected cells were shown to be microglia in brain samples from CHPV-infected 
mice (Figure 5.26 e).  Infection of microglia with a number of viruses including 
HIV-1 (Wang et al., 2008) and herpes simplex virus 1 (Lokensgard et al., 2002) have 
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been shown to be important contributing factors in the virus-mediated 
neuropathology.      
In rCVeGFP-infected cerebellar slice cultures approximately 1-3% and 5-8% of 
virus-infected cells were shown to co-localise with immature and mature 
oligodendrocytes  at 12 and 24 hours post-infection respectively (Figure 5.9, 5.10), 
indicating that while oligodendrocytes are permissive to CHPV replication, infection 
of these cells occurs infrequently.  This is consistent with the analysis of brain slices 
from infected mice, which found 1-3% of virus-infected cells were oligodendrocytes 
(Figure 5.26).  There was limited evidence for signal overlap between astrocytes and 
virus-infected cells following ex vivo infection of brain tissue, while 1% of virus-
infected cells from virus-infected mice were shown to be positive for the astrocyte 
specific marker protein.  Taken together, the results suggest CHPV predominantly 
infects neurone progenitor cells, granule cells and microglia with only a few fully 
differentiated neurones, oligodendrocytes and astrocytes infected by the virus.       
Pathological analysis of brains from mice infected in vivo with CHPV showed 
pronounced damage to the cerebellum.  Signs of virus infection including 
inflammation, neuronal lesions and regions of complete cell death were first 
observed at day 2 post-infection and were more pronounced at day 3 post-infection.  
Small areas of cell death were observed in the hippocampus and cortex at day 3 post-
infection.  However, samples from uninfected mice used as a control in the analysis 
were only prepared on post-infection day 3 when the mice were 11 days old.  As the 
developing mouse brain changes very rapidly further control samples from post-
infection day 1 and 2 will be necessary to properly assess any virus-induced changes 
on each day of the timecourse. The pathological process seen by analysis of samples 
taken from animals infected in vivo was consistent with those from the examination 
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of ex vivo tissue sections from rCVeGFP-infected mice which found that virus-
infected cells were predominantly restricted to the cerebellum (Figure 5.26 a-g).  In 
samples taken from in vivo infections low levels of GFP expression were found in 
the hippocampus in some of the samples with high virus titres (Figure 5.26 h).  A 
prominent characteristic of SFV-induced disease is the CD8+ T lymphocyte-
dependent generation of lesions of demyelination (Fazakerley & Walker, 2003).  
CHPV has also been shown to cause some demyelination, although lesions in grey 
matter occurred with increased frequency and severity (Jortner et al., 1973).  
However no signs of demyelination following infection were observed in this study 
of CHPV disease.  The analysis of the sections detected clear evidence of severe 
damage to the Purkinje cell layer including cell shrinkage and pyknotic nuclei.  This 
is also the first report of significant damage occurring outside of the cerebellum in 
CHPV infected mice. 
 
Despite the clear CNS involvement in CHPV disease, cell tropism which underpins 
many aspects of disease has not been extensively investigated for this virus and 
neurones are the only brain cell type currently known to be susceptible to infection 
(Ghosh et al., 2013; Jortner et al., 1973).  Viruses can have strict tropisms for 
specific cell types, for example SFV almost exclusively infects neurones and 
oligodendrocytes in the CNS (Fazakerley, 2004).  SFV infection of astrocytes has not 
been demonstrated.  The CHPV reverse genetics system (Marriott & Hornsey, 2011) 
provided an opportunity to investigate the site of CHPV infection in the mouse brain 
and the cell tropism of the virus by permitting the generation of recombinant viruses 
containing reporter genes including rCVeGFP, which was used in this study.  
Introduction of large reporter genes can alter virus characteristics.  Also, the 
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pathogenicity of viruses grown in tissue culture can differ substantially from the wild 
type counterpart, due to the accumulation of point mutations and epigenetic changes.  
A dose-response analysis showed that 1000 pfu of rCHPV and rCVeGFP induced 
neurological disease when administered intraperitoneally to 8 day old mice, 20-fold 
higher than the dose of CHPV strain I653514 shown to induce encephalitis.  There 
was a 2 day delay in the onset of rCVeGFP-induced disease compared with rCHPV, 
with the first symptoms observed on day 3 and day 5 post-infection, respectively.  
Also, in contrast with mice infected with rCHPV, which displayed significant weight 
loss compared to the uninfected control group on days 4 and 5 post-infection, the 
weight change of mice infected with rCVeGFP remained comparable to the 
uninfected mice throughout the timecourse.  Thus, the addition of the eGFP gene in 
the genome of CHPV generated a virus with different characteristics in vivo.  
However, the histopathological changes in the brains of rCHPV and rCVeGFP-
infected mice were comparable with each other and to CHPV strain I653514, 
validating their use in the investigation.  Importantly, all three viruses produced 
pathological changes (evidence of inflammation and neuronal damage) which were 
almost exclusively restricted to the cerebellum.        
The temperature-dependent host range mutants (tdCE) of CHPV are severely 
impaired in their growth in vitro under non-permissive conditions due to single 
amino acid changes residing in the RNA polymerase protein.  These changes were 
also shown to have marked effects on the assembly of replication complexes.  
Intraperitoneal inoculation of two of these viruses, namely rCV 112 (C7217 → U) and 
rCV 157 (G9735 → U) into young mice showed that these viruses have reduced 
pathogenicity in vivo in comparison with the rCHPV.  Interestingly, slower disease 
progression and increased propensity for immune-mediated demyelination was 
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exhibited by a temperature-sensitive mutant of CHPV (ts472) (Dal Canto et al., 
1979).  This CHPV mutant was also shown to have a reduced capacity for neuronal 
replication (Dal Canto et al., 1979).            
The data presented in this chapter indicate that the site of CHPV-infection in the 
mouse brain is the cerebellum with immature neurones, granule cells and microglia 
preferentially infected.  However, a broad range of brain cells (both neurones and 
glial cells including astrocytes and oligodendrocytes) were shown to be permissive to 
infection with CHPV.  In addition, two tdCE mutants of CHPV exhibited attenuated 
growth in vivo.       
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CHAPTER 6 
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Chapter 6: Conclusions and future questions 
 
Viruses are obligate intracellular parasites and the small coding capacity of viruses 
ensures their dependence on an array of cellular machinery and factors at every stage 
of their replication cycles.  Thus, host range underpins every stage of virus infection.  
Specific cellular proteins are utilised as receptors and co-receptors to initiate 
infection and viral entry often involves the hijacking of the endocytic pathway of the 
cell and the host cytoskeleton. Once inside the cell cellular proteins are required to 
transport the virus to its favoured site of replication.  Virus gene expression and 
replication itself is dependent on numerous host factors such as helicases, 
transcription factors, eukaryotic translation initiation factors and proteases.  Viruses 
also interact with a plethora of host factors and signalling pathways to modulate host 
protein synthesis, the host immune response, apoptosis and the cell cycle to produce 
a cellular environment conducive to virus replication, enabling the establishment of 
persistency in the case of some viruses or a timely exit from the cell in the case of 
others.  Host cell proteins such as cellular chaperones and proteases are also 
frequently exploited by viruses for the assembly and maturation of their particles.  
Lastly, exit of progeny virions from the host cell ready for dissemination and 
infection of other hosts is intimately associated with cellular factors. This research 
explored aspects of the host range of the vesiculovirus Chandipura virus (CHPV).   
 
Temperature-dependent host range (tdCE) mutants of CHPV are characterised by a 
severe growth defect under non-permissive conditions; growth in chicken embryo at 
39°C (Gadkari & Pringle, 1980; Rasool & Pringle, 1986).  However, their growth at 
31°C in chicken embryo and at 31°C or 39°C in mammalian cells is unaffected, 
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growing to titres comparable to the wild type virus.  The characterisation of host 
restricted and conditional host range mutants have proved powerful mechanisms for 
uncovering aspects of vesiculovirus replication, with several key amino acid residues 
in the methlytransferase (MTase) domain of the L protein delineated through the 
study of mutants of VSV Indiana (Grdzelishvili et al., 2005; 2006; Simpson & 
Obijeski, 1974).  The genomes of three tdCE mutants of CHPV; CH112, CH157 and 
CH256 were sequenced in this study and compared with the wild type virus.  
Generation of recombinant viruses containing the identified point mutations using 
the reverse genetics system of CHPV (Marriott & Hornsey, 2011) demonstrated that 
a single point mutation within the L gene of each mutant, which resulted in a single 
coding change in the amino acid sequence of the catalytic component of the virus 
RNA-dependent RNA polymerase confers the host range phenotype described.  The 
lesions responsible for the host range specificity are located between domains III and 
IV (CH112 C7217 → U) or within domain IV (CH256 G7694 → A) or VI (CH157 G9735 
→ U) of the CHPV L gene.  Domain VI of the L gene encodes the virus MTase, 
though the mutant containing a lesion in this domain possesses normal MTase 
activity (Rasool & Pringle, 1986).  This lesion is located in a region of highly 
invariant amino acids which contain an important binding site for the MTase, the 
GXGXG motif (Rahmeh et al., 2010).   
 
The role of the tdCE mutations in giving rise to the conditional host range phenotype 
is unknown.  As the cofactor of the polymerase, the direct binding of the P protein to 
the L protein is essential for virus replication.  A series of recombinant viruses 
encoding wild type or mutant L proteins and the P/RFP fusion protein were 
generated to allow visualisation of the replication complexes in cells under 
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permissive and non-permissive conditions.  Analysis of these viruses showed that for 
each of the three mutants analysed the host range lesions inhibit the formation of 
large replication complexes in the cytoplasm of host cells in non-permissive 
conditions.  These complexes are postulated to bring together the viral RNA and 
viral replicative machinery with an array of essential cellular proteins for efficient 
replication, although their assembly may be host cell mediated (Dinh et al., 2013a).  
This strongly suggests that the single point mutations lead to an altered L protein that 
is incapable of forming the replication complex in chick embryo cells at high 
temperature.  The host-range nature of the phenotype suggests that this is due to an 
altered interaction with a host cell factor found in the chick embryo cells. 
 
As a preliminary step in identifying host cell proteins that interact with the CHPV 
replication complex a recombinant virus containing a Flag tag at the carboxy 
terminus of the CHPV L protein was used to infect mammalian and avian cells.  126 
mammalian and 25 avian potential CHPV L interacting proteins were identified by 
immunoprecipitating the L/Flag protein and analysing L/Flag fusion proteins by 
mass spectrometry.  In assessing the roles of the interacting proteins it is important to 
appreciate that the approach used to identify potential interacting proteins in this 
study was unable to discriminate between proteins which bind directly to the L 
protein and those that indirectly interact with L protein via other host factors or viral 
proteins (N and P).  The majority of the proteins identified have cellular functions 
principally in gene expression (including eukaryotic translation initiation factors, 
ribosome subunits, hnRNP proteins), cytoskeleton architecture and protein folding 
(Figure 4.10).  Many viruses have been shown to be reliant on the cytoskeleton at 
various stages in their lifecycles including VSV and RSV which require tubulin and 
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actin, respectively for their mRNA synthesis (Burke et al., 1998; Heinrich et al., 
2010).  The data presented here identified actin as a cellular protein which may 
associate with CHPV L, the first report of actin interacting with a vesiculovirus 
protein.  The intermediate filament protein vimentin was also identified as a possible 
CHPV L protein partner.  Association with, and regulation of, vimentin by the HIV-1 
protease (Honer et al., 1991) and VSV M (Lyles & McKenzie, 1997) proteins have 
previously been demonstrated suggesting that this is a common factor associated 
with the replication of a range of viruses.    
 
A particularly interesting potential cellular protein interacting with the CHPV L 
protein was Hsp-90.  This protein chaperone is essential for the accurate folding of 
viral polymerases from diverse virus families including rhabdoviruses (Momose et 
al., 2002).  The VSV N protein has been shown to interact with Hsp90 to ensure L 
protein stability (Connor et al., 2007) and therefore the identification of Hsp90 in this 
study may be due to an indirect interaction through the N protein.  Hsp70, which 
triggers an antiviral response against VSV replication through its ability to induce the 
type 1 interferon response (Kim et al., 2013), was also identified in this analysis. 
 
Several members of the hnRNP family of proteins were identified as possible CHPV 
L protein partners.  While these are nuclear proteins their increased presence in the 
cytoplasm of VSV-infected cells has been described and hnRNPK and hnRNPU in 
particular have been shown to play essential roles in VSV infection by regulating an 
array of cellular proteins with the effect of suppressing apoptosis (Dinh et al., 2013b) 
and inhibiting host cell mRNA production via an association with leader RNA 
(Gupta et al., 1998a).  hnRNP family members have also been shown to support the 
222 
 
replication of a variety of other viruses including flaviviruses (Hsieh et al., 1998), 
togaviruses (Burnham et al., 2007), herpesviruses (Gross et al., 2012), caliciviruses 
(Lopez-Manriquez et al., 2013) and paramyxoviruses (Hino et al., 2013).        
 
To confirm the potential partners involved in CHPV L protein interactions further 
investigation will be required.  Firstly, it will be necessary to perform Western blot 
analysis of selected cellular proteins in the L/Flag immunoprecipitated samples.  An 
additional control for non-specific binding of proteins to the anti-flag M2 magnetic 
beads is also required and the experiments will need to be repeated at least three 
times for quantitative statistical analysis of the mass spectrometry results.  Also, it 
would be of interest to explore whether any of the L interacting proteins are required 
for CHPV replication and RNAi could be performed to knockdown selected cellular 
proteins to investigate this.  Drugs which affect cytoskeletal arrangement such as 
nocodazole, colcemid and cytochalasin D could also be utilised to explore the roles 
of cytoskeletal proteins in CHPV replication.  The use of various drugs to inhibit 
actin assembly enabled a requirement for actin at the internalisation stage of VSV 
infection to be deduced (Cureton et al., 2009).   
 
The nature of the tdCE mutant phenotype is suggestive of the involvement of an 
essential host cell factor(s) and the immunoprecipitation/mass spectrometry approach 
could be employed to look for differences in the cellular proteins bound to the 
polymerase proteins during permissive and non-permissive conditions.  This would 
further characterise the tdCE phenotype.  The required immunoprecipitations for this 
have been carried out although time constraints did not permit the mass spectrometry 
analysis to be completed.  Wild-type and tdCE mutant P/RFP fusion proteins from 
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mammalian and avian cells at 31°C and 39°C have also been immunoprecipitated.  
Mass spectrometry analysis of these samples would further substantiate the findings 
from the L fusion protein work as the P and L proteins are binding partners.   
 
An interesting facet of CHPV host range is the marked differences in replication of 
the virus in mammalian versus insect cells.  This could also be investigated using the 
approach outlined above for the characterisation of the tdCE mutants with pull down 
experiments in mammalian and insect cells to identify differences in cellular binding 
partners.  It would also be interesting to study the M protein of the virus during 
infection of mammalian and insect cells, as expression of the M protein alone is 
cytotoxic to mammalian cells (Blondel et al., 1990) and the CHPV M protein has 
been shown to inhibit cellular transcription (Taylor et al., 1999).  Alteration of the 
37PSAP40 motif in the M protein of VSV to four alanines was sufficient to induce 
cytopathogenicity in the insect cell line C6/36 and attenuate pathogenicity in mice, 
highlighting the key role of the motif in host range (Irie et al., 2012).     
 
CHPV has been associated with several outbreaks of neurological disease in children 
and also induces encephalitis in peripherally infected young but not adult mice.  This 
reflects a different aspect of host range specificity in terms of replication in the CNS 
and neuropathogenesis in young rather than older hosts.  An in vivo model of CHPV-
induced encephalitis was established and used the recombinant virus rCVeGFP 
(Marriott & Hornsey, 2011) to follow the progress of disease.  Peripheral infection of 
young mice with rCVeGFP induced encephalitis but the onset and progression of 
disease occurred two days later than infection with rCHPV.  GFP expression was 
found to be predominantly localised to the cerebellum in brain samples from mice 
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infected with rCVeGFP, implicating the cerebellum as the principle site of CHPV 
replication in the mouse brain.  This was supported by histopathological analysis of 
brain samples from recombinant wild type CHPV (rCHPV)-infected mice, showing 
large zones of cell death and neuronal damage which was almost completely 
restricted to the cerebellum.   
 
To further the neuropathogenesis work, it would be interesting to ascertain whether 
the attachment protein (G protein) of the virus is responsible for the identified 
tropism of CHPV.  The established HIV-1-based self-inactivating lentiviral vector 
system (Coleman et al., 2003) was used to generate lentivirus pseudotyped with the 
CHPV G glycoprotein to investigate this, but due to time limitations the experiments 
were not carried out.  CHPV strains obtained during outbreaks in India contain 
several point mutations in the G gene raising questions about the effects of these 
changes on the pathogenicity of the virus which could be tested in the mouse model 
to further identify virus factors associated with pathogenesis.  An important 
associated question is whether specific genotypes of CHPV are found in different 
geographical areas which may explain the restriction of disease to specific areas.   
 
Defining and characterising the age-related virulence of CHPV is an important aspect 
of pathogenesis that remains unexplored.  It has been shown that the disease 
produced by several strains of SFV is strongly linked to the age of the host.  The age-
dependent virulence of SFV strain A7(74) was shown to be a consequence of neuron 
maturity with mature neurons unable to support a productive virus infection and 
induce apoptosis to enable virus spread (Fazakerley et al., 1993).   In addition, an 
intact interferon response is essential for the control and clearance of many viruses 
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and the role of interferon in CHPV pathogenesis has not yet been established.  This 
could be investigated using IFNAR-1
-/- mice which lack the α chain of the interferon 
receptor.  The potential role of the immune system in the age-related pathogenicity of 
the virus could be explored using a range of adult genetically modified mice, for 
example severe combined immunodeficiency (SCID), athymic nu/nu, microMT mice 
to dissect the parts of the immune system involved in the host restriction.      
 
The recombinant rCVeGFP virus was also used to uncover the cellular tropism of the 
virus following in vivo infection of suckling mice and ex vivo infection of cerebellar 
slice cultures.  By examining rCVeGFP-infected brain slices following 
immunohistochemistry using a number of antibodies which are specific for a range 
of brain cell specific proteins CHPV was shown to predominantly infect immature 
neurons, granule cells and microglia.  A low level of CHPV-infection of mature 
neurones, astrocytes and oligodendrocytes was also demonstrated.  Thus, the data 
indicate that CHPV infection of immature neurones may be important for the 
establishment of disease in young animals.  Staining rCVeGFP-infected brain 
samples with an antibody specific for nestin, which is an intermediate filament 
protein expressed in progenitor cells of the nervous system would help to further 
define the cellular tropism of CHPV.  Interestingly, pathological analysis of brain 
samples from CHPV-infected mice found evidence of inflammation in the rostral 
migratory stream in the subventricular zone.  Neurogenesis takes place in the 
subventricular zone and neurons then relocate to other regions of the brain via the 
rostral migratory stream.  Taken together, this data indicates that infection of this 
region of the brain may be due to a propensity of the virus for infection of immature 
226 
 
neurons.  The level of neuronal maturity as a key determinant for virus infection has 
been previously demonstrated for the A7(74) strain of SFV (Fazakerley et al., 1993).   
 
The CHPV system offers an opportunity to explore the interaction of a vesiculovirus 
within a host at the cellular and whole animal levels.  The data presented here show 
that it is a tractable system in which the application of reverse genetics can be used to 
study the role of virus proteins in host range at both levels.  The data has shown for 
the first time that CHPV directly targets specific cells within the developing brains of 
suckling mice and further work will provide insight into the specific key molecular 
interactions involved in CHPV neuropathogenesis. 
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Appendix 1: Primer sequences 
Sequences of primers used in this investigation and their corresponding nucleotide 
positions in the CHPV genome (shown in brackets).  Point mutations within 
mutagenic primers are shown in bold.    
* CH112 C5760U R also contains the C5691→U point mutation but this change was 
not made in the resultant product 
 
Name Primer sequence (5’-3’) Use 
N1F ATGGTACCACGAAGAAAAACAAACC
AATTAAAC (1-25 from nt 9 of primer) 
To generate PCR product 1   
P8R ATTGGATCGGAAGCAGGTGA (1901-
1882) 
To generate PCR product 1  
P7F CTGAGTGCTCTCCAACTTCT (1741-
1760) 
To generate PCR product 2  
G7R TAACTCAATCTGCAAGTTCGA (3780-
3760) 
To generate PCR product 2  
G2F GAATTCATGACTTCTTCAGTGACAAT
TAG (3052-3075 from nt6 of primer) 
To generate PCR product 3  
L32R CGCTGATCTAAGACAATGAAG (5400-
5380) 
To generate PCR product 3  
L16F GTTGTACTCAAAGCATGGCA (5050-
5069) 
To generate PCR product 4  
L4R AGTCTGCAGATTGCATRGTCTCATC 
(7044-7025 from nt6 of primer) 
To generate PCR product 4  
L10F GAGTTGAGACAAGCCCTGAACCAAA
T (6926-6951) 
To generate PCR product 5  
L34R GCAACACTTCTCCTGTGGATC (9000-
8980) 
To generate PCR product 5  
L20F AGGGAAGGACGTCCATTTAG (8686-
8705) 
To generate PCR product 6  
L27R ATTGCAAAGTCTCTCACCTC (10038-
10019) 
To generate PCR product 6  
L26F GCTGGGACCCTACAAGCTC (9411-
9429) 
To generate PCR product 7  
L35R ATG GGC CCA CGA AGA AAA CAA 
AAC CAG TTA TA (11119-11096 from 
nt9 of primer) 
To generate PCR product 7  
CH112 
C5691U F 
CAG GAG ACA TAT TGA ATT GAC 
TGT AGA TGA ACT GAG TGC G (5674-
5713) 
Mutagenic forward primer to 
generate C5691 → U  
CH112 
C5691U R 
CGC ACT CAG TTC ATC TAC AGT 
CAA TTC AAT ATG TCT CCT G (5713-
5674) 
Mutagenic reverse primer to 
generate C5691 → U  
CH112 
C5760U F 
GTG CGA AGA CTC CAT TGA TCA 
GAG AAT TAT TCT CAC TGA TTG 
ATA CTT CTC TTA ATG TAG (5709-
5768) 
Mutagenic forward primer to 
generate C5760 → U  
CH112 
C5760U R* 
TGA GAA TAA TTC TCT GAT CAA 
TGG AGT CTT CGC ACT CAG TTC ATC 
Mutagenic reverse primer to 
generate C5760 → U  
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TAC AGT CAA TTC AAT (5743-5684) 
CH112 
C7217T F 
GTG GCA CAT TTT GAT GTA CAC 
TCA TTG AAT GCA ATG ATT C (7196-
7235) 
Mutagenic forward primer to 
generate C7217 → U  
CH112 
C7217T R 
GAA TCA TTG CAT TCA ATG AGT 
GTA CAT CAA AAT GTG CCA C (7235-
7196) 
Mutagenic reverse primer to 
generate C7217 → U  
CH157 
G9735U F 
TAC AGG GAT GCA CTG TGT GTG 
GGT GAT GGA TCA GGA GGT A (9755-
9716) 
Mutagenic forward primer to 
generate G9735 → U  
CH157 
G9735U R 
TAC CTC CTG ATC CAT CAC CCA 
CAC ACA GTG CAT CCC TGT A (9716-
9755) 
 
Mutagenic reverse primer to 
generate G9735 → U  
CH256 
G7694A F 
GGA ATC AGA TAG TCA AAG ACA 
CCG TAT ACT ACA TAC ACT C (7674-
7713) 
Mutagenic forward primer to 
generate U4034 → C  
CH256 
G7694A R 
GAG TGT ATG TAG TAT ACG GTG 
TCT TTG ACT ATC TGA TTC C (7713-
7674) 
Mutagenic reverse primer to 
generate U4034 → C  
CH112  
U3941C F 
GGGCTCAAGTCTTGACCCCAGAGATT
CAGAGGATTTTGG (3924-3962) 
Mutagenic forward primer to 
generate U3941 → C  
CH112  
U3941C R 
CCAAAATCCTCTGAATCTCTGGGGTC
AAGACTTGAGCCCC (3962-3924) 
Mutagenic reverse primer to 
generate U3941 → C  
CH256 
U4034 C F 
GTCTCCATTGGATCTAAGCCATTTGG
CATCTAAATCTCCG (4015-4054) 
Mutagenic forward primer to 
generate U4034 → C  
CH256 
U4034 C R 
CGGAGATTTAGATGCCAAATGGCTT
AGATCCAATGGAGAC (4054-4015) 
Mutagenic reverse primer to 
generate U4034 → C  
Sal1 F AGTTTGGAATTCCAAAAGTCGACTT
ATCACTTAAGTTTGA  
Insertion of a Sal1 restriction 
site in pT7CV at nucleotide 
9502 
Sal1 R TCAAACTTAAGTGATAAGTCGACTT
TTGGAATTCCAAACT 
Insertion of a Sal1 restriction 
site in pT7CV at nucleotide 
9502 
L F TAT TAC ATC TCA AAT CCT AGT ATG 
TAA TGA GGA AAT CAG 
Insertion of C-terminus Flag 
tag to L 
LFlag R ATATCATTACTTGTCATCGTCGTCC
TTGTAGTCATCTACCCAATGCTCAG 
Insertion of C-terminus Flag 
tag to L 
LFlag F GTAGATGACTACAAGGACGACGAT
GACAAGTAATGATATGAAAAAAACT
AAGGGTG 
Insertion of C-terminus Flag 
tag to L 
L R CATCCGAGTGGACGACGTCCTCCTTC
GGATGCCCAGGTC 
Insertion of C-terminus Flag 
tag to L 
MGFPF CCA ATC CTC AAC CCG GTC AAT 
TTC 
 
Sequence eGFP insert in 
CVeGFP 
GGFPR CTT GTA ACC CTG GTT CTA GAA 
ACC 
 
Sequence eGFP insert in 
CVeGFP 
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Appendix 2: Plasmid maps 
T7CHPV (full length genome clone) 
 
T7CVeGFP 
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T7CVP/RFP 
 
pT7N 
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pT7P 
 
pT7L 
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Minigenome MGeGFP 
 
 
